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DEVELOPMENT OF THE ENTERIC NERVOUS SYSTEM 
 
The enteric nervous system (ENS) is the complex network of neurons and glial 
cells that occurs along the entire length of the gastrointestinal tract and is 
responsible for the peristaltic movements of the bowel, as well as regulation of gut 
metabolism. Although the ENS is partially controlled by the central nervous system 
(CNS), it largely functions autonomously. The neurons and glial cells of the ENS are 
organized in interconnected ganglia that are localized in two plexuses in the gut 
wall. The myenteric (Auerbach’s) plexus is located between the longitudinal and 
circular muscles of the gut wall and innervates these muscular layers. The 
submucosal (Meissner) plexus is localized within the submucosa and regulates gut 
homeostasis1,2. The ENS is entirely derived from the neural crest, a cell population 
that originates at the border of the non-neural ectoderm and the neural plate. 
Upon closure of the neural tube, neural crest cells delaminate and migrate 
throughout the body and differentiate into various cell types including 
melanocytes, craniofacial cartilage, adrenal medulla, dorsal root ganglia and the 
neurons and glia of the ENS3.  
The majority of the ENS is derived from vagal neural crest cells that 
originate from the neural tube at the level of somites 1 to 74. Vagal neural crest 
cells invade the foregut at 4 weeks of gestation in human embryonic development5. 
These enteric neural crest cells (ENCCs) proliferate extensively. Vagal neural crest 
cells migrate in a rostral to caudal direction to colonize the foregut, midgut and 
hindgut, whereas sacral neural crest cells move in the opposite direction. 
Colonization of the entire length of the human gastrointestinal tract is completed 
by the 7th week of gestation5.  
The development of ENS has been studied in detail in mice, where neural 
crest cells colonize the gut between embryonic day 9.5 (E9.5) and E13.56 (Figure 
1). Time-lapse microscopy of fluorescently labeled ENCCs in mice has shown that 
ENCCs migrate along the gut in interconnected strands7. Individual cells break 
from these strands at the wavefront and assemble into new chains of migrating 
cells. As the gastrointestinal tract develops, the midgut and hindgut become 
juxtaposed in a hairpin loop at mouse embryonic day 11.5. A subpopulation of the 
migrating ENCCs use this spatial organization as a shortcut from the midgut to the 
hindgut via the mesentry (Figure 1). These trans-mesenteric ENCCs extensively 
contribute to the ENS in the murine hindgut8. Although the hairpin loop is also 
observed in human embryonic development, it is yet unclear whether ENCCs cross 
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1 the mesentery in humans8. Interestingly, advancing murine ENCCs pause their 
migration for approximately 12 hours when reaching the caecum, before 
continuing colonization of the hindgut and caecum7. Whether this pause in 
migration occurs in humans is also as yet unknown.  
The hindgut is partially colonized by sacral neural crest cells that originate 
at the level of somite 24 in mice. Sacral neural crest cells enter the hindgut late 
during ENS development and migrate in the opposite direction to the vagal neural 
crest cells (Figure 1)7,9–11. Studies using quail-chick chimeras showed that the 
contribution of the sacral neural crest to the ENS is limited, but contributes up to 
17% of neurons in the chick hindgut9. Although vagal and sacral neural crest cells 
have different migratory properties, they are morphologically indistinguishable 




Figure 1. Colonization of the developing gastrointestinal tract by ENCCs in the mouse. Vagal 
neural crest cells delaminate from the neural tube (E9.5) and migrate in a rostro-caudal direction to 
colonize the gut (E10.5-E13.5). Sacral neural crest cells contribute to the colonization of the hindgut in 
opposite direction later during development. Adapted from Heanue & Pachnis (2007) and Sasselli et al. 
(2012)2,16. 
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In order to form a functional ENS, ENCCs have to differentiate into many 
neuronal subtypes and glia. Markers of early neuronal and glial differentiation are 
found in ENCCs that are actively migrating and proliferating12. Early differentiating 
enteric neurons are found just behind the migratory wavefront, while glial 
precursors are found further away from the wavefront, indicating that enteric 
neuronal differentiation precedes glial differentiation13. ENCCs are a 
heterogeneous cell population. Terminally differentiated neurons are observed 
when ENCCs are still mitotic and migratory. However, these represent different 
cell populations, as markers of terminally differentiated neurons are found 
exclusively in post-mitotic, non-migratory cells12,14. Different neuronal subtypes 
arise at different developmental stages. Serotoninergic (5-HT) and cholinergic 
(ChAT) neurons arise early, whereas neurons expressing ENK, NPY, VIP and CGRP 






Hirschsprung disease (HSCR) is a congenital disorder that is characterized by the 
absence of enteric ganglia in the distal region of the intestine and it is thought to be 
the result from incomplete colonization of the gut by ENCCs. The absence of enteric 
ganglia (aganglionosis) results in tonic contraction of the muscles in the affected 
segment of the bowel, leading to abdominal distension (megacolon) proximal to 
the affected segment (Figure 2A-C). HSCR patients commonly present with 
vomiting, chronic constipation, failure to pass meconium, and less frequently with 
enterocolitis. Aganglionosis generally affects the most distal region of the bowel 
and the length of the affected segment varies between patients. Aganglionosis from 
the anal sphincter up to the rectosigmoid or sigmoid colon is defined as short-
segment HSCR and comprises 80% of the HSCR cases (Figure 2A). In long-segment 
HSCR (15% of the cases) the aganglionosis extends beyond the sigmoid colon and 
in total colonic aganglionosis (5% of the cases) there is a lack of enteric ganglia 
along the entire length of the colon17. In rare cases, termed total intestinal 








The majority of HSCR patients are diagnosed within the first 48 hours after birth. 
HSCR is sometimes diagnosed during childhood and in rare occasions during adult 
life. The absence of ganglia in a rectal biopsy confirms a HSCR diagnosis19. 
Aganglionosis can also be detected by increased immunoreactivity for 
acetylcholinesterase in hypertrophied extrinsic nerve fibers20. Additional 
diagnostic proof can be obtained using anorectal manometry21; measurement of 
the relaxation of the rectum in response to inflation of a rectal balloon. Barium 
enema radiography may be used to assess the length of obstructed colon and may 




Figure 2. Intestinal aganglionosis and clinical presentation of HSCR. A) Schematic representation 
of a normal colon, displaying the different colonic segments, and a HSCR-affected colon. B) X-ray of a 
HSCR patient showing tonic contraction of the affected segment and dilatation of the proximal bowel. C) 
Abdominal distension in a newborn suffering from HSCR. Adapted from http://www.ShowMe.com and 
http://www.artikelkeperawatan.info. 




Left untreated, the mortality rate of HSCR is ~75%22. Treatment consists of 
surgical resection of the aganglionic segment and rejoining of the ganglionic gut 
with the anal sphincter. This so-called pull-through surgery was first performed by 
Dr. Orvar Swenson in 194823 and several modifications to the original procedure 
have been described. These are known as the Soave, Duhamel and Boley 
procedures. From the 1990’s open surgical methods have started to be replaced by 
laparoscopic and transanal endorectal resection and pull-through surgeries24,25. 
These procedures require reduced operating and hospitalization times, and show 
improved clinical outcome26–28. Depending on the physical condition of the patient, 
a colostomy might be created proximally of the aganglionic segment to bypass the 
abdominal obstruction. In these cases a second surgical procedure is required to 
perform the pull-through surgery. Even though surgical treatment reduces the 
mortality rate of HSCR to as little as a few percent29, long-term follow-up studies 
showed that many patients suffer from impaired bowel function, constipation, 
fecal soiling, perianal dermatitis, enterocolitis and associated social problems30,31. 
It has been hypothesized that replenishment of the aganglionic gut with 
neuronal progenitor cells (NPCs) may provide a future therapy for HSCR. NPCs 
have successfully been isolated from human embryonic and postnatal mucosal 
gut32–35. Moreover, these cells can be expanded in vitro when cultured as 
neurosphere-like bodies (NLBs) and can be differentiated into neurons and glia. 
Metzger and co-workers have transplanted human NLBs into aganglionic gut 
segments derived from HSCR patients. Transplanted NPCs migrated away from the 
NLBs to colonize the aganglionic gut and differentiated into functional enteric 
neurons35. Importantly, these authors and others33 showed that NLBs can be 
generated from HSCR patient biopsies with similar efficiency as from non-HSCR 
gut. Although this is an important step towards the clinical use of autologous stem 
cells in transplantations, cell numbers are currently too low to replenish 
aganglionic gut segments of HSCR patients.  
An alternative and unlimited source of neural crest cells for 
transplantation to HSCR patients could be provided by human induced pluripotent 
stem (iPS) cells. Human iPS cells can be differentiated in vitro into neural crest 
cells, can be purified by flow cytometry, and can subsequently be differentiated 
into peripheral neurons and glial cells36. When transplanted into chick embryos or 
mice, human embryonic stem cell-derived neural crest cells are migratory and 
differentiate in vivo37. In vitro neural crest differentiation has been further 
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1 optimized to obtain neural crest cells of vagal origin38. When transplanted into a 
transgenic mouse model for HSCR, these cells extensively migrate, up to the distal 
colon, and completely rescue disease-related mortality38. Moreover, pepstatin A 
was found to rescue the impaired migratory capacity of neural crest cells in a 
genetically engineered HSCR model system, suggesting that pepstatin A could 
improve the outcome of therapeutic neural crest cell transplantations in HSCR 
patients38. Despite their clinical promise, a current limitation of hiPS cell-derived 
neural crest cells for transplantations is their safety, as remaining undifferentiated 
hiPS cells in the graft can lead to tumor formation in the donor39.  
 
Epidemiology 
The prevalence of HSCR is around 1:5,000 live births, but varies between ethnic 
groups. The disease is 2-fold and 3-fold more common among Asians than among 
Caucasians and Hispanics, respectively40. In all ethnicities, the prevalence of HSCR 
is higher in males than in females, but it is unclear what causes this bias. This 
gender bias is most prominent in short-segment HSCR, with a 4:1 male:female 
ratio, compared to a 2:1 ratio in long-segment HSCR41. Although HSCR mostly 
presents sporadically (non-familial), HSCR can present in a familial form (5-20% of 
cases). In general, the risk for siblings of HSCR patients to develop the disease as 
well (recurrence risk) is 4%, but ranges from 1 to 33% depending on the extent of 
aganglionosis and the gender of both the patient and sibling (Figure 3). Long-
segment HSCR gives a high recurrence risk and has a dominant mode of 
inheritance with incomplete penetrance. Short-segment HSCR has a much lower 
recurrence risk and follows a multifactorial or recessive mode of inheritance41. 
Most HSCR cases present as an isolated trait. However, 30% of the HSCR cases are 
associated with congenital syndromes, including Down syndrome (Trisomy 21) 
that accounts for 7% of all HSCR cases42. 
 
 
GENES ASSOCIATED WITH HIRSCHSPRUNG DISEASE 
 
RET signaling pathway 
Linkage analysis on familial HSCR patients found that the major gene for HSCR 
maps to chromosome band 10q11.244,45 and RET was identified as the gene 
carrying mutations in this locus46,47 (see Table 1 for a list of all HSCR-associated 
genes). Mutations in the coding regions of RET have been found in ~50% of 
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familial HSCR cases and 15-35% of sporadic cases48,49. Even though coding RET 
mutations have a dominant mode of inheritance, coding RET mutations have an 
incomplete penetrance in HSCR (72% in males and 51% in females)48, suggesting 
that other genetic aberrations are needed for disease development. In addition to 
HSCR, RET mutations are involved in Multiple Endocrine Neoplasia type 2 (MEN2) 
and Familial Medullary Thyroid Carcinoma (FMTC)50. RET mutations in MEN2 and 
FMTC are restricted to specific domains of RET and are activating, gain of function 
mutations. RET mutations in HSCR, on the other hand, are scattered throughout the 
coding sequence of RET48. A wide variety of coding RET mutations has been 
identified in HSCR patients, including large and small deletions, missense, 
nonsense, and splice-site mutations. In HSCR, RET mutations generally result in a 
loss of RET function and lead to haploinsufficiency51. However, activating 
mutations that are associated with MEN2 have been reported in HSCR patients as 
well52–54.  
Besides rare, coding mutations, also common, non-coding variants in RET 
have been associated with HSCR. Two independent haplotypes in the RET locus 




Figure 3. Recurrence risk and incidence of HSCR by phenotype and contributing genetic variant. 
HSCR mostly affects a short segment of the bowel, is most common in males and predominantly occurs 
sporadically. The recurrence risk is higher for long-segment HSCR, females and familial cases. The more 
common forms of HSCR have a large contribution of common genetic variants with low penetrance, 
whereas the rare and more heritable forms of HSCR are caused by more penetrant, rare variants. 
Adapted from Emison et al. (2010)43. 
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1 the RET promoter, 2 SNPs in an evolutionary conserved enhancer in intron 1 and a 
synonymous SNP in exon 2. The two SNPs in the RET promoter sequence reduce 
the binding affinity of NKX2-1 (TTF1) to the RET promoter, but the contribution of 
these SNPs to RET promoter activity is limited56. Similarly, the synonymous SNP in 
exon 2 does not influence RET expression levels57. The two SNPs in the conserved 
enhancer in intron 1 are in strong linkage disequilibrium. Nevertheless, both SNPs 
influence the activity of the enhancer independently58,59. Mice expressing the LacZ 
reporter gene under control of the enhancer element containing both SNPs show 
that the temporospatial expression of LacZ is similar to that of RET, suggesting that 
the enhancer element is indeed regulating RET expression60. Interestingly, the 
penetrance of the intron 1 enhancer SNPs is higher in males than in females. 
Overall, these SNPs have a 10 to 20-fold higher contribution to disease risk than 
coding mutations58. The predisposing haplotype is present in ~60% of Caucasian 
patients, compared to 20% of controls. In Asians, the frequency of the predisposing 
haplotype is higher; 85% in patients and 40% in controls61. The high frequency of 
the predisposing haplotype might contribute to the higher incidence of HSCR 
among Asians. The second HSCR-associated RET haplotype contains a synonymous 
SNP in exon 14 and a SNP in the 3’UTR. The 3’UTR SNPs is protective against HSCR 
by increasing the stability of RET mRNA62. Again, the frequency of the haplotype in 
different ethnicities is concordant with the prevalence of HSCR, as the protective 
haplotype is present in 4-8% of Caucasians and is virtually absent in the Asian 
population63.  
Both rare, coding mutations and common, non-coding variants in RET 
contribute to the risk of developing HSCR. However, their relative contributions 
depend on gender, length of the aganglionic segment and familiality43. The 
enhancer SNPs are more common in males, short-segment HSCR and sporadic 
cases. Rare, coding mutations on the other hand, are more frequent in females, 
long-segment HSCR and familial cases. The presence of rare and common genetic 
variants in RET, and possibly also in other genes, therefore contributes to the 
gender-, segment length- and familiality-dependent bias in recurrence risk and 
incidence of HSCR. 
 
RET signaling in ENS development 
RET is a receptor tyrosine kinase that is expressed by ENCCs throughout ENS 
development. RET can be activated by four different ligands, glial cell line- 
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Table 1. HSCR-associated genes and loci. 
HSCR: Hirschsprung disease, MEN2A: Multiple endocrine neoplasia type 2, WS: Waardenburg-Shah 
syndrome, CCHS: Congenital central hypoventilation syndrome, DS: Down syndrome 
 
 
derived neurotrophic factor (GDNF), neurturin (NRTN), artemin (ARTN) and 
persephin (PSPN). These ligands bind to GDNF family receptor alpha (GFRα) 1-4, 
respectively, that act as co-receptors in RET signaling. Ligand binding to RET, and 
GFRα co-receptors result in RET dimerization and trans-phosphorylation of 
tyrosine residues in the intracellular domain of RET. The phosphorylated tyrosine 





Non-syndromic HSCR / 
MEN2A 
50% familial,  
15–35% sporadic 
Dominant, incomplete penetrance 
GDNF 5p13.1 Non-syndromic HSCR Rare Non-Mendelian 
GFRA1 10q25.3 Non-syndromic HSCR 1 case reported Dominant 
NRTN 19p13.3 Non-syndromic HSCR Very rare Non-Mendelian 











Dominant, incomplete penetrance 
Recessive 
ECE1 1p36.12 
HSCR, craniofacial and 
cardiac defects 
1 case reported Dominant 
NRG1 8p12 Non-syndromic HSCR 6% Dominant, incomplete penetrance 
NRG3 10q23.1 Non-syndromic HSCR Rare Dominant, incomplete penetrance 
SEMA3C 7q21.11 Non-syndromic HSCR Rare Non-Mendelian 




>5% Dominant (de novo in 75%) 
PHOX2B 4p13 CCHS <5% Dominant (de novo in 90%) 
ZFHX1B / 
ZEB2 
2q22.3 Mowat-Wilson syndrome <5% Dominant (de novo in 100%) 
TCF4 18q21.2 Pitt-Hopkins syndrome  1 case reported Dominant 
NKX2-1 / 
TTF1 

















DNMT3B 20q11.21 Non-syndromic HSCR Rare Dominant, incomplete penetrance 













Dominant, incomplete penetrance 
unknown 3p21 Non-syndromic HSCR 
 
Non-Mendelian 
unknown 16q23 WS 
 
Non-Mendelian 
unknown 4q31-q32  Non-syndromic HSCR 
 
Dominant, incomplete penetrance 
unknown 19q12 Non-syndromic HSCR 
 
Non-Mendelian 
unknown 21q22  WS 
 
Recessive 
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1 residues function as docking sites for a wide range of downstream signaling 
cascades, including the ERK, PI3K/AKT, p38-MAPK and JNK pathways, that are 
critical for proliferation, migration, differentiation and survival of ENCCs and their 
derivatives64. Evidence that RET is required for the development of the ENS has 
been obtained in Ret knockout mice, as these mice fail to colonize the bowel 
beyond the stomach65. However, the required RET gene dosage differs between 
humans and mice. Only homozygous Ret knockout mice are aganglionic, but 
heterozygous animals develop normally. In humans, on the other hand, mutations 
in RET are heterozygous and lead to a disease phenotype with reduced penetrance. 
Like Ret-deficient mice, mice lacking the RET ligand GDNF, or its co-
receptor GFRα1, also display total intestinal aganglionosis66–69. GDNF acts as a 
chemoattractant to vagal ENCCs as they migrate along the developing gut70. In 
addition, GDNF is required for the proliferation and survival of ENCCs, induces 
neuronal differentiation, and is a chemoattractant for outgrowing neurites71–75. In 
humans, heterozygous mutations in GDNF have been found sporadically in isolated 
HSCR cases49,76,77.  
Of the remaining RET ligands, mutations in NRTN and PSPN have been 
identified in HSCR patients, but RET signaling by NRTN and PSPN is less critical for 
ENS development than signaling by GDNF78,79. NRTN is involved in neuronal 
differentiation of ENCCs, as mice lacking the NRTN co-receptor GFRα2 exhibit a 
reduced density of cholinergic projections and decreased intestinal motility80. 
Despite the indispensable role for the GFRα co-receptors in RET signaling, 
mutations in these genes have not yet been reported in HSCR patients, except for a 
GFRα1 deletion in a single patient81.  
 
Endothelin signaling pathway 
In addition to RET, signaling through the endothelin receptor type B (EDNRB) is 
also critical for the development of the ENS. EDNRB is a G protein-coupled 
receptor that is expressed by ENCCs and activated by its ligands endothelin (EDN) 
1-3 that are secreted by the gut mesenchyme. Mutations in the endothelin pathway 
account for ~5% of all HSCR cases55. Most of these mutations were found in 
EDNRB, but mutations in EDN3 have been reported as well82–87. In addition, a 
single mutation has been found in endothelin converting enzyme 1 (ECE1), an 
enzyme that processes endothelins in the gut mesenchyme before secretion into 
the lumen of the gut88. Mutations in EDNRB were first identified in a Mennonite 
population with a high prevalence of HSCR82. Both heterozygous and homozygous 
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ENDRB mutations occurred in this population. Several homozygous patients 
presented with additional symptoms, including deafness and hypopigmentation, a 
condition known as Shah-Waardenburg syndrome. The presence of heterozygous 
EDNRB mutations in isolated HSCR has later been confirmed83. Likewise, 
homozygous mutations in the ligand EDN3 cause Shah-Waardenburg syndrome, 
whereas heterozygous mutations in EDN3 lead to isolated HSCR86,87. 
Disruption of Ednrb, Edn3 or Ece1 in mice leads to aganglionosis and 
abnormal pigmentation, resembling the Shah-Waardenburg phenotype89–91. In the 
mouse gut, EDNRB signaling is required for the migration of ENCCs towards EDN3 
between developmental stage E10 and E12.592,93. Additionally, activation of 
EDNRB by EDN3 induces ENCCs to proliferate, maintains their precursor state and 
prevents premature differentiation74,94,95.  
 
Neuregulin signaling 
A genome-wide association study (GWAS) performed on HSCR patients revealed a 
strong association of SNPs in intron 1 of neuregulin 1 (NRG1) in a Chinese 
population96. Subsequent fine-mapping of the NRG1 locus showed that the four 
most highly associated SNPs map to the NRG1 promoter region and these variants 
reduce NRG1 expression levels in gut tissue97. The association between common 
variants in NRG1 and HSCR has been confirmed in independent Thai and 
Indonesian populations, but no significant association between NRG1 and HSCR 
was found in patients of European ancestry98–101. Sequencing analysis of the NRG1 
coding region revealed that, in addition to common variants, also rare, coding 
variants are found in HSCR patients. These were found in both Chinese and 
Spanish patient cohorts, implicating NRG1 in the development of HSCR not only in 
Asians, but also in Caucasians102,103.  
Following up on the initial GWAS performed on Chinese HSCR patients, 
these data were re-purposed to assess the role of copy number variants (CNVs) in 
HSCR. In this study, CNVs in NRG3, a paralog of NRG1, were found to be associated 
to HSCR104. Additional evidence implicating NRG3 in HSCR was obtained in an 
exome sequencing study on a Chinese HSCR family that identified NRG3 as the top 
candidate gene in this family105.  
Neuregulins are a family of proteins that are involved in synaptic plasticity 
in neurons and differentiation into glial cells106. The different neuregulins (NRG1-
4) have many splice variants that are either membrane bound or secreted. 
Secreted neuregulins bind to various different heterodimers of ErbB receptors 1-4. 
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1 The importance of Nrg-ErbB signaling in the murine ENS has been shown by 
conditional knockout of ErbB2 in Nestin-expressing cells. These mice displayed a 
loss of enteric neurons and glia and distension of the colon, reminiscent of HSCR107.  
 
Semaphorin class 3 signaling 
A GWAS study on HSCR patients of European ancestry detected an association to 
the semaphorin class 3 locus, that contains seven SEMA3 genes (SEMA3A through 
SEMA3G)101. These authors found that SEMA3A, SEMA3C and SEMA3D were 
expressed in the mouse ENS, and therefore performed targeted sequencing of 
these genes in HSCR cases. Damaging variants were found in SEMA3A, SEMA3C and 
SEMA3D and knockdown of sema3c and sema3d in zebrafish embryos resulted in 
HSCR-like phenotype. The strongest association within the semaphorin class 3 
locus maps in between SEMA3A and SEMA3D. This inspired a mutational screening 
of SEMA3A and SEMA3D that identified several coding variants in these two 
genes108.  
 
HSCR-associated transcription factors 
Mutations in transcription factors have mostly been implicated in the genetic 
etiology of syndromic forms of HSCR, such as Shah-Waardenburg syndrome, 
congenital central hypoventilation syndrome (CCHS), Mowat-Wilson syndrome 
and Pitt-Hopkins syndrome.  
Heterozygous mutations in SOX10 cause Shah-Waardenburg 
syndrome109,110. This is opposed to the Endothelin pathway in Shah-Waardenburg, 
where homozygous mutations are involved. SOX10 mutations were originally 
restricted to syndromic HSCR, however a single case was reported of a truncating 
mutation in a non-syndromic HSCR patient111. SOX10 is expressed by ENCCs as 
they invade the foregut and is critical for maintenance of their progenitor state112. 
SOX10 mutations are also found in another neurocristopathy, namely Kallmann 
syndrome113. 
CCHS is a rare respiratory disorder that is associated with HSCR and is 
primarily caused by mutations in PHOX2B114. CCHS results from loss of autonomic 
neurons that fail to develop in the absence of PHOX2B115.  
Mowat-Wilson syndrome, which is characterized by mental retardation, 
facial abnormalities, epilepsy and HSCR, is caused by mutations in ZFHX1B (official 
name ZEB2, sometimes referred to as SIP1)116,117. ZFHX1B is required for the 
formation of vagal neural crest cells118. 
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Pitt-Hopkins syndrome is a rare genetic disorder that is characterized by 
mental retardation, wide mouth and distinctive facial features, and intermittent 
hyperventilation followed by apnea. Pitt-Hopkins syndrome is caused by 
mutations in TCF4119,120. A single patient has been reported that, in addition to the 
characteristic features of Pitt-Hopkins syndrome, presented with HSCR121. 
As mentioned earlier, two SNPs in the promoter region of RET overlap 
with a binding site of the transcription factor NKX2-1. Sequence analysis of the 
coding regions of NKX2-1 identified one heterozygous mutation in the DNA binding 
domain of the gene56. Functional analysis showed that the mutant NKX2-1 caused a 
reduction in RET promoter activity, but only in combination with the predisposing 
SNPs in the RET promoter. In contrast to the other transcription factors involved in 
HSCR (SOX10, PHOX2B, ZFHX1B and TCF4), which are associated with syndromic 
forms of the disease, the NKX2-1mutation was found in a patient with non-
syndromic HSCR. However, NKX2-1 mutations are also associated with congenital 
hypothyroidism, a condition that can present in syndromic HSCR122,123.  
 
Other genes in HSCR 
Mutations in cell adhesion molecule L1CAM have been reported in patients 
suffering from the rare comorbidity of X-linked hydrocephalus and HSCR124–127. 
The phenotypic spectrum of L1CAM mutations is extensive however, and one case 
was reported of two siblings who presented with HSCR and a hypoplastic corpus 
callosum, but without hydrocephalus128. Another cell adhesion molecule, DSCAM, 
was found to be associated with HSCR through a chromosome 21 scan in Down 
syndrome patients with HSCR129. Although the gene was identified in patients with 
Down syndrome and HSCR, a replication study on non-syndromic HSCR patients 
confirmed the association between DSCAM and HSCR129. 
Homozygosity mapping in a family presenting with Goldberg-Shprintzen 
syndrome identified homozygous nonsense mutations in KBP (KIAA1279, official 
name KIF1BP) as a cause for this syndromic form of HSCR130. Recently, the role of 
KBP in Goldberg-Shprintzen syndrome was confirmed by two reports who found 
homozygous nonsense mutations and deletions in KBP, respectively131,132. KBP 
interacts with microtubule-associated proteins and is required for neuronal 
differentiation and neurite outgrowth133.  
Due to the multipotent character of ENCCs, a study was performed to 
determine the expression levels of stem cell-expressed genes in ENCCs from gut 
biopsies. The authors found a low expression level of DNMT3B in ENCCs isolated 
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1 from HSCR patients compared to control individuals. Subsequent genetic analysis 
of a large patient cohort found three potential damaging variants in DNMT3B134. 
DNMT3B regulates the expression of neural crest specifier genes and loss of 
DNMT3B prolongs the duration of neural crest production and emigration from 
the neural tube135,136.  
Through pathway-based epistasis analysis of GWAS data on Chinese 
patients, PTCH1 and DLL3 were identified as susceptibility genes for HSCR137. The 
association between PTCH1 and HSCR has later been confirmed in an independent 
patient cohort138. PTCH1 acts as a receptor in hedgehog signaling and DLL3 
encodes a ligand for Notch. Both hedgehog and Notch signaling are involved in 
gliogenesis, underlining the critical balance between neuronal and glial 
differentiation in ENS development. 
 
HSCR susceptibility regions 
Linkage analysis on HSCR families has been a widely adopted methodology to 
identify HSCR-associated loci and led to the identification of 10q11, the locus that 
contains RET44,45. A study by Bolk et al. showed that in fact the majority of HSCR 
families have linkage to the RET locus, although only half of these families carry 
coding RET variants139. Interestingly, this study identified 9q31 as a second 
susceptibility region exclusively in patients without coding RET variants. Fine 
mapping of the 9q31 locus in Dutch families detected association to SVEP1 in the 
absence of RET variants, but could not be replicated in Chinese samples. The 
Chinese population did show association to IKBKAP. However, in contrast to the 
linkage analysis by Bolk et al., this association was most significant in patients 
carrying coding RET variants140. Ikbkap is important for ENS development in 
zebrafish, as knockdown of the gene causes aganglionosis141. Several other loci 
have been found by linkage analysis and for some of these loci, no causal gene has 
yet been identified. In the Mennonite population where EDNRB was discovered, 
there was not only linkage to the EDNRB locus, but this study also found that the 
21q22 locus is a risk modifier of HSCR142. Other studies reported linkage to 3p21 
and 19q12 in addition to the RET locus143 and linkage to 16q23 in addition to the 
RET and EDNRB loci144. Finally, the 4q31-q32 locus was identified in a HSCR family 
that showed no linkage to any of the known HSCR genes, yet the 4q31-q32 locus 
was not sufficient to cause the disease145.  
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Interactions between HSCR pathways 
The genetics of HSCR are complex and genetic variants in the above-mentioned 
genes contribute to HSCR, but are not sufficient to cause the disease. It is a 
combination of predisposing factors that leads to the development of HSCR. For 
example, a HSCR patient was reported to have mutations in both RET and EDNRB, 
each inherited from a healthy parent146. Furthermore, the joint transmission of 
RET and EDNRB haplotypes was demonstrated in a Mennonite population82,144. 
These genetic interactions were corroborated by the functional interaction 
between Ret and Ednrb in mouse models of aganglionosis144,147,148. Association 
studies of RET and NRG1 in HSCR have shown that the combination of SNPs in 
these genes gives a higher disease risk than SNPs in RET or NRG1 alone98,99,149. The 
balance between RET and NRG signaling is important for ENS development, as it 
was shown that NRG1 inhibits GDNF-induced neuronal differentiation of ENCCs, 
while GDNF downregulates the expression of the NRG1 receptor ErbB2149. 
Epistasis between RET and SEMA3 was demonstrated and the risk of developing 
HSCR correlates with the number of risk alleles in these genes100. Indeed, 
knockdown of sema3c in zebrafish increases the extent of aganglionosis in 
conjunction with knockdown of ret101. In several congenital syndromes that are 
associated with HSCR, the predisposing RET allele in intron 1 is overrepresented in 




ENS DEVELOPMENT GENES NOT ASSOCIATED WITH HSCR 
 
As described here, a large number of genes have been associated with HSCR and 
these genes have functional roles in the development of the ENS. In addition to 
these HSCR-associated genes, many other genes play a role during ENS 
development and are therefore candidate HSCR genes. For example, loss of Indian 
hedgehog (Ihh) causes segmental aganglionosis in mice and loss of Sonic hedgehog 
(Shh) results in abnormal innervations in the gut151. Total colonic aganglionosis is 
observed in homozygous Pax3 mutant mice, or in Pax3/Tcof1 double 
heterozygotes152,153. Other mouse models of aganglionosis include Sall4 and β1-
integrin knockout mice that fail to colonize the distal bowel and Mash1 knockout 
mice display aganglionosis of the esophagus154–156. Furthermore, mice lacking Dcc 
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1 fail to develop submucosal ganglia and loss of TrkC, its ligand Nt3 or Hlx1 results in 
reduced numbers of enteric ganglia157,158.  
A forward genetic screen for loci affecting ENS development found 
partially penetrant aganglionosis in the ´TashT´ mouse line159. Interestingly, the 
penetrance of aganglionosis was higher in males than in females, strongly 
resembling the gender-bias that is observed in HSCR. The inserted transgene was 
mapped to a gene desert on chromosome 10 that physically interacts with the 
nearby gene Fam162b. Many X-linked genes were found to be downregulated in 
ENCCs from ‘TashT’ mouse embryos, and known HSCR genes were differentially 
expressed.  
It has been suggested that the sexual dimorphism in HSCR may result from 
expression of SRY, which is encoded on the male Y-chromosome. The transcription 
factor SOX10 positively regulates RET expression by binding to its promoter 
region. In contrast, SRY represses RET transcription and can competitively replace 
SOX10 on the RET promoter160. Since SRY is expressed exclusively in males, the 
gene could contribute to HSCR in males by reducing RET expression. 
The Notch, WNT, TGF-β and FGF signaling pathways are involved in the 
specification of numerous lineages during embryonic development, including the 
development of the ENS. Notch is required for maintaining the progenitor state of 
ENCC by regulating SOX10 expression and conditional inactivation of Notch 
signaling in neural crest cells results in premature neurogenesis161. Wnt signaling 
is involved in multiple aspects of ENS development. Non-canonical signaling by 
Wnt11 regulates the specification of the neural crest, proliferation of ENCC 
depends on Wnt1 and Wnt3a, and Wnt5 is required for axon guidance162–164. BMP 
proteins are part of the TGF-β superfamily and have been implicated in the 
development of the ENS. BMP2 and 4 are required for the migration of ENCCs 
along the gut and loss of BMP signaling causes hypoganglionosis165,166. Moreover, 
ENCCs fail to organize into ganglia in the absence of BMPs. FGF signaling is 
required for specification of the neural crest and FGF2 regulates proliferation of 
neural crest cells167,168. 
 
 
COMMON, RARE AND DE NOVO VARIANTS IN HSCR 
 
As summarized in Table 1, a large number of genes have been associated to HSCR. 
Most of these genes have been identified through linkage analysis in HSCR families, 
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the analysis of syndromic HSCR cases and by genetic studies in genetically isolated 
populations. These cases show a Mendelian mode of inheritance, either recessive 
or dominant with reduced penetrance. However, the majority of HSCR cases are 
sporadic and non-syndromic, and show a non-Mendelian mode of inheritance41. 
Consequently, only ~25% of the heritability in HSCR can currently be explained. 
Part of the missing heritability is likely due to genetic variation in yet unidentified 
HSCR genes. The introduction of GWAS has allowed the identification of 
predisposing variants in sporadic HSCR cases on a genome-wide scale and has 
implicated the neuregulin and semaphorin class 3 pathways in the etiology of 
HSCR96,101. In addition to the common variants associated with HSCR, targeted 
sequencing has revealed that rare variants contribute to sporadic HSCR as well.  
Next-generation sequencing (NGS) has revolutionized the genome-wide 
analysis of rare variants. However, it remains challenging to assess the 
contribution of rare variants to sporadic, non-Mendelian disease. Although rare 
variants with a relatively large effect size may be identified through exome 
sequencing, their allele frequency is usually too low for statistical significant 
associations. Moreover, the large number of genotyped base pairs in exome 
sequencing requires a large multiple-testing correction, further reducing statistical 
power. Thus far, exome sequencing studies in HSCR have focused on known and 
candidate disease genes or have been performed on familial HSCR cases105,169,170.  
When it comes to discovering pathogenic rare variants in sporadic disease, 
exome sequencing has been most successful for de novo mutations. De novo 
mutations are newly occurring genetic variants that are caused by errors in DNA 
replication or environmental factors. When de novo mutations occur in the 
germline they can be passed on to the next generation. Consequently, germline de 
novo mutations can be found in the somatic cells of a child, but not in somatic cells 
of its parents. De novo mutations are a major cause of syndromic HSCR, 
particularly in the HSCR-associated syndromes Waardenburg-Shah (de novo 
mutations in SOX10), congenital central hypoventilation syndrome (PHOX2B) and 
Mowat-Wilson syndrome (ZFHX1B)111,114,117. In sporadic HSCR, mutations in RET 
and EDNRB have been reported to occur de novo, mainly in patients with long-
segment HSCR48,49,171–173. Given its high heritability, it is conceivable that long-
segment HSCR can be caused by de novo mutations in other, not previously 
associated genes as well. Genome-wide screens for de novo mutations in 
neurodevelopmental disorders found that de novo mutations contribute to the 
genetic etiology of these disorders and have led to the identification of new disease 
 GENERAL INTRODUCTION 
 
27 
1 genes174. A genome-wide screen for de novo mutations in sporadic HSCR cases may 
therefore identify new genes for HSCR and help our understanding of HSCR 
genetics, which could have important implications for genetic counseling.  
 
 
DE NOVO MUTATIONS 
 
Patterns and rates of de novo mutations in the human genome 
The rate at which de novo mutations occur in the human genome is 1.20x10-8 per 
nucleotide per generation for single nucleotide variants (SNVs)175,176. This comes 
down to an average of 63.2 de novo SNVs in the human genome175. Measurements 
of de novo SNV rates in the exome (the coding regions of the genome) are slightly 
higher, with observed rates of 1.31-2.17x10-8 (176). This difference may be partly 
explained by the high GC content of the exome and by transcription-induced 
mutagenesis177. The de novo mutation rates of small insertions and deletions and 
large copy number variations (CNVs) are orders of magnitude lower178,179. 
However, due to their large size, the total number of base pairs affected by de novo 
CNVs exceeds the number of de novo SNVs. De novo mutations are not randomly 
distributed over paternally and maternally inherited chromosomes. In fact, 75% of 
de novo SNVs are located on a chromosome that is inherited from the 
father175,176,180. Moreover, the number of germline de novo mutations increases 
with the father’s age. For every added year to the father’s age at time of conception, 
the child will have 2 additional de novo mutations175,180. The age of the mother at 
time of conception does not affect the number of de novo mutations in the 
offspring. The high number of cell divisions during male spermatogenesis can 
explain the gender and age bias, which continues to increase with age.  
The Genome of the Netherlands (GoNL) consortium has analyzed the 
patterns of de novo mutations in 250 Dutch parent-offspring trios in great detail181. 
The GoNL study found that the genomic position of de novo mutations is not 
random and depends on the father’s age. De novo mutations in offspring from 
young fathers reside in late-replicating genomic regions. With increasing paternal 
age, de novo mutations are more likely to be found in early-replicating loci181. In 
addition, de novo mutations in offspring from older fathers are more often located 
in the proximity of genes, suggesting that older fathers not only transmit a higher 
number of de novo mutations, but their de novo mutations are also more likely to 
have a functional impact181. In line with other reports, the GoNL study found 
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clusters of 2-3 de novo mutations within 20 kb182,183. Interestingly, the clustered de 
novo mutations contained few C>T substitutions in CpG islands and many C>G 
substitutions compared to non-clustered de novo mutations181. This finding 
suggests that the clustered de novo mutations arise by a different mechanism than 
non-clustered de novo mutations. 
 
De novo mutations in human disease 
The introduction of new genetic variation by de novo mutations is a requirement 
for evolution. However, only a fraction of all de novo mutations will be 
advantageous for an individual. In fact, de novo mutations are an important cause 
of human diseases174. Somatic de novo mutations are involved in cancer and many 
genetic diseases are caused by germline de novo mutations. Rare developmental 
disorders are generally caused by de novo mutations in a single gene. These include 
CHARGE syndrome (mutations in CHD7), Schinzel-Giedion syndrome (SETBP1), 
Kabuki syndrome (MLL2), Bohring-Opitz syndrome (ASXL1) and KBG syndrome 
(ANKRD11)184–188. Besides rare developmental disorders, de novo mutations can 
also contribute to more common genetic diseases. De novo CNVs have been 
identified in a wide range of neuropsychiatric disorders and the frequency of CNVs 
in these patients is far higher than in the general population189. Targeted 
sequencing of known disease genes for autism spectrum disorders (ASD), 
schizophrenia and intellectual disability (ID) showed that de novo SNVs in multiple, 
different genes play a role in these diseases190,191.  
The introduction of NGS has allowed the genome-wide study of de novo 
SNVs. In reality, researchers often limit their study to the exome, because exome 
sequencing is less expensive than whole genome sequencing and non-coding 
variants remain difficult to annotate and interpret. Four large exome sequencing 
studies on ASD found de novo SNVs in many interconnected genes that act together 
in neuronal development192–195. The fraction of de novo mutations that was 
deleterious was higher in ASD patients than in their unaffected siblings192,195. An 
excess of nonsynonymous de novo SNVs was also reported in schizophrenia196. 
Another exome sequencing study on schizophrenia reported an increased de novo 
mutation rate in patients197. However, it must be noted here that the de novo 
mutation rate in schizophrenic patients was not compared to unaffected controls, 
but to publically available whole-genome sequencing data. Since mutation rates 
from exome sequencing data are higher than those from whole-genome 
sequencing data176, it is unclear whether the increased de novo mutation rate is 
 GENERAL INTRODUCTION 
 
29 
1 attributable to the phenotype or the sequencing technology. A whole genome 
sequencing study on patients with ID found de novo SNVs and CNVs in known ID 
genes in 20 out of 50 patients198. Combined with other technologies, these authors 
reported de novo events in ID genes in 60% of their patient cohort. The largest de 
novo mutation screen by exome sequencing was performed on 1,213 patients with 
congenital heart disease (CHD)199. The de novo SNV rate in these patients was not 
different from controls, but patients carried significantly more damaging de novo 
mutations. The enrichment for damaging mutations was even more pronounced in 
patients that were diagnosed with neurodevelopmental disability or other 
congenital anomalies in addition to CHD. In line with the phenotypes, heart- and 
brain-expressed genes carried an excess of damaging de novo mutations.  
In general, patients with ASD, schizophrenia or CHD with neuro-
developmental involvement are enriched for deleterious de novo mutations, but do 
not show an increase in the total number of de novo mutations192,195,196,199. 
Nevertheless, offspring from older fathers are at increased risk of developing 
psychiatric disorders, including autism, attention-deficit/hyperactivity disorder 
(ADHD) and bipolar disorder200. This finding suggests that psychiatric patients 
carry increased numbers of de novo mutations, a hypothesis that thus far has not 
been confirmed by exome sequencing studies.  
Owing to its time- and cost-efficiency, NGS has made its way into clinical 
genetic diagnostics. A report has been published on 250 patients with suspected 
genetic disorders with Mendelian inheritance, who had been subjected to exome 
sequencing. A molecular diagnosis could be made for 25% of the cases. This study 
found that 83% of autosomal dominant mutations and 40% of X-linked mutations 




AIMS AND OUTLINE OF THIS THESIS 
 
The aim of the work described in this thesis is to assess the contribution of rare 
variants to the development of HSCR. The advent of NGS has allowed the genome-
wide identification of rare variants, including de novo mutations. The role of de 
novo mutations in long-segment HSCR is described in chapter 2. Since genes 
carrying de novo mutations were not linked to ENS development based on 
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bioinformatics prediction, we tested the functional contribution of these genes to 
ENS development in a zebrafish model. 
The interpretation and selection of candidate genes in HSCR relies on our 
understanding of the biological processes underlying ENS development. To better 
understand these processes, we analyzed the gene expression profiles of enteric 
neural crest cells and the long-term effect of RET signaling in these cells. As 
described in chapter 3, predicted regulatory genes in ENS development included 
known HSCR genes and provided novel candidate genes for HSCR.  
Although NGS offers new possibilities in the genetic dissection of HSCR 
and other genetic disorders and traits, the application of the technology remains 
challenging. The identification of de novo mutations in exome sequencing data is 
best described as looking for a needle in a haystack, since the number of technical 
artefacts in NGS data is orders of magnitude larger than the true number of de novo 
mutations. Chapter 4 describes how sequencing quality parameters can be applied 
to discriminate de novo mutations from false positives and allow their efficient 
detection.  
In addition to de novo mutations, the exome contains many rare, inherited 
variants. Association studies for rare variants generally suffer from a lack of 
statistical power. In chapter 5 we describe how a combination of strategies can be 
applied to approach this problem and to extract useful data from such studies.  
The incidence of HSCR is over a hundred times higher in Down syndrome 
patients than in the general population, suggesting that the trisomy of one or more 
genes on chromosome 21 predisposes to HSCR. We overexpressed genes from 
chromosome 21 in a transgenic zebrafish model to identify chromosome 21 genes 
linking HSCR to Down syndrome, as described in chapter 6. 
Finally, chapter 7 summarizes and discusses the work presented in this 
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Hirschsprung disease (HSCR), the most common form of congenital bowel 
obstruction, results from a failure of enteric nervous system (ENS) progenitors to 
migrate, proliferate, differentiate or survive to and within the gastrointestinal 
tract, resulting in aganglionosis in the distal colon. The HSCR genes identified to 
date are known to be involved in ENS development. Therefore, the search for genes 
solving the missing heritability in HSCR has focused on ENS-related pathways. A de 
novo mutation (DNM) screening in 24 HSCR patients revealed 20 DNMs in 20 genes 
besides 8 DNMs in the known HSCR gene RET. Knockdown of genes carrying 
missense and loss of function DNMs identified 4 genes indispensable for ENS 
development in zebrafish. Moreover, these 4 genes, which are expressed in the gut 
or ENS progenitors, are also involved in central nervous system (CNS) 
development. These newly identified HSCR genes indicate that CNS-associated 
genes also play a major role in ENS development. 
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Hirschsprung disease (HSCR) is the most common form of congenital obstruction 
of the bowel, with an incidence of ~1 per 5,000 live births. However, the incidence 
varies significantly between ethnic groups with the highest incidence reported in 
the Asian population, with 2.8 per 10,000 live births1,2. HSCR results from a failure 
of the neural crest cells, that give rise to the enteric nervous system (ENS), to 
migrate, proliferate, differentiate or survive in the bowel wall, resulting in 
aganglionosis of the distal part of the gastrointestinal tract. This results in clinically 
severe and sometimes life-threatening bowel obstruction. As HSCR is a highly 
heritable disorder, genetic variation (mutations) in the genomes of these patients 
must largely explain disease development. The mode of inheritance of HSCR can be 
recessive mostly in syndromic cases, or dominant with incomplete penetrance in 
non-syndromic HSCR families, to oligogenic/polygenic in sporadic cases3. So far 
>15 HSCR susceptibility genes have been found as are 6 linkage regions1 and three 
associated loci2,4. The genes identified belong to a limited number of pathways, 
which have been shown to be relevant to the development of the ENS, of which the 
RET pathway and the endothelin pathway are the most important ones. However, 
the identified genes and variants in these genes explain no more than 25% of the 
overall genetic risk2,4. Thus, the vast majority of cases cannot yet be explained by 
the identified HSCR-associated variants. These findings indicate that the majority 
of the disease risk must be due to as yet unidentified rare or common variants in 
the known HSCR genes or, more likely, variants in yet unknown genes, acting alone 
or in combination.  
Exome sequencing followed by selection of genes that can be functionally 
linked to the pathways already known to be involved in the disease is the current 
approach in the field of human genetics. Variants in genes totally unlinked to the 
known genes or pathways are largely neglected. This study aimed to determine the 
contribution of rare exonic, non-synonymous de novo mutations (DNMs) to HSCR 
without any a priori selection. Therefore, not only did we perform ‘standard’ 
exome sequencing analyses, followed by burden tests and in silico prediction, but 











A total of 24 trios (affected child and unaffected parents) without family history of 
HSCR recruited in 5 different centers were included for Whole Exome Sequencing 
(WES). The patients were all non-syndromic. Five trios were of Chinese origin 
whereas 19 were of Caucasian ancestry. We prioritized the most/more severe and 
rarer HSCR cases for this study, namely female patients with long segment or total 
colonic aganglionosis. Sixteen out of the 24 patients had previously tested negative 
for RET damaging variants by traditional technologies. Characteristics of the 
patients are presented in Supplementary Table 1. Informed consent was obtained 
from all participants.  
 
Case-control 
WES data from 28 additional sporadic HSCR patients without sub-phenotype 
limitation (singletons) and 212 controls were used to check gene recurrence and 
assess the gene burden for rare variants (Supplementary Table 1).  
 
Data generation 
Whole exome sequencing 
DNA samples were sequenced in four centers. The exome-capture kit and sequence 
platforms used per center are detailed in Supplementary Table 2. Appropriate 
mapping tools (Burrows-Wheeler aligner–BWA- for Illumina data and Bfast for 
Solid data) were used to align sequence reads to the human reference genome 
(build 19)5. Sequence quality was re-evaluated using the FastQC toolbox, Picard’s 
metric summary and the GATK Depth-of-Coverage module. After initial quality 
control (QC) all eligible sequences were pre-processed for local indel realignment, 
PCR duplicate removal and base quality recalibration6. 
 
Genome-wide SNP array 
To determine copy number variants (CNVs) and regions of homozygosity, DNA was 
hybridized to the HumanCyto SNP12 BeadChip (Illumina, San Diego, CA, USA) 
according to standard protocols. 




Variant calling and prioritization 
Aligned reads from all sequenced samples were pre-processed according to 
standard guidelines6. Variant calling was done independently for Illumina reads or 
Solid reads using the Genome Analysis Toolkit (GATK) unified Genotyper 2.07. To 
avoid mismatched regions across different capture kits, calling was performed on 
whole genome wide without limiting on any capture array. Special setting (allow 
potentially miscoded quality scores) was used to make color-spaced solid reads 
compatible to the program (Broad institute). Raw variants (including single 
nucleotide variants and short insertions/deletions) with individual genotypes and 
their affiliated quality scores were stored in a standard VCF format after calling. 
Quality assessment (QA) and QC were then adopted on a few set of variants (raw 
variants, exonic variants, rare variants) to generate a confident variant set for 
downstream prioritization (Supplementary Note). 
Clean variant set at exonic regions was produced after variant-level and 
genotype-level quality control. Rare coding sequence variants were then 
prioritized by filtering out those variants with minor allele frequency >0.01 in any 
of these public databases (dbSNP137, 1000 Human Genome project and NHLBI 
Exome Sequencing project). An automatic pipeline integrating GATK, KGGSeq, 
Annovar and Plink was used to generate final set of qualified variants 
(Supplementary Figure 1). 
 
Identification of DNM  
WES DNM detection 
Rare, exonic variants present in the probands but absent in both parents were 
considered DNM. To select putative DNM (or de novo variations) the following 
criteria were used: 1) minimal coverage of 5 in patients and parents; 2) a minimal 
genotype quality score of 10 for both patients and parents; 3) at least 10% of the 
reads showed the alternative allele in patients; and 4) not more than 10% of the 
reads showed the alternative allele in parents. Subsequently all remaining DNM 
variants were manually inspected using the Integrated Genome Viewer (IGV) and 
classified into 5 different confidence ranks according to their base-calling quality 
and strand bias. The first two ranks of DNM candidates were selected for 
validation by Sanger sequencing; while the other three classes of candidates were 
re-evaluated by a model trained from variants submitted for Sanger sequencing 
(Supplementary Note). 
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RET gene inspection 
To guarantee that no de novo mutations had been missed in the major HSCR gene, 
the depth of coverage of each of the 21 exons of RET was manually inspected for 
each patient. All exons with a coverage <10 were Sanger sequenced. Mutation 
Detector software (Thermo Fisher Scientific) was used to identify rare coding 
sequencing mutations from raw Sanger sequences; any mutation found in trio 
proband was further checked in his/her parents. Besides rare mutations, bi-allelic 
genotypes for the common risk single nucleotide polymorphisms (IVS1+9494, 
rs2435357T) were extracted from local databases or newly genotyped.  
 
Copy number variation detection 
The Nexus®software program (Biodiscovery, El Segundo, CA, USA) was used to 
normalize and analyse the SNP array data as mentioned above. Loss is defined as 
the loss of a minimum of 5 probes in a 150kb region, with a minimum Log R ratio – 
0.2. Gain is defined as the gain of a minimum of 7 probes in 200kb region, with 
minimum Log R ratio 0.15. The minimum length of regions of homozygosity 
analysed was 2Mb. The identified CNVs were reviewed for pathogenicity using the 
genome browser UCSC (http://genome.ucsc.edu), the DGV database (http:// 
dgv.tcag.ca/dgv/app/home), the Decipher database (https://decipher.sanger. 
ac.uk/) and our in-house local reference data base that consists of 250 healthy 
controls and 250 individuals of the general population.  
 
Statistical tests  
De novo mutation rate 
All proven DNMs were classified into loss-of-function (nonsense Single Nucleotide 
Variants (SNVs), frame-shift indels and splicing sites), missense SNVs, in-frame 
indels and synonymous SNVs. The counts of DNM per trio were fitted to Poisson 
distribution with lamda as observed mean. De novo mutation rates were calculated 
for these DNM subtypes and compared to 677 published healthy trios and 
neurodevelopmental disease trios using a binomial test8–13. Given per-gene 
mutation rate in Samocha et al. paper14, statistical over-representation of 
mutations in all 24 genes were calculated using Fisher’s exact test. 
 
Gene-wide burden analysis 
Genes with DNM were further scrutinized for the presence of inherited rare 
damaging variants in the trios as well as in HSCR singletons for whom WES data 




were available. A detailed analytical protocol was shared before running 
association in each centre. Briefly, genotypes of rare damaging variants (as 
previously defined) in genes carrying ≥1 de novo mutation were extracted from 
raw sequencing reads. CMC test in Rvtest package was used to collapse multiple 
variants into the same gene (boundary defined using hg19 refgene) and compare 
overall burden between cases and local matched controls15. P-values were 
estimated by asymptotic chi-square distribution. Gene-wise p-value, burden 
direction and variant count per gene were exported. Ultimately sample-size 
weighted Z-score method was used to conduct meta-analysis on gene-wise 




The impact of each DNM to its carrying gene was predicted using several of 
bioinformatics tools or databases. The conservation of missense SNVs was 
predicted using GERP and PhyloP across 29 different species. The deleteriousness 
of missense or nonsense SNVs were determined by a logit model incorporating 5 
prediction programs (Polyphen2, Sift, MutationTaster, PhyloP and Likelihood 
ratio)16. Human Splicing finder was used to predict whether DNMs causing 
synonymous change or locating at splicing sites (exon +/- 2bp) created or 
disrupted splice sites17. To further implicate the possible role of synonymous 
DNMs on transcription, RNAmute was used to predicted the RNA substructure 
change due to corresponding site mutation18. Finally, ClinVar and PubMed were 
searched for the same or similar mutations in the same gene that present in 
healthy controls or other disease patients. 
 
Gene-level implication 
The evidence of gene-level implication was collected from two aspects. On one 
side, those 24 genes carrying DNMs were searched against databases (ATGU’s 
Server) for other disease patients or healthy samples14. On the other side, ENS 
candidate genes/gene-sets (Supplementary Table 8; Supplementary Note) were 
linked to newly identified genes using pathway or PPI network information. 
Disease Association Protein-Protein Link Evaluator (DAPPLE) was used to test 
whether the genes carrying DNM in our study are functionally connected to each 
other. The significance of observed pathway enrichment and network connectivity 
was evaluated empirically using randomly selected genes, genes having the same 
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genomic size as the identified DNM genes. InWeb and Ingenuity Pathway Analysis 
were used to detect direct and indirect protein interactions between ENS-related 
genes and genes with DNMs. 
 
Gene expression in ENS 
In order to test the involvement of the newly identified genes in enteric nervous 
system development, in house expression data was shared from other in-parallel 
projects in Hong Kong, Rotterdam centre. The first expression dataset was from 
RNA sequencing on an iPSC-induced enteric neural crest cell (ENCC) for a HSCR 
patient; the second and third expression dataset was from microarray chips on 
embryonic mouse gut and ENCC. 
 
Zebrafish 
Tg(-8.3bphox2b:Kaede) transgenic zebrafish (Danio rerio) embryos were obtained 
from natural spawning. Maintenance of zebrafish and culture of embryos were 
carried out as described previously. Embryos were staged by days post-
fertilization (dpf) at 28.5°C. 
 
Gene knockdown by antisense morpholino 
Antisense morpholinos (MO) (Gene Tools LLC) targeting the zebrafish orthologues 
of the candidate genes, by blocking either translation or splicing, were 
microinjected to 1 to 4-cell stage Tg(-8.3bphox2b:Kaede) transgenic zebrafish 
embryos as previously described19. For candidate genes that are duplicated in the 
zebrafish genome, morpholinos targeting all paralogs were co-injected. Standard 
control morpholino and 5-nucleotide mismatch control morpholino for ckap2l, 
dennd3a, dennd3b, ncl1, nup98 and tbata were used as negative control. Embryos 
were raised to 5 dpf, analysed and imaged under a stereo fluorescence microscope 
(Leica MZ16FA and DFC300FX). An HSCR-like phenotype was defined as the 
absence of enteric neurons in the distal intestine in 5 dpf embryos. Sequences and 
dosages of all morpholinos used are listed in Supplementary table 9. 
 
Expression analysis 
To confirm the target gene were successfully knockdown, total RNA were 
extracted from 1 dpf embryos (n=50) injected with the splice blocking morpholino 
using RNA Bee (Amsbio) and cDNA were reverse transcribed using iScript cDNA 
Synthesis Kit (Bio-rad). qPCR was performed using KAPA Sybr® Fast qPCR Kit 




(KAPA Biosystems; see Supplemantary Table 10 for primer details) and the 
expression of the target gene was normalized by the mean expression of two 
housekeeping genes (elfa and actb). Relative expression of the target gene in the 
splice blocking morpholino-injected embryos to the control morpholino-injected 
embryos was determined by Livak method20.  
To determine the temporal expression of the zebrafish orthologues, RT-
PCR was performed at various time points with primers used to amplify up a 
segment of the open reading frame of each gene. To determine the spatial 
expression patterns of dennd3a, dennd3b, ncl1, nup98 and tbata, antisense 
Digoxigenin-labeled probes for both genes were generated and whole-mount in 





Identification of de novo mutations  
We performed whole-exome sequencing (WES) on 24 trios composed of a sporadic 
non-syndromic HSCR patient and the unaffected parents (72 individuals; 
Supplementary Table 1) and focused on de novo variants. Sporadic female cases 
with a long segment (LS) HSCR were overrepresented as the load of de novo rare 
coding variant is presumed to be the highest in this group. The depth coverage of 
the targeted sequences ranged from 18X to 74X (average 46X), and the targeted 
exome covered by at least 10 sequence reads ranged from 65% to 98% (average 
88%). Sequencing metrics after standard analytical pipeline (Supplementary 
Figure 1) were in normal ranges (Supplementary Note; see Supplementary Table 2 
and Supplementary Figure 2 for detail). 
All de novo variations were carefully selected, validated and/or 
statistically predicted (Methods and Supplementary Note; see prediction result in 
Supplementary Table 3). After Sanger sequencing validation, a total of 28 DNMs in 
14 patients were identified (Table 1). The overall DNM rate per individual was 1.2 
per exome per generation (Poisson distribution with λ=1.2; Kolmogorov-Smirnov 
test, p=0.893; Supplementary Figure 3) which is in accordance with the expected 
mutation rate in the general population. Several studies have shown that the DNM 
rates are similar between patients and healthy controls, but found that patients 
have a significantly higher fraction of loss of function (LOF) DNMs8,9. Indeed, in our 
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1 L, F RET 3splicing9+1 splicing - N / N 
    RBM25 c.474C>T: p.L158L synonymous - N / N 
2 L, F RET 
c.2511_2519delCCCTGG
ACC:p.S837fs 
frameshift - N / N 




3 L, F RET 
c.1818_1819insGGCAC: 
p.Y606fs 
frameshift - N / N 
4 L, F DAB2IP c.2339C>T:p.T780M
#
 missense No N / N 
  
ISG20L2 c.961G>A:p.G321R missense Yes N / N 
  




 nonsense - N / N 
  
NUP98 c.5207A>G:p.N1736S missense Yes N / N 
  
VEZF1 c.584C>T:p.S195F missense Yes N / N 
    ZNF57 c.570C>T:p.D190D synonymous - N / N 
5 L, F RET c.1761delG :p.G588fs frameshift - N / N 
    SCUBE3 c.1493A>T:p.N498I missense No N / N 
6 L, M AFF3 c.1975G>C:p.V659L missense No N / N 
    PLEKHG5 c.2628G>T:p.T876T synonymous - N / N 
7 L, M KDM4A c.26A>G:p.N9S missense No N / N 
8 L, M MAP4 c.3351C>T:p.G1117G synonymous - N / N 
9 L, F RET c.1858T>C:p.C620R missense Yes 
0 (rs77316810) 
/ N 
10 TCA, M CKAP2L 
c.555_556delAA: 
p.E186fs 
frameshift - N / 0.00002 
11 L, F RET c.409T>G:p.C137G missense Yes N / N 
  
HMCN1 c.10366G>A:p.A3456T missense No N / N 
    TUBG1 c.699T>C:p.S233S synonymous - N / N 
12 L, F CCR2 c.848T>A:p.L283Q missense Yes N / N 
    DENND3 c.1921delT:p.K640fs frameshift - N / N 
13 L, F RET c.1710C>A:p.C570X nonsense - N / N 
14 L, F RET 
c.526_528delGCA: 
p.R175del 
non-frameshift - N / N 
    TBATA c.157C>T:p.R53C missense No N / N 
F: Female; M: Male; L: Long-segment HSCR; TCA: Total Colonic Aganglionosis; *: Disease-causal 
prediction by KGGSeq57, a software that uses a weighted logistic regression to combine multiple 
prediction scores; #mosaic mutation; Dark grey: de novo RET mutations; Light grey: genes giving a 
HSCR-like phenotype in zebrafish; %: minor allele frequency in dbSNP137 or ESP database, with ‘N’ 
standing for no data available.  
 




HSCR patient cohort, the rate of loss of function DNMs (LOF; N=8, including 
nonsense, frameshift and splice site changes) is significantly higher than that of 
healthy trios (p=0.011) or unaffected siblings of neuropsychiatric patients 
(p=0.001) from multiple published studies8,10–12,22 (Supplementary Table 4). The 
28 DNMs were localised in 21 genes. 8 DNMs were found in RET, the major HSCR 
gene23. Among the DNMs in RET was the Cys620Arg variant, known to cause both 
HSCR and Multiple Endocrine Neoplasia type 2A24. In this study, the observed rate 
for RET DNMs (0.33 per trio) was significantly higher (binomial test, p<2*10-16) 
than that modelled for RET DNMs in the general population (0.000133 per trio) 
according to Samocha et al.14. 
One of the patients analysed carried a total of 7 DNMs, two of which (in 
NCLN and DAB2IP) were mosaic mutations (Supplementary Figure 4). This finding 
is in line with a recent report stating that 6.5% of all DNMs are in fact mosaic and 
occur post-zygotic25. Within the 24 patients we looked for inherited rare damaging 
variants in the 21 genes that carried DNMs (Supplementary Note, Methods). 
Inherited damaging mutations were found in RET, HMCN1, PLEKHG5, MAP4, 
SCUBE3, and KDM4A (Supplementary Table 5). Neither de novo nor inherited copy 
number variants (CNVs) were detected in any of the trios. 
 
Mutation profile of HSCR patients 
In general, disease-associated common variants confer a liability to disease to the 
individuals of the general population. These common variants, in combination with 
environmental and/or rare variants finally result in manifestation of the disease. 
Thus, since both rare and common variants jointly contribute to HSCR we carefully 
examined the genetic profile of our patients to assess the genetic background on 
which the DNMs reside. Each patient was investigated for the presence or absence 
of the common HSCR-associated RET allele (IVS1+9494, rs2435357T)26–29 as well 
as for the presence of rare variants (inherited from unaffected parents) in a set of 
116 pre-selected genes known to be involved in ENS development (Supplementary 
Notes; Supplementary Tables 3 and 6). 
The mutation profile for all patients is shown in Supplementary Table 5. 
We observe that 29% of the patients with ≥ 1 DNM and 60% of the patients 
without any DNM carry the common RET risk genotype TT (rs2435357T). 
Moreover, patients with DNM carry on average 1.4 inherited rare damaging 
variants in ENS genes, compared to an average of 2.4 in patients without any 
DNM. Notably, six out of the 14 patients carried DNMs without co-occurrence of 
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a RET coding sequence mutation. Although the differences are not statistically 
significant, these observations suggest that the new genes identified may, 
independently of the genetic background, play a role in the pathology of the 
disorder, and prompted us to further investigate those genes using in silico and in 
vivo approaches. 
 
Determining pathogenicity of the DNMs in silico 
The recurrence of a mutation or the identification of a recurrently mutated gene in 
an independent group of patients or unrelated controls can provide corroborating 
evidence of pathogenicity or neutrality30. Therefore, all the genes in which we 
identified DNMs were checked against public databases (ATGU’s Gene-Mutation-
Constraint Server) for DNM recurrence. Only one missense DNM (different from 
that identified in this study) in MAP4 was found in a patient with autism spectrum 
disorder (ASD). A few genes (SCUBE3, RBM25 and TUBG1; Table 2) were identified 
evolutionary constrained genes in which functional variants are more likely to be 
deleterious14.  
To establish whether genes with DNMs carry significantly more rare 
variants in HSCR patients than in controls, we used the WES data from the 20 
eligible HSCR trio-probands, 28 additional HSCR patients and 212 control 
individuals to calculate the variation burden per gene (Methods). Nine of the 
twenty-one genes (RET, KDM4A, HMCN1, MAP4, NUP98, AFF3, COL6A3, CCR2, and 
CKAP2L) were found recurrently mutated in multiple HSCR patients with different 
rare damaging mutation sites (Supplementary Table 7). Meta-analysis of our gene 
burden tests showed that RET and CKAP2L were enriched for rare damaging 
variants in the HSCR patients (nominal p<0.05; Table 2 and Supplementary Table 
7). However, cross-checking of these 21 genes in another in-parallel HSCR exome 
study (190 cases and 740 controls) revealed only RET was significantly 
overrepresented with deleterious variants (p < 0.001; manuscript in preparation, 
A. Chakravarti). 
The possible impact of DNMs on gene function was explored using 
bioinformatic prediction tools (Methods). Besides the 8 LOF mutations, 6 out of 
twelve missense mutations were consistently predicted deleterious (Table 1). As 
for the seven synonymous DNMs, we found no in silico evidence indicating that 
those changes interfered with splicing and/or significantly changed the RNA 
structure (Supplementary Table 8).  




We next checked whether the genes with DNMs are functionally related to 
each other and/or to the signalling networks known to govern ENS development. 
ISG20L2 and MAP4 showed more indirect interactions with other genes carrying 
DNMs than expected by chance (p=0.0063 and p=0.0167 respectively) as predicted 
by DAPPLE, though no direct in silico interactions were found among those 21 
genes. A list of 116 known ENS related genes (Supplementary Table 6) was used to 
study the functional link between genes with DNMs (other than RET) and the ENS. 
Only a single interaction was identified in the InWeb protein interaction catalogue 
(COL6A3 interacts with ITGB1). Using Ingenuity Pathway Analysis, we identified 
additional direct and indirect relationships with ENS-related genes for MAP4, 
COL6A3, RBM25 and TUBG1 (Supplementary Figure 5). All genes carrying DNMs 
were either expressed in human iPSC-derived enteric neuron precursors or in 
primary murine enteric neuron precursors (Table 2). 
 


















PLEKHG5 1062 No 0.3997 NT Yes; Yes; - 
KDM4A 1064 No 0.1190 No Yes; Yes;- 
ISG20L2 353 No 0.4949 No Yes; Yes; - 
HMCN1 5635 Yes 0.9789 No Yes; Yes; - 
AFF3 1226 No 0.4745 No Yes; Yes; - 
CKAP2L 745 No 0.0178 No Yes; Yes: - 
COL6A3 3177 Yes 0.6398 NT Yes; Yes; - 
CCR2 374 No 0.4745 No Yes; Yes; - 
MAP4 1152 No 0.4851 NT Yes; No; - 
SCUBE3* 993 Yes 0.7133 No Yes; Yes;- 
DENND3 1198 No 0.5977 Yes Yes; Yes; Yes 
DAB2IP 1189 No 0.9819 No Yes; Yes; - 
RET 1114 - 0.0078 Yes Yes; Yes; - 
TBATA 351 Yes 0.8028 Yes No; Yes; Yes 
NUP98 1817 No 0.7243 Yes Yes; Yes; Yes 
RBM25* 843 Yes 0.0846 NT Yes; Yes; - 
TUBG1* 451 Yes 1.0000 NT Yes; Yes; - 
VEZF1 521 No 0.6717 No Yes; Yes; - 
ZNF57 555 No 0.3808 NT Yes; No: - 
NCLN 563 No 1.0000 Yes Yes; Yes; Yes 
MED26 600 No 1.0000 NT Yes; Yes; - 
*genes evolutionary constrained as per Samocha et al. 2014; NT: not tested (gene carries synonymous 
mutation and/or has no orthologue in zebrafish); #data from in-house hIPSC-derived neural crest, 
mouse expression data, and RT-PCR in zebrafish (test only for 4 novel genes). 
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Determining pathogenicity of the DNMs in vivo 
As no proof of functional effects for any of the synonymous DNMs was found, we 
further focused on the 13 genes (other than RET) that have a LOF or missense 
mutation. Because none of these 13 genes were obvious candidates for HSCR we 
used the zebrafish model system to further investigate the function of these genes 
in ENS development. Previous studies have shown that morpholino-mediated 
knockdown of orthologues of known HSCR genes results in an HSCR-like 
phenotype in zebrafish4,31–35. Except CCR2, all 13 genes with nonsynonymous 
DNMs have zebrafish orthologues. Splice-blocking morpholinos (SBMOs) were 
designed to knock down the orthologues for these 12 genes (Methods). The SBMOs 
were injected into Tg(-8.3bphox2b:Kaede) transgenic zebrafish19 embryos that 
express the fluorescent protein Kaede in enteric neuron precursors and 
differentiated enteric neurons. Initially, knockdown of 5 orthologues (ckap2l, 
dennd3a and dennd3b, ncl1, nup98 and tbata) resulted in a HSCR-like phenotype as 
enteric neuron were absent in the distal intestine of 5 dpf embryos, while embryos 
injected with 5-nucleotide mismatch control morpholinos had normal ENS 
development with enteric neurons present along the entire length of intestine. We 
then co-injected the SBMOs with p53 morpholinos to verify the phenotype did not 
result from non-specific, p53-induced apoptosis. Co-injection of p53 morpholino 
with dennd3a and dennd3b, ncl1, nup98 or tbata SBMOs resulted in the same 
phenotype (Figure 1), indicating the phenotype was not caused by non-specific 
apoptosis. On the contrary, the phenotype could not be reproduced in ckap2l SBMO 
and p53 morpholino co-injection (Figure 1). To further demonstrate the absence of 
enteric neuron was specific to the knockdown of the orthologues, we repeated the 
experiment by injecting translation-blocking morpholinos (TBMOs) against 
dennd3a, dennd3b, ncl1, nup98 and tbata and the phenotype was reproduced (data 
not shown). Therefore we concluded that knockdown of the DENND3, NCLN, 
NUP98 and TBATA orthologues disrupted ENS development and caused a HSCR-
like phenotype in vivo. 
To confirm the SBMOs knockdown effect, qPCR was performed to compare 
the expression of the target genes between SBMO-injected and control 
morpholino-injected embryos. Expression of dennd3a, dennd3b, nup98 and tbata 
was markedly reduced in the SBMO-injected embryos (Supplementary Figure 6). 
Intriguingly, there was no significant reduction in ncl1 expression in the ncl1 SBMO 
injected embryos. 




Therefore we further investigated it by performing RT-PCR on individual 
embryos and found that there was a large variation in ncl1 expression between 
embryos injected with the SBMO, with some of them showing a clear reduction in 
ncl1 transcript level (Supplementary Figure 7). Of the zebrafish orthologues that 
did not show a specific HSCR-like phenotype after SBMOs injection, all 
demonstrated significant reductions in expressions except for aff3, scube3 and 
vezf1a (Supplementary Figure 6).  
In addition we performed RT-PCR and whole mount in situ hybridization 
(WISH) experiments to determine if the gene expression patterns of the zebrafish 
orthologues were consistent with a predicted role in ENS development. Temporal 
analysis using RT-PCR revealed that zebrafish orthologues of DENND3, NCLN and 
NUP98 were maternally and zygotically expressed from 0-120hpf while the TBATA 




Figure 1. Pathogenicity analysis in vivo by morpholino gene knockdown in zebrafish. Knockdown 
of ncl1, dennd3, nup98 and tbata resulted in HSCR-like phenotype that kaede-expressing enteric 
neurons were absent in the distal intestine at 5 dpf and the results were reproduced in the presence of 
p53 morpholino. Aganglionosis observed in ckap2l knockdown was caused by non-specific apoptosis as 
the result was not reproducible in p53 morpholino co-injection. Number of embryos with phenotype 
out of total number of embryos observed is shown. Dotted lines outline the intestines. Asterisks 
indicate the positions of anus. Arrows indicate the position where the aganglionic region begins.  
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WISH analysis showed that the orthologues for all 4 genes were expressed in 
distinct spatial locations specifically in the intestine and the anterior CNS from 24-





Over the last years a large number of papers have been published on de novo 
mutation screening in human diseases. This has resulted in the identification of 
many new disease-associated genes. Genes are considered as true disease causing 
when at least two unlinked patients are found with a mutation in the same gene. 
This works well for diseases that are relatively homogeneous or for which many 
patients can be investigated. For the more heterogeneous rare diseases for which 
only small cohorts are available this poses a problem. Often possible disease 
causing genes are found in a single patient. How to decide whether this finding is of 
importance? Expression of the gene in the relevant tissues can be considered as 
additional evidence, as is networks analysis. However, making strong statements 
for private disease genes is, and will be, extremely difficult. It also results in a bias 
towards genes in the known disease causing gene networks. Genes not fitting the 
current knowledge are often discarded as uninteresting. In the current study we 
wanted to take this all one step further. 
Therefore, we decided that the best way to obtain sound evidence for 
involvement of new candidate genes in HSCR should come from functional 
analysis. We opted for an in vivo approach using the zebrafish model system. We 
knocked down the expression of zebrafish orthologues of 12 of the 13 genes in 
which loss of function or missense DNMs were identified in a transgenic reporter 
zebrafish line (Tg(-8.3bphox2b:Kaede)). The orthologues of 9 of the 12 genes were 
successfully knockdown by morpholinos, and from which we discovered that 4 
genes when functionally perturbed resulted in loss of neurons in the distal gut, as 
in the HSCR patients. It is noteworthy that the SBMOs targeting 3 of the 
orthologues (aff3, scube3 and vezf1a) did not knock down the target transcripts as 
expected, which highlighted the limitation of morpholinos and might lead to false-
negative results36. To bypass this limitation, other loss-of-function approaches 
should be considered to further study these genes, such as CRISPR/Cas9 
knockout37. Finding 4 genes that when knocked down in zebrafish give a hindgut 
phenotype resembling the human patients in which the DNMs were found, clearly 




demonstrates that genes that never would have been followed up, based on the 
usual gene selection criteria, should not be ignored.  
Using the bioinformatics prediction and statistics, we would have focused 
on RET and CKAP2L only as they were significantly enriched for rare variants in the 
HSCR patients (nominal p<0.05; Table 2).  
We wondered whether any or all of these 4 genes can be linked to the ENS 
or whether they play relevant roles in neuronal development or neural crest 
derived cell types in general. In fact by studying these genes in more depth we 
noticed that all 4, despite lack of obvious connection to the known ENS pathways, 
are involved in the development of the CNS or the neural crest, making these not as 
random as they might first appear.  
DENN/MADD Domain Containing 3 (DENND3) is a guanine nucleotide 
exchange factor (GEF) that is involved in intracellular trafficking by activation of 
the small GTPase RAB1238. In zebrafish, Rab12 and other Rab GTPases are highly 
expressed by pre-migratory neural crest cells and their expression is dysregulated 
in Ovo1 morphant zebrafish that display altered migration of neural crest cells39. 
Independently of RAB12, DENND3 also regulates Akt activity, which is involved in 





Figure 2. Temporal and spatial expression patterns of zebrafish orthologues. Whole mount in situ 
hybridized embryos hybridized with antisense riboprobes for dennd3a, dennd3b, ncl1, nup98 and tbata 
at the indicated developmental stages. All columns show lateral views. Anterior CNS expression is 
apparent at all stages for all probes while intestinal expression for all probes is apparent from 48hpf 
onwards. 
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Nicalin (NCLN) is a key component of a protein complex that antagonizes 
Nodal signalling41. In vertebrates, Nodal signalling is involved in induction of the 
mesoderm and endoderm42. In contrast, inhibition of Nodal signalling is required 
for the specification of human embryonic stem cells into neuroectoderm, including 
the neural crest43,44. The antagonizing function of Nicalin on Nodal signalling is 
therefore consistent with the neural crest specification that is required for ENS 
development. 
The NUP98 gene encodes a precursor protein that is autoproteolytically 
cleaved to produce two proteins: NUP98 from the N-terminus and NUP96 from the 
C-terminus45,46. A missense DNM was identified in the last exon of the NUP98 gene 
and therefore affects the NUP96 protein. As in humans, zebrafish Nup96 is 
produced by cleavage of the Nup98 precursor protein. Since morpholino’s act on 
mRNA level, both nup98 and nup96 were targeted in our zebrafish experiments. It 
is therefore unclear whether the observed aganglionosis is caused by loss of 
Nup98 or Nup96. NUP96 is one of approximately 30 proteins in the nuclear pore 
complex (NPC)47 and its expression level regulates the rate of proliferation48. Two 
other members of the NPC (Nup133 and Nup210) are involved in neural 
differentiation in mice49,50. Moreover, NUP96 interacts with NUP98 and NUP98 is 
involved in the transcriptional regulation of the HSCR genes SEMA3A, DSCAM, 
NRG1 and the NRG1 receptor ERBB4 in human neural progenitor cells51. Therefore, 
it is likely that loss of either NUP protein (NUP96 or NUP98) could contribute to 
HSCR development. 
The mouse orthologue of Thymus, Brain And Testes Associated (TBATA) is 
called Spatial and is highly expressed during differentiation of several tissues52. 
These include the cerebellum, hippocampus and Purkinje cells in the brain, where 
TBATA/Spatial is expressed in early differentiating neurons53. In mouse 
hippocampal neurons, TBATA/Spatial is required for neurite outgrowth and 
dendrite patterning54.  
The 4 newly identified candidate genes for HSCR all seem to play a role in 
neuronal development and could potentially be involved in HSCR (Figure 3). This 
also suggests a clear link between CNS and ENS development. This is not 
surprising as a number of studies have described the strong correlation between 
Down syndrome and syndromic HSCR and several known HSCR genes (e.g. KBP, 
SOX10, NRG1, IKBKAP, ZEB2, PHOX2B) have been reported to be involved in both 
CNS and ENS pathologies2,55–57. In humans, SOX10 mutations cause myelin 
deficiencies and sensory neuropathies as well as the neurological variant of 




Waardenburg-Shah syndrome which includes HSCR in the phenotypic spectrum. 
Likewise, NRG1 is associated with schizophrenia and Nrg1 mutations in mice cause 
peripheral sensory neuropathies46. IKBKAP mutations are associated with the 
Riley-Day syndrome or familial dysautonomia (FD)58,59. Notably, some patients 
with FD also suffer from gastrointestinal dysfunction shortly after birth and 
interestingly, the co-occurrence of both FD and HSCR has been reported60. In 
addition, knockdown of ikbkap in zebrafish also generates a HSCR-like 
phenotype35. Further, KBP mutations are associated with Goldberg-Shprintzen 
syndrome61 (MIM 609460), a rare autosomal recessive inherited syndrome, where 
patients present with HSCR, microcephaly polymicrogyria and moderate mental 
retardation. 
Besides the fact that several HSCR/neuromuscular genes are known to be 




Figure 3. Newly identified genes in ENS development. All symbols represent proteins coded by 
Hirschsprung known genes or novel genes identified in this study. The effect of gene NUP98 is shown by 
protein NUP96. The interaction effects between different proteins are illustrated by four different lines 
representing binding, secreted/express, phosphorylation and activation. ENCC, enteric neural crest cell. 
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psychiatric disorders are associated with constipation, and sometimes defects in 
the ENS are reported62. For instance, it has recently been described that mutations 
in CDH8 result in a specific subtype of autism in combination with gastrointestinal 
problems. A cdh8-/- zebrafish recapitulates the human phenotype, including 
increased head size (expansion of the forebrain/midbrain), an impairment of 
gastrointestinal motility and a reduction in post-mitotic enteric neurons63. Besides, 
a search of CNS and autism in Phenolyzer64 returned two genes (APP and MECP2) 
that have been implicated in ENS development65,66. 
Thus, given all of the above, and the fact that HSCR occurs with 
neurological disorders more often than would be expected by chance, it is not 
surprising that dysfunction of these newly identified neurological related genes 
results in dysregulation of the neural crest-derived cells that form the ENS, and 
hence in HSCR. These data are further corroborated by the expression patterns we 
observed for the orthologues of these 4 genes in zebrafish embryos (Figure 2), 
with all 4 having clear expression in both the brain and the gut. 
Finding a niche for these genes in ENS development will help to open new 
avenues of research which, eventually, will enhance our knowledge about ENS 
development and HSCR disease mechanisms. Until now, we believed that the 
number of cellular processes involved in the development of HSCR was limited. 
Clearly this idea needs to be revisited as the novel genes we identified are not 
directly linked to any of the currently known HSCR gene networks. In spite of the 
plethora of databases and prediction tools available, very little is known about the 
intricate ways in which genes interact in the development of the ENS, or the 
function of many genes. 
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Quality assessment and control for exome variants 
Concrete criterions in quality assessment (QA) include: total number of variants; 
dbSNP137 coverage; Transition/Transversion (Ti/Tv) ratio; genotype 
concordance rate and cross-sample identical-by-decent (IBD) relatedness1. Two 
complementary steps were applied in quality control (QC), including variant-level 
filtering (hard filtration or variant quality recalibration (VQSR)) and genotype-
level filtering. In detail, we annotated GATK-called variants as low quality SNPs 
(“QD <2.0” or "MQ <40.0" or "FS >60.0" or "HaplotypeScore >13.0" or 
"MQRankSum <-12.5" or "ReadPosRankSum <-8.0" in their ‘info’ field) and low 
quality Indels (“QD <2.0" or "ReadPosRankSum <-20.0" or "InbreedingCoeff <-0.8" 
or "FS >200.0 in ‘info’ field); in addition, VQSR differentiated a few relatively low 
quality SNVs (labeled as “TruthSensitivityTranche99.90to100.00” after Gaussian 
mixture modeling at true sensitivity 99%) from other passed SNVs. On the other 
hand, individual genotypes were evaluated by quality parameters in the field of 
genotyping, mainly reflecting the likelihood of three possible genotypes (reference 
homozygous, heterozygous and alternative homozygous). A heterozygous 
genotype was kept only if it was supported by >4 total reads, and the ratio for 
alternative allele is above 0.25. Comparatively, a reference or alternative 
homozygous genotype was accepted if it was supported by > 4 total reads, and 
ratio for reference or alternative allele is above 0.95. 
Supplementary Table 2 shows the details of quality statistics for samples 
from different sequencing centers at variant level. The total count of SNVs 
(20~30K) or Indels (1~2K), Transition/Transversion (Ti/Tv) ratio (above 3.0), 
dbSNP137 coverage (above 95%) and GWAS genotype concordance (>99%) are all 
in normal range. No trio violated relatedness checking; meanwhile, no batch effects 
or close relatedness (pi-hat coefficient > 0.125 as first cousin or above) were found 
among the HSCR patients from different centers (Supplementary Figure 2). All 
these quality metrics or statistics showed data quality at exonic regions that were 
comparatively good for trios from different platforms or resources, and justified 
our unbiased searching of de novo mutations in the following stages. 
 
Mutation validation and prediction 
Each DNM candidate was manually inspected using the Integrative Genomic 
Viewer (IGV) and they were categorized into five different groups: probably true 
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positive, possibly true positive, unclear, possibly false positive and probably false 
positive. Two lists of putative DNM candidates were generated for confirmation by 
Sanger sequencing. The first list contains 74 variants with high confidence ranking 
(probably true positive and possibly true positive). Raw data were then re-
evaluated to generate 48 candidates with relatively low-confidence (unclear), 
especially for those trios without any confirmed DNM in the first round. Rare 
(minor allele frequency < 0.01 in public databases) predicted damaging variants in 
genes carrying confirmed de novo mutations were extracted from exome calls and 
submitted for Sanger validation. The allele origin was determined by checking the 
mutation site in both parents. Phasing of DNM and inherited variants in the same 
gene was also performed by Sanger sequencing. Rare damaging inherited variants 
located in 116 ENS candidate genes were extracted from exome reads using the 
same pipeline (Supplementary Figure 1); and the transmission patterns of these 
variants were determined by referring to parental and maternal genotypes at the 
same site. 
 Stepwise logistic regression was used to select effective predictors of the 
de novo status in a trio and for the presence or absence of a mutation in a given 
individual. The performance of these prediction models was evaluated using 10-
fold cross validation by the software WEKA. For model fitting to DNM status in the 
trios, genotype quality (represented by normalized phred likelihood score for the 
second most likely genotype) in the child and alternative allelic ratio in the parents 
were prioritized. The Area Under the Receiver Operating Characteristic Curve 
(AUC) was 0.959 (Supplementary Table 3) which suggests that the model predicts 
the DNM status accurately. This model was then adopted to test all other 
unvalidated de novo candidates (falling under the ”unclear”, “possibly false 
positive” or “probably false positive” categories), which all turned out to be 
negatives. For model fitting to the presence or absence of a variant in the patients, 
genotype quality and alternative allelic ratio in each individual were retained. The 
AUC was 0.824 (Supplementary Table 3). This second model was then used to help 
predict the presence of rare variants in the DNM genes or ENS genes. Only those 
variants predicted as positive candidates were shown (Supplementary Table 5). 
  
Generation of ENS candidate genes 
Candidate genes were selected by a literature review on Hirschsprung disease 
research, which included both genetic and functional studies. Most of them were 
also covered in Jiang et al.2 and Gui et al.3, which previously summarized possible 




genes related to HSCR or involved in ENS development. The genes were 
categorized into 4 major types, genes selected based on: genetic linkage, genetic 
association, microarray expression, and animal models. In total 116 genes were 
selected that fit more than 1 category (Supplementary Table 6). A few of these 
genes fall into the same pathways previously implicated in neural crest cell 
migration, proliferation and differentiation. Three pathways (RET signaling 
pathway, EDNRB signaling pathway and KBP signaling pathway) were key partners 









Trios (N=24) Singletons (N=28) 
Controls 
(N=212) 
Short Long/TCA  Short Long/TCA  
(N=1) (N=23)  (N=15) (N=13) 
Males 0 7 (4) 13 4 117 
Females 1 (0) 16 (10) 2 9 95 
Trios used to detect de novo mutations in coding sequences. Case/control samples were exome 
sequenced by the same protocol in each cohort, and used to calculate gene-level burden for all genes 




Supplementary Table 2. Quality metrics for sequencing reads and variants from different 
cohorts. 
 
This shows comparable read depth and % of targeted exonic bases on the intersected exonic regions (~ 
30Mb) for different cohorts; in addition, variant-level metrics are also comparable at exonic regions 
(Ti/Tv ratio, SNP/Indel counts, dbSNP137 coverage). *: SNVs passing variant quality recalibration 
filtering were counted; #: only SNVs in exonic regions were used to estimate Ti/Tv ratio; %: 
concordance between GWAS array and exome data, NA data not available; $: RV, rare variants with 
minor allele frequency < 0.01 in dbsnp137, 1000 genome 2012 and ESP 6500 databases; SS: Sure Select.  
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+ FA parents 
93 3 








+ FA patient 
68 10 
0.703 0.872 0.839 0.765 0.824 
22 52 
Two models were trained by stepwise logistic regression on sequencing quality metrics and then used 
to predict the de novo mutation status in a trio or the variant presence/absence status in exome 
individuals. Training data was from true or false variants validated by Sanger sequencing, as shown in 
confusion matrix. *: 2ndPL_patient means “second minimum phred-scaled likelihood (PL) score” in the 
trio proband; FA_parents means maximum ”fractions of reads (FA) supporting each reported 
alternative allele” from two parents. 2ndPL_patient, FA_patient means PL or FA value for given patient. 
#: Area under curve (AUC) calculated from 10-fold cross-validation. Confusion matrix, F-measure and 





Supplementary Table 4. Comparison of de novo mutation rates  
 A B  C  










  Count (rate) Count (rate) A vs. B Count (rate) A vs. C 
All DNMs  28 (1.17) 44 (0.81) 0.159 547 (0.81) 0.065 
LOF DNMs  8 (0.33) 4 (0.07) 0.011
#





3 (0.13) 4 (0.07) 0.447 54 (0.08) 0.447 
Synonymous 
DNMs  
7 (0.29) 12 (0.22) 0.62 143 (0.21) 0.365 
DNM mutation rate by different categories (All, LOF only, non-RET LOF, synonymous) were compared 
between HSCR trios included in this study and those published healthy trios or unaffected siblings to 
neurodevelopmental diseases. *: Data from Rauch (2012) and Xu (2012); &: data from Iossifov (2012), 
O’Roak (2012), Sanders (2012) and Gulsuner (2013); #: nominally significant at 0.05; ##: significant 






















 Inherited mutations in 
genes in which de 









L, F CC RET: 3splicing9+1 (splicing 




SMO (P), KIAA1279 
(M) 
L, F CC COL6A3: H1109H 
(synonymous); RET:S837fs 
(frameshift) 
 DCC (P) 
L, F TC RET:Y606fs (frameshift);  SON (M) 






NCLN:Q166* (stopgain)   
NUP98:I1609T 
(missense) (M) 
IKBKAP (P), SOX10 
(M) 
L, F CC SCUBE3: N498I (missense);        




L, M TT PLEKHG5:T876T (synonymous); 
AFF3:V659L(missense) 
  
L, M TT KDM4A: N9S (missense) MAP4: A882G 
(missense) (M) 
ECE1 (P), JAG1 (P) 
L, M CT MAP4:G1117G (synonymous)  PCDHA1 (P), DCC 
(M), NOTCH3 (P) 
L, F TT RET:C620R (missense)   
TCA, M TT CKAP2L:E186fs (frameshift)  CBR1 (M) 




L, F C/T CCR2:L283Q (missense); 
DENND3:K640fs (frameshift) 
 IKBKAP (P), JAG1 
(M) 
L, F C/T RET:C570* (stopgain)  ECE1 (P) 
L, F C/T RET:R175del (non-frameshift); 
TBATA:R53C (missense) 
 NOTCH1 (P), PFKL 
(P) 
L, F CC  HMCN1: P1269T 
(missense) (P) 
IKBKAP (P), EDNRB 
(P), JAG1 (M) 
L, F CC  HMCN1: N2461S 
(missense) (M) 
PHACTR4 (P), GLI3 
(M), SHH (M), HMX3 
(M), NAV2 (M), PRPH 
(P), PSPN (P) 
L, M TT   IHH (P), PFKL (P, M) 
S, F TT   JAG1 (P) 
TCA, M TT   ELAVL4 (P), 
SERPINI1 (U), 
PTCH1 (U), IKBKAP 
(M) 
TCA, M TT   JAG1 (M) 
L, F TT   PLXNB1 (P) 
L, F TT  SCUBE3:R907C 
(missense) (P) 
NRG1 (M), IFNGR2 
(P) 
L, F TC   TAGLN3 (P) 
L, F TC  DAB2IP:A338T 
(missense) (P); 
KDM4A: V988M (M) 
SON (P) 
Common risk SNP (RET rs2435357), DNMs, inherited damaging variants in genes carrying DNMs, rare 
damaging variants in ENS candidate genes were tabulated for each HSCR patient. DNMs and inherited 
variants in DNM genes were confirmed by Sanger sequencing. Rare damaging variants in ENS candidate 
genes were all predicted as true according to training model 2 (see Supplementary Table 3). *: L: Long 
segment aganglionosis; S: Short segment aganglionosis; TCA: Total colonic aganglionosis; F: Female; M: 
Male. #: rs2435357, T is risk allele and minor allele. %: genes functionally validated in bold; $: parent of 
origin for mutation in candidate genes, P for paternal (P); M for Maternal, U for Unsure; &: 116 ENS-
related HSCR candidate genes (as listed in Supplementary Table 6). 
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Supplementary Table 6. Characteristics of 116 ENS-related HSCR candidate genes. 
Gene Gene name Chromosome Evidence Ref 
ALDH1A2 
aldehyde dehydrogenase 1 family, 
member A2 
15q22.1 Mouse (Absence EN) 5 
ARHGEF3 
Rho guanine nucleotide exchange 
factor (GEF) 3 
3p14.3 Expression 6,7 
ARTN artemin 1p34.1 










CADM1 cell adhesion molecule 1 11q23.2 Expression 7,12 
CARTPT CART prepropeptide 5q13.2 Expression 7 
CBR1 carbonyl reductase 1 21q22.13 Expression 13 
CDH2 
cadherin 2, type 1, N-cadherin 
(neuronal) 
18q11.2 Expression 7,14 
CRMP1 collapsin response mediator protein 1 4p16.1 Expression 7,15 
CSTB cystatin B (stefin B) 21q22.3 Expression 16 
CTNNAL1 
catenin (cadherin-associated protein), 
alpha-like 1 
9q31.3 Expression 7 




DCX doublecortin Xq22.3-q23 Expression 7 
DLL1 delta-like 1 (Drosophila) 6q27 Not described 10,11 
DLL3 delta-like 3 (Drosophila) 19q13.2 Not described 10,11 
DLX1 distal-less homeobox 1 2q32 Expression 
7,18,1
9 
DPYSL3 dihydropyrimidinase-like 3 5q32 Expression 7,20 
EBF3 early B-cell factor 3 10q26.3 Expression 7,21 

















ELAV (embryonic lethal, abnormal 
vision, Drosophila)-like 2 (Hu antigen B) 
9p21 Expression 7,28 
ELAVL4 
ELAV (embryonic lethal, abnormal 
vision, Drosophila)-like 4 (Hu antigen D) 
1p34 Expression 7,29 
ERBB2 
v-erb-b2 erythroblastic leukemia viral 
oncogene homolog 2, 
neuro/glioblastoma derived oncogene 
homolog (avian) 
17q12 




v-erb-b2 erythroblastic leukemia viral 
oncogene homolog 3 (avian) 
12q13.2 




v-erb-a erythroblastic leukemia viral 
oncogene homolog 4 (avian) 
2q33.3-q34 Human (CNV) 32 
ETV1 ets variant 1 7p21.3 Expression 7,33 
FGF13 fibroblast growth factor 13 Xq26.3 Expression 7,34 
GAP43 growth associated protein 43 3q13.1-q13.2 Expression 7,35 





GFRA1 GDNF family receptor alpha 1 10q25 





similar to GDNF family receptor alpha 
2; GDNF family receptor alpha 2 
8p21.3 
Mouse (Abnormal ENS 
morphology) 
8 




GFRA4 GDNF family receptor alpha 4 20p13 Not described 8 













guanine nucleotide binding protein (G 
protein), gamma 2 
14q21 Expression 7 





guanine nucleotide binding protein (G 
protein), gamma 3 
11p11 Expression 7,43 
GRB10 growth factor receptor-bound protein 10 7p12.2 Human (Linkage) 38 
HES1 










HMP19 HMP19 protein 5q35.2 Expression 7 
HMX3 H6 family homeobox 3 10q26.13 Expression 7,44 
HOXB5 homeobox B5 17q21.3 Expression 7,45 
HOXD4 homeobox D4 2q31.1 Expression 7,46 
IFNGR2 
interferon gamma receptor 2 (interferon 
gamma transducer 1) 
21q22.11 Expression 47 
IHH Indian hedgehog homolog (Drosophila) 2q35 Mouse (Absence EN) 41,42 
IKBKAP 
inhibitor of kappa light polypeptide gene 
enhancer in B-cells, kinase complex-
associated protein 
9q31.3 Human (Co-Expression) 48 
IL10RB interleukin 10 receptor, beta 21q22.11 Expression 49 
ITGB1 
integrin, beta 1 (fibronectin receptor, 
beta polypeptide, antigen CD29 
includes MDF2, MSK12) 
10p11.22 Mouse (Absence EN) 17 
JAG1 jagged 1 (Alagille syndrome) 20p12.1 Not described 10,11 
JAG2 jagged 2 14q32.33 Not described 10,11 















MAB21L1 mab-21-like 1 (C. elegans) 13q13 Expression 7,54 
MAPK10 mitogen-activated protein kinase 10 4q22.1-q23 Expression 7,55 
MAPT microtubule-associated protein tau 17q21.1 Expression 7 
MLLT11 
myeloid/lymphoid or mixed-lineage 
leukemia (trithorax homolog, 
Drosophila); translocated to, 11 
1q21 Expression 7,56 
NAV2 neuron navigator 2 11p15.1 Human (Exome) 57 
NKX2-1 NK2 homeobox 1 14q13 Human (Case report) 17,22 
NOTCH1 
Notch homolog 1, translocation-
associated (Drosophila) 
9q34 Not described 10,11 
NOTCH2 Notch homolog 2 (Drosophila) 6q27 Not described 10,11 
NOTCH3 Notch homolog 3 (Drosophila) 19p13.12 Not described 10,11 





NRG3 neuregulin 3 10q22-q23 Human (CNV/Exome) 32,59 
NRP1 neuropilin 1 10p11.22 Not described 60,61 




NTF3 3'-nucleotidase 1p36.11 




neurotrophic tyrosine kinase, receptor, 
type 3 
15q25 
Mouse (Reduced enteric 
ganglia) 
17 





protocadherin alpha 1; protocadherin 
alpha 4 
5q31 Expression 7,63 
PFKL phosphofructokinase, liver 21q22.3 Expression 64 
PHACTR4 phosphatase and actin regulator 4 1p35.3 Mouse 65,66 
PHOX2A paired-like homeobox 2a 11q13.2 Expression 7,67 







PLXNA1 plexin A1 3q21.3 Not described 60,61 
PLXNB1 plexin B1 3p21 Human (Linkage) 70,71 
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POFUT1 protein O-fucosyltransferase 1 20q11.21 Mouse (Absence EN) 10,11 
PROK1 prokineticin 1 1p13 Not described 72,73 
PROK2 prokineticin 2 3p13 Not described 72,73 
PROKR1 prokineticin receptor 1 2p14 Not described 72,73 
PROKR2 prokineticin receptor 2 20p12 Not described 72,73 
PRPH peripherin 12q12-q13 Expression 7,74 
PSPN persephin 19p13.3 Not described 8 




RET ret proto-oncogene 10q11 
Human 
(Linkage/CNV/Exome)/Mo
use (Absence EN) 
7,57, 
75,76 
SALL4 sal-like 4 (Drosophila) 20q13.2 Mouse (Absence EN) 17 
SCG3 secretogranin III 15q21 Expression 7 
SEMA3A 
sema domain, immunoglobulin domain 









sema domain, immunoglobulin domain 







serpin peptidase inhibitor, clade I 




SHH sonic hedgehog homolog (Drosophila) 7q36 
Mouse (Ectopic enteric 
ganglia formation) 
41,42 
SMO smoothened homolog (Drosophila) 7q32 
Mouse (Abnormal neural 
crest cell migration) 
41,42 
SOD1 superoxide dismutase 1, soluble 21q22.11 Expression 80,81 
SON SON DNA binding protein 21q22.11 Expression 82 





SOX2 SRY (sex determining region Y)-box 2 3q26.3-q27 Expression 7,84 
SPRY2 sprouty homolog 2 (Drosophila) 13q31.1 Mouse (Increased EN) 17 
STMN2 stathmin-like 2 8q21.13 Expression 7,85 
STMN3 stathmin-like 3 20q13.3 Expression 7 
SUFU 
suppressor of fused homolog 
(Drosophila) 
10q24.32 
Mouse (Abnormal neural 
tube morphology) 
41,42 
SYT11 synaptotagmin XI 1q21.2 Expression 7,86 
TAGLN3 transgelin 3 3q13.2 Expression 7 
TBX3 T-box 3 12q24.1 Expression 87,88 
TFF3 trefoil factor 3 (intestinal) 21q22.3 Expression 
7,89, 
90 
TGFB2 transforming growth factor, beta 2 1q41 Expression 7,91 
TMEFF2 
transmembrane protein with EGF-like 
and two follistatin-like domains 2 
2q32.3 Expression 7,92 
TREX1 three prime repair exonuclease 1 3p21.31 Human (Linkage) 70,71 
TTC3 
tetratricopeptide repeat domain 3; 
tetratricopeptide repeat domain 3-like 
21q22.2 Expression 93 
TUBB3 
tubulin, beta 3; melanocortin 1 receptor 
(alpha melanocyte stimulating hormone 
receptor) 
16q24.3 Expression 7,94 
UCHL1 
ubiquitin carboxyl-terminal esterase L1 
(ubiquitin thiolesterase) 
4p14 Expression 7,95 
VIP vasoactive intestinal peptide 6q25 Expression 7,96 












Notes: updated gene symbols used for ZFHX1B (replaced by ZEB2), TRKC (replaced by NTRK3) and 
RALDH2 (replaced by ALDH1A2); EN: enteric neurons; NCC: neural crest cells. 
 
 




Supplementary Table 7. Gene recurrence and burden test.  
Gene 
symbol 
HK (14/73) Spain (15/100)
#
 Rotterdam (19/39) 
Meta-analysis 
(48/212) 
p-value Direction* p-value Direction* p-value direction p-value Direction* 
AFF3 1.0000 -1 0.6973 -1 0.0392 1 0.4745 1 
CCR2 1.0000 -1 0.6973 -1 0.0392 1 0.4745 1 
CKAP2L 0.0216 1 0.1175 1 1.0000 -1 0.0178 1 
COL6A3 0.5883 -1 0.5430 -1 0.5970 1 0.6398 -1 
DAB2IP 0.4402 -1 0.6973 -1 0.1484 1 0.9819 -1 
DENND3 0.3699 -1 0.6973 -1 0.5970 1 0.5977 -1 
HMCN1 0.4308 -1 0.3662 1 0.8013 -1 0.9789 1 
ISG20L2 1.0000 -1 1.0000 -1 0.1484 1 0.4949 1 
KDM4A 0.0216 1 0.4967 -1 0.1484 1 0.1190 1 
MAP4 0.6596 -1 0.2903 1 0.5970 1 0.4851 1 
MED26 1.0000 -1 1.0000 -1 1.0000 -1 1.0000 -1 
NCLN 1.0000 -1 1.0000 -1 0.1484 1 0.4949 -1 
NUP98 0.5309 -1 0.6973 -1 0.0392 1 0.7243 1 
PLEKHG5 1.0000 -1 0.1999 -1 0.9826 1 0.3997 -1 
RBM25 1.0000 -1 0.0095 1 1.0000 -1 0.0846 1 
RET 0.1867 1 0.6367 1 0.0008 1 0.0078 1 
SCUBE3 1.0000 -1 0.5806 -1 1.0000 -1 0.7133 -1 
TBATA 1.0000 -1 1.0000 -1 0.5970 1 0.8028 1 
TUBG1 1.0000 -1 1.0000 -1 1.0000 -1 1.0000 -1 
VEZF1 1.0000 -1 0.6973 -1 0.1484 1 0.6717 1 
ZNF57 0.0216 1 0.4967 -1 1.0000 -1 0.3808 1 
Genes with DNMs were checked for the presence of rare damaging mutations in additional HSCR 
patients. The burden of rare, damaging mutations in HSCR patients was compared to that of a local 
population-matched controls; in addition, gene-wise burden test p-values from three cohorts (HK, Spain 
and Rotterdam) were combined using meta-analysis. Number of cases and controls are given in 
parentheses. *: Direction 1 means rare damaging variants enriched in cases, -1 means rare variants 
enriched in controls; #: 4 HSCR patients in discovery trios were not included due to mismatched 
platform with control data. Nominal P-values from meta-analyses < 0.05 are given in bold (CKAP2L and 
RET). 
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, interacts with PAX3 
RET:S837fs NA 
  
Major HSCR gene 
COL6A3:H1109H 0.4898 
  
Interacts with ERBB2, ITGB1, shares pathway 
with NRTN, GDNF 
RET:Y606fs NA 
  











Pathway sharing with NOTCH genes 
NCLN:Q166* 0.5467 
 















Major HSCR gene 
SCUBE3:N498I 0.5473 
 
1.96 Hedgehog signaling 
KDM4A:N9S 0.5813 
 
3.54 Neural crest specification in chicken 
PLEKHG5:T876T 0.4096 







1.40 Interacts with CDH2, ERBB2, MAPT and DCX 
RET:C620R 0.4286 
 
4.80 Major HSCR gene 
CKAP2L:E186fs NA 
  
Involves in CNS development 
RET:C137G 0.6841 
 















Involves in CNS development 
RET:C570* 0.1453 
 
-0.02 Major HSCR gene 
RET:R175del NA 
  
Major HSCR gene 
TBATA:R53C 0.5526 
 
1.71 Involves in CNS development 
Bioinformatics prediction tools, databases and literature were used to predict functional impact of 
DNMs and the genes carrying DNMs. *: significant changes (< 0.2) are in bold; #: only potential splice 
sites (donor or acceptor) are shown; %: PhyloP score > 2 means conservative; $: evidence collected 









Supplementary Table 9. Sequence and dosage of antisense morpholino.  
a. Splice-blocking morpholino 
Target gene Human ortholog Sequence Dosage (ng) 
aff3 AFF3 AAATGTCTTTCCCCCCTCACCTTTC 6 
ckap2l CKAP2L TGAAGTAAACTCACAGTCTTTCCTC 6 
dab2ipa DAB2IP* AGGTCAGCAGACTCACCTCGAAGCA 6 
dab2ipb DAB2IP* GCTTTCCACTAACACCTTACCCAGC 6 
dennd3a DENND3* CATCTTTACCCTGTGCGAAAAGTTA 6 
dennd3b DENND3* CCATTCAATTTTGTTTCACCTGGAA 6 
hmcn1 HMCN1 GCACAAAGATTTCCCCTTACCCTGA 6 
isg20l2 ISG20L2 CTACTGATGCTTATTTCATACCTCT 6 
kdm4aa KDM4A* GACACAAGCAATGACAGTACCAGGA 6 
kdm4ab KDM4A* AGTTGAACAGAACATACTTGTCGCT 6 
ncl1 NCLN GAACCTGCCAATGGATGTGGTTTAT 6 
nup98 NUP98 GTATGGAGCAGCTAAACTTACGGTT 1 
scube3 SCUBE3 ACTAGATGAAGGGACTCACTCTTGC 6 
tbata TBATA GATAGAGCCCAATACTGTACCTCCC 4 
vezf1a VEZF1* AGCCAATCGCACTAGCCTTACCTTT 6 
vezf1b VEZF1* ATCCAAAATGCTAAACCCACCTAGA 6 
 
b. Translation-blocking morpholino 
Target gene Human ortholog Sequence Dosage (ng) 
ckap2l CKAP2L GTCTTCATCAGTCATCGTTTCCATC 6 
dennd3a DENND3* GACCACACGGCACATTATCAGCCAT 8 
dennd3b DENND3* GACCGTCTGCCATTGAAAATCAACA 8 
ncl1 NCLN ACCTCACCAGCCTCCTCGAACATGC 0.8 





c. Control morpholino 
Target gene Human ortholog Sequence
%
 Dosage (ng) 
ckap2l CKAP2L TGtAcTAAAgTCACAcTgTTTCCTC 6 
dennd3a DENND3* CAaCaTTACgCTGTGCcAAAAcTTA 6 
dennd3b DENND3* CCAaTgAATTTTcTTTCACgTcGAA 6 
ncl1 NCLN GAACaTcCCAATGaATcTGaTTTAT 6 
nup98 NUP98 GTtTcGAGCAcCTAAAgTTACcGTT 1 
tbata TBATA GAaAcAGCCgAATACTcTAgCTCCC 4 
p53 P53 GCGCCATTGCTTTGCAAGAATTG 2 
HBB
$
   CCTCTTACCTCAGTTACAATTTATA 12 
*: DENND3, DAB2IP, KDM4A and VEZF1 are duplicated in zebrafish genome. #: There was no suitable 
target site in tbata for translation-blocking morpholino. A second non-overlapping splice-blocking 
morpholino was used instead. %: Small letters indicate the mismatch nucleotides to the corresponding 
splice-blocking morpholino. $: morpholino against human beta-globin as an universal negative control. 
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Supplementary Table 10. qPCR/RT-PCR primers. 
































































Supplementary Figure 1. Analytical pipeline for exome sequence filtration and prioritization. 1: 
GATK; 2: KGGSeq; 3: PLINK; 4: ANNOVAR. KGGSeq integrates different kinds of knowledge resources 
from (epi)genetic databases, pathways databases and protein-protein interaction networks to annotate 
the genes that harbor any post-QC variants as well as to predict the potential pathogenicity of their 
variants. For deleteriousness prediction, KGGSeq integrates 5 prediction programs (Polyphen2, Sift, 
MutationTaster, PhyloP and Likelihood ratio) which are weighted by logistic regression103. Annovar is 
mainly used to double-check the final remaining variant for annotation, and provides supplementary 
features from Database of genomic variation (DGV) and clinical variation database (ClinVAR). 
  




Supplementary Figure 2. Relatedness plotting of HSCR exome sequences. Around 17K common 
SNPs (minor allele frequency > 0.01 in 1000Genomes European populations) were used to calculate 
identical by descent (IBD) and identical by state (IBS) proportion. Each cell shows pi_hat statistics1 (IBD 
proportion, calculated from P(IBD=2)+0.5*P(IBD=1); http://pngu.mgh.harvard.edu/~purcell/ 
plink/ibdibs.shtml) between two patients. No pairwise pi_hat coefficients are above 0.125 (the first 
cousin relationship); the light blue cells represent 0.07~0.11 for samples mainly from HK population, 
which is expected to be different from other European patients. 
  









Supplementary Figure 3. Distribution of de novo mutations per trio. A) Number of DNMs 
(separated by mutation type) in each trio, categorized into three different types (Loss of function, 
synonymous and others). B) Distribution of observed counts of DNMs per trio and expected counts per 
trio calculated from Poisson distribution (lambda at 1.2). 
  








Supplementary Figure 4. Sanger confirmation of mosaic DNMs in DAB2IP and NCLN. Two out of 28 
de novo mutations (in DAB2IP and NCLN) were confirmed as mosaic mutations by Sanger sequencing 
(forward and reverse Sequencing direction). A) Peak for the DAB2IP heterozygous mosaic mutation. B) 
Peak for the NCLN heterozygous mosaic mutation.  
  




































































































































































































































Supplementary Figure 6. qPCR confirmation of gene knockdown by SBMO. Relative expression of 
the candidate genes between SBMO-injected (grey bar) and control morpholino-injected embryos 
(black bar) by qPCR.  
  





Supplementary Figure 7. RT-PCR confirmation of ncl1 SBMO knockdown. ncl1 expressions in six 
1dpf embryos injected with ncl1 SBMO were compared to control MO injected embryos. Arrow 
indicated the expected amplicon. L: ladder; C1: control MO-injected embryo; C2: RT negative control. 
 
 
Supplementary Figure 8. RT-PCR for expression of 4 candidate genes in zebrafish. Temporal 
expression pattern of zebrafish orthologue genes. RT-PCR for dennd3a, dennd3b, ncl1, nup98 and tbata 
was performed on RNA isolated from wild type embryos at 0, 24, 48, 72, 96 and 120 hpf. 
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The enteric nervous system (ENS) is required for peristalsis of the gut and is 
derived from enteric neural crest cells (ENCCs). During ENS development, the RET 
receptor tyrosine kinase plays a critical role in the proliferation and survival of 
ENCCs, their migration along the developing gut, and differentiation into enteric 
neurons. Mutations in RET and its ligand GDNF cause Hirschsprung disease 
(HSCR), a complex genetic disorder in which ENCCs fail to colonize variable lengths 
of the distal bowel. To identify key regulators of ENCCs and the pathways 
underlying RET signaling, gene expression profiles of untreated and GDNF-treated 
ENCCs from E14.5 mouse embryos were generated. ENCCs express genes that are 
involved in both early and late neuronal development, whereas GDNF treatment 
induced neuronal maturation. Predicted regulators of gene expression in ENCCs 
include the known HSCR genes Ret and Sox10, as well as Bdnf, App, Mapk10 and 
Timp1. The regulatory overlap and functional interactions between these genes 
were used to construct a regulatory network that is underlying ENS development 
and connects to known HSCR genes. In addition, the adenosine receptor A2a 
(Adora2a) and neuropeptide Y receptor Y2 (Npy2r) were identified as possible 
regulators of terminal neuronal differentiation in GDNF-treated ENCCs. The human 
orthologue of Npy2r maps to the HSCR susceptibility locus 4q31.3-q32.3, 
suggesting a role for NPY2R both in ENS development and in HSCR. 
 
Keywords: Hirschsprung disease; Enteric Nervous System; Transcriptome; 
Upstream Regulators 
  






The enteric nervous system (ENS) of the gastrointestinal tract is composed of 
neurons and glial cells that are organized in interconnected ganglia in the 
myenteric and submucosal plexuses. The ENS controls the peristaltic movements 
of the bowel, fluid exchange between the gut and its lumen, and local blood flow1,2. 
In vertebrates, the ENS is entirely derived from neural crest cells3. Vagal 
(hindbrain) neural crest cells invade the foregut at around E9 in mice4, at which 
point they are referred to as enteric neural crest cells (ENCCs). The intestinal wall 
is colonized by ENCCs in a rostral to caudal direction between E9 and E15 in mice 
and sacral neural crest cells contribute to colonization of the hindgut late during 
ENS development5,6. 
Glial cell line-derived neurotrophic factor (GDNF) acts as a chemo-
attractant to migrating vagal ENCCs and directs the migration of ENCCs along the 
gut7. ENCCs express the REarranged during Transfection (RET) receptor tyrosine 
kinase, and RET with its co-receptor GFRα1 is the receptor for GDNF8. Mice lacking 
Ret, Gfrα1 or Gdnf fail to colonize the bowel beyond the stomach, leading to 
intestinal aganglionosis9–13. Besides its role in migration, RET signaling is 
important for proliferation of ENCCs at E12 and for their survival at E14-E16 in 
mice14–17. In order to develop into a mature ENS, post-migratory ENCCs 
differentiate into various neuronal subtypes and glial cells. GDNF promotes 
neuronal, but not glial differentiation of ENCCs in vitro, and acts a chemoattractant 
to outgrowing neurites7,15,18,19. The mature ENS contains sensory neurons, 
interneurons and excitatory and inhibitory motor neurons that use a wide range of 
neurotransmitters, similar to those found in the CNS20. 
  Mutations in RET and GDNF in humans contribute to Hirschsprung disease 
(HSCR), a congenital disorder that is characterized by intestinal aganglionosis in a 
variable segment of the distal gut. HSCR patients present with tonic contraction of 
the muscle layers in the affected segment, which consequently leads to dilatation 
of the proximal bowel. The prevalence of HSCR is 1:5,000 live births and it is 
considered an inherited disease. Based on the families reported, the mode of 
inheritance can differ. Most non-syndromic familial HSCR cases show a dominant 
pattern of inheritance, mostly with reduced penetrance, whereas many syndromic 
HSCR families show a recessive pattern of inheritance. The sporadic cases are 
considered polygenic or oligogenic. Of the approximately 15 HSCR genes identified 
so far, the RET gene is by far the most important gene. Coding mutations in RET are 
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found in ~50% of familial and 15-35% of sporadic HSCR patients and represent 
the great majority of genetic mutations found in HSCR patients21,22. Mutations in all 
other HSCR-associated genes, including GDNF, are rare23–25. 
The colonization of the intestine by ENCCs, followed by their neuronal and 
glial differentiation, is a complex process controlled by various signaling pathways. 
These include Hedgehog, Notch, Wnt, retinoic acid and TGF-β/BMP signaling26–30. 
Several other pathways that are important for ENS development have been 
identified in gene expression profiling studies. Iwashita et al. (2003) reported that 
the HSCR genes Ret, Gfrα1, Ednrb and Sox10 are highly expressed by ENCCs in mice, 
thereby explaining how mutations in these genes contribute to aganglionosis31. A 
subsequent expression study by Heanue and Pachnis (2006) showed that at E15.5 
in mice, ENCCs express markers of early and late neuronal development and glial 
differentiation, representing different stages of ENS development. These authors 
identified Sox2, Cart, Sema, Fgf and Jnk as novel signaling pathways in ENCCs32. In 
addition, Vohra et al. (2006) found that E14 mouse ENCCs highly express genes 
with synaptic functions and showed that these genes are important for ENCC 
migration and neurite outgrowth33. Some insight in the pathways downstream of 
RET signaling has come from expression profiling of GDNF-treated ENCCs by Ngan 
et al. (2008), who analyzed the changes in gene expression in ENCCs after 8 and 16 
hours of GDNF treatment. These authors showed that the Prokineticin pathway is 
activated by RET signaling, but found that few other genes were differentially 
expressed by the short-term GDNF treatment of ENCCs34. 
These gene expression studies have focused on individual genes that are 
highly expressed by ENCCs and showed that some of these genes are critical for the 
development of the ENS. However, for many highly expressed genes it is still 
unknown if and how they contribute to ENS development. In this study, we used an 
unbiased, systematic pathway analysis to identify the biological processes that are 
important for ENS development. Moreover, we treated ENCC cultures with GDNF 
for 14 days to identify the stable, long-term gene expression changes induced by 
RET signaling. We show that the expression of differentially expressed genes is 
regulated by known ENS-related genes, and by several genes not previously 
implicated in ENS development. These regulatory genes present novel candidates 








MATERIALS AND METHODS 
 
Animals 
Male C57BL/6 mice carrying Wnt1-Cre+/- were mated with C57BL/6 females that 
were homozygous for the Rosa26-LoxP-Stop-LoxP-YFP reporter locus. The stage of 
embryonic development was set to E0.5 on the day the vaginal plug was seen. 
Embryos carrying both Wnt1-Cre and Rosa26-LoxP-Stop-LoxP-YFP were identified 
based on YFP expression in the gastrointestinal tract and craniofacial tissues. 
 
ENCC isolation, culture conditions and RET activation 
Full length guts (foregut to hindgut) were dissected from E14.5 embryos. Single 
cell suspensions were made using 0.05 mg/ml Collagenase XI/Dispase II (Sigma 
Aldrich, St. Louis, MO, USA), followed by incubation for 3-5 min at 37⁰C and 
trituration. YFP-positive ENCCs were FACS sorted and directly seeded into 
Fibronectin-coated plates containing DMEM/F-12 medium (Invitrogen, Carlsbad, 
CA, USA) supplemented with 1% N2 supplement (Invitrogen), 2% B27 supplement 
(Invitrogen), 20 ng/ml FGF (Peprotech EC, London, UK), 20 ng/ml EGF (Peprotech 
EC) and 1% Penicillin-Streptomycin (Invitrogen). YFP-positive ENCCs from one gut 
were equally divided over two wells; one of which was supplemented with 50 
ng/ml GDNF (Peprotech EC). ENCCs were incubated at 37⁰C for 14 days in a 
humidified atmosphere with 5% CO2. Neurosphere-like bodies appeared after 3-5 
days and were kept in culture for 14 days without passaging. 
 
Immunostaining 
Wells with neurosphere-like bodies were fixed with 4% PFA for 15 minutes at 
room temperature (RT) and washed with PBS+1%Triton X 100 (PBT) for 2x5 
minutes. They were incubated in blocking solution (PBT + 1%BSA + 0.15% 
glycine) for 1 hour at RT followed by primary antibodies diluted in blocking 
solution overnight (O/N) at 4⁰C: rabbit anti-human p75 (1:500, Promega, UK), 
mouse-anti βIII-Tubulin (1:500, Covance UK). After several washes in PBT, 
secondary antibodies were applied: goat anti-rabbit Alexa Fluor 568 and goat anti-
mouse Alexa Fluor 568 (1:500, Invitrogen) O/N. DAPI was added to secondary 
antibodies (1:1000). Antibody was washed off (3x15 minutes with PBT). Slides 
were mounted using Vectashield (Vector labs, UK) and visualized using confocal 
microscopy imaging on Zeiss LSM 710 (Zeiss, Cambridge, UK). 
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RNA isolation and gene expression quantification 
RNA was isolated from untreated and GDNF-treated ENCC cultures, as well as from 
uncultured E14.5 embryonic guts using the RNeasy Mini Kit (Qiagen, Crawel, UK). 
RNA yield, purity and integrity were determined using the Agilent 2100 
BioAnalyzer with 6000 Nano Chips (Agilent Technologies, Amsterdam, The 
Netherlands). DNA microarray analyses and RNA quality controls were performed 
by ServiceXS (Leiden, The Netherlands) using GeneChip Mouse Genome 430 2.0 
arrays (Affymetrix, Santa Clara, CA, USA). For the ENCC vs gut experiment, 3 ENCC 
samples and 8 mouse gut samples entered the analysis. For the ENCC+GDNF vs 
ENCC experiment, 7 pairs of untreated and GNDF-treated ENCC cultures were 
analyzed. 
 
Data normalization, statistical analysis and functional analysis 
Quantile normalization and background correction were applied to the raw 
intensity values of all samples using Partek version 6.4 (Partek Incorporated, St. 
Louis, MO, USA) via GC Robust Multichip Analysis. For the ENCC vs gut analysis, 2 
sample T test statistics were applied in Partek to calculate the fold changes with 
associated p-values. Paired T test statistics were applied to calculate the fold 
changes with associated p-values for the ENCC+GDNF vs ENCC analysis. The fold 
change and p-value data were uploaded into Ingenuity Pathway Analysis (IPA) 
(Ingenuity/Qiagen, Redwood City, CA, USA). The probe level data was mapped to 
the gene level and averaged based on the median fold change values. For the 
differential gene expression analysis, significance thresholds of fold change >5 and 
p-value <1E-5 were applied for the ENCC vs gut comparison. For the ENCC+GDNF 
vs ENCC analysis, significance thresholds were set at fold change >1.8 and p-value 
<0.05. Gene Ontology enrichment was performed using DAVID Bioinformatics 
Resources 6.7 and Upstream Regulator Analysis was performed in IPA. For the 
Upstream Regulator Analysis the significance thresholds were set to z-score >1.8 
and p-value <0.05. Hierarchical clustering of Upstream Regulators and their 
downstream target genes was performed using the heatmap functionality in the 










Isolation of Enteric Neural Crest Cells  
To identify genes that are involved in ENS development, gene expression profiles 
of pure populations of ENCCs were generated. Mice expressing Cre recombinase 
under the neural crest-specific Wnt1 promoter were crossed with mice carrying 
the Rosa26-LoxP-Stop-LoxP-YFP locus. ENCCs were isolated at embryonic day 
E14.5, since at this stage ENCCs express markers of both early and late ENS 
development32. Double transgenic mouse embryos expressed YFP in neural crest 
cells in craniofacial and gastrointestinal tissues as expected (Figure 1A). YFP-
expressing cells were isolated from E14.5 gut using Fluorescence activated cell 
sorting (FACS) (Figure 1B). In culture, these cells formed neurosphere-like bodies 
(NLBs) within 3 to 5 days (Figure 1C). Notably, NLBs from GDNF-treated ENCCs 
were larger than NLBs from untreated ENCCs. Compared to untreated cultures, 
GDNF-treated ENCC cultures showed marked βIII-Tubulin-positive connections 
between NLBs, indicating that GDNF treatment induced neuronal differentiation of 
ENCCs (Figure 1C). Both untreated and GDNF-treated ENCC cultures expressed the 
neural crest marker p75/NGFR at 24 hours and 14 days in vitro. 
 
E14.5 ENCCs are enriched for markers of neuronal development and 
neuronal signaling 
The gene expression profile of cultured ENCCs (harvested from E14.5 embryos) 
was compared to E14.5 embryonic gut to identify genes that are highly expressed 
by ENCCs. Since whole gut samples contain a variety of cell types, such as 
endothelial cells, smooth muscle, connective tissue, serosa, enterochromaffin cells 
and approximately 5% ENCCs, the expression profiles of ENCCs and whole gut 
tissue are expected to be very different. Therefore, only genes with an >5-fold 
change in gene expression (975 genes) were included in downstream analyses. 
Gene Ontology analysis was performed to identify the biological pathways these 
genes are involved in. ENCC-expressed genes were highly enriched for the Gene 
Ontology terms transmission of nerve impulse, synaptic signaling and cell-cell 
signaling, that are associated with neuronal signaling (Figure 2). In addition, genes 
that are highly expressed in ENCCs play a role in biological-/cell adhesion and 
neuron differentiation. 1187 genes were >5 times less abundantly expressed in 
ENCCs than in the gut and these genes are involved in cell cycle control, in 
 




Figure 1. Isolation and characterization of ENCCs. A) Schematic overview of the Wnt1-Cre:Rosa26-
YFP mouse model. At embryonic day 14.5, transgenic mouse embryos expressed YFP in neural crest-
derived cells, including craniofacial tissue and ENCCs. B) YFP-expressing ENCCs were FACS-sorted from 
dissected guts and were cultured in the presence or absence of GDNF for 14 days. RNA was isolated 
from ENCCs as well as whole gut tissue and relative RNA expression levels were quantified by 
microarray analysis. C) ENCCs expressed the neural crest marker p75/NGFR at both 24 hours and 14 
days after isolation. Pronounced βIII-Tubulin-positive connections between NLBs were observed in 
ENCC cultures treated with GNDF. 




particular during active cell division (M-phase). This finding is consistent with the 
high proliferation rate of intestinal epithelial cells. Interestingly, genes highly 
expressed by ENCCs (and low in gut tissue) and genes highly expressed in total gut 
tissue (and low in ENCCs), are both significantly enriched for Gene Ontology terms 
biological- and cell adhesion and regulation of cell proliferation (Figure 2). 
However, these represent sets of genes with different properties and localizations. 
Adhesion molecules in ENCCs included genes expressed in the ENS, such as 
Immunoglobulin superfamily cell adhesion molecules (Ncam1, Ncam2, L1cam, 
Nrcam), (proto-) cadherins (Cdh2, Cdh6, Pcdh15, Pcdha4) and integrins (Itga4)35. 
Of note, Cdh13 was highly expressed by ENCCs and its human orthologue CDH13 
maps to the HSCR susceptibility locus 16q23.336. Adhesion molecules that were 
highly expressed in total gut tissue included Cdh1, which is expressed by Paneth 
cells and goblet cells in the intestinal epithelium37, the Claudin family of tight 
junction molecules (CLDN 2, 3, 4, 5, 6, 7, 8, 15 and 23), as well as genes involved in 
the apical junction complex (Desmocollin 2, Desmoglein 2, Plakophilin 2 and 3). 
These gut-expressed junction molecules are most likely expressed by the 
enterocytes of the intestinal epithelium.  
 
GDNF treatment of ENCCs induces terminal neuronal differentiation 
RET signaling is critical during all stages of ENS development and is important for 
survival, neuronal differentiation and neurite outgrowth at E14-E167,14,15,18,19. To 
identify the molecular pathways underlying these processes, the changes in gene 
expression in ENCCs after 14 days of GDNF treatment were analyzed. Compared to 
untreated ENCCs, the expression of 445 genes was at least 1.8 times higher in 
GDNF-treated ENCCs. The neuronal signaling genes that were highly expressed by 
ENCCs compared to the gut were even further up-regulated upon GDNF treatment 
(Figure 2). This finding suggests that GDNF treatment induced terminal neuronal 
differentiation in E14.5 ENCCs and is consistent with the pronounced βIII-Tubulin-
positive connections that were observed between NLBs grown from GDNF-treated 
ENCCs (Figure 1C). Additionally, the expression levels of 352 genes was at least 1.8 
times reduced by treatment with GDNF, including genes involved in biological- and 
cell adhesion and neuron differentiation. The adhesion molecules that are down-
regulated by GDNF include Cdh13, Col5a1, Fibronectin-1, Reelin, Thrombospondin 1 
and 4, and Vcam1. These adhesion molecules are involved in cell migration and cell 
motility, and thus corroborate the observation that ENCCs stop migrating when 
they undergo terminal neuronal differentiation38,39. Consistent with its 
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proliferative role in ENCCs and its inhibitory effect on neuronal differentiation, 
endothelin receptor type B (Ednrb) was down-regulated by GDNF. The down- 




Figure 2. Gene Ontology analysis of differentially expressed genes. Differentially expressed genes 
between ENCCs and the gut, and between untreated and GDNF-treated ENCCs were annotated by Gene 
Ontology enrichment analysis. Values represent multiple testing corrected (Benjamini) p-values. The 
six most significant Gene Ontology terms per gene set are given and these are partially overlapping 
between the different sets of genes. 




neuronal signaling genes, shows that different genes are involved in early and late 
neuronal development. 
The mature ENS displays a great diversity in neuronal subtypes, but the 
molecular mechanisms controlling neuronal subtype specification in the ENS are 
poorly understood. To test whether RET signaling in ENCCs contributes to the 
specification of neuronal subtypes, the expression of neuronal subtypes markers 
was determined in untreated and GDNF-treated ENCCs. The expression levels of 
cholinergic (Acat2, Ache, Chrna5), glutamatergic (Grik2, Gria1, Grid2) and 
GABAergic (Gabra1, Gabrg2, Gabrg3) markers were increased by GDNF, as well as 
the expression of CART prepropeptide (Cartpt), NPY receptor Y2 (Npy2r), 
Substance P precursor Tac1, Dopamine beta-hydroxylase (Dbh) and Vasoactive 
intestinal peptide (Vip). The elevated expression of these subtype markers 
supports our observation that RET signaling is involved in terminal neuronal 
differentiation of ENCCs. Although several other subtype markers, such as 5-HT, 
Calbindin, Calretinin, CGRP, Enkephalin, and NOS were not found to be 
differentially expressed, the wide range of neuronal subtypes markers that are up-
regulated by GDNF suggests that RET signaling might be involved in the 
specification of different neuronal subtypes. 
 
Upstream Regulator Analysis identifies known and new genes important for 
ENS development 
Having identified gene expression patterns in untreated and GDNF-treated ENCCs, 
we next aimed to identify regulatory genes in ENCCs and in GDNF-induced 
neuronal maturation. To address this, we used the Upstream Regulator Analysis 
tool in Ingenuity Pathway Analysis (IPA). Upstream Regulators are predicted to 
regulate the expression of differentially expressed genes, taking into account the 
enrichment for genes that are known to be regulated by a particular Upstream 
Regulator (p-value of overlap) and the direction of differential gene expression 
(activation z-score)40. Many genes that are known to have important regulatory 
functions in ENS development are highly expressed by ENCCs. Therefore, genes 
were selected from the Upstream Regulator Analysis that were either highly 
expressed by ENCCs or up-regulated by GDNF. The Upstream Regulator Analysis of 
differentially gene expression between ENCCs and the gut yielded nine regulatory 
genes that are highly expressed by ENCCs themselves (Table 1). 
The most significant Upstream Regulator, in terms of both activation z-
score and fold change in expression, is Cdkn2a (p16). CDKN2A induces cell cycle 
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arrest and thereby inhibits proliferation. Another Upstream Regulator, Elavl1, 
mediates the anti-proliferative activity of CDKN2A. Cdkn2a and Elavl1 activity thus 
explain the low expression of cell cycle-related genes in ENCCs compared to the 
gut. Nupr1 is a predicted Upstream Regulator that is also involved in cell cycle 
control, and is important for cell cycle progression during cellular stress41–43. In 
our study, Nupr1 might be up-regulated in ENCCs to counteract the stress induced 
by in vitro culturing of ENCCs. 
In line with its function in ENS development, Ret is a predicted Upstream 
Regulator of gene expression in ENCCs. Another gene that is known to regulate 
ENS development, Sox10, is a predicted Upstream Regulator as well. SOX10 is a 
  
 












Link to HSCR 
High in 
ENCCs 
Cdkn2a 5.196 1.65E-07 55 467.6 
 
Nupr1 4.740 2.51E-16 127 6.2 
 
Bdnf 3.286 1.37E-05 46 9.2 
Regulator of SNAP25 and VAMP2; migration of 
ENCCs (33) 
App 2.931 1.47E-12 157 7.1 
Overexpression (Down syndrome) causes neuronal 
loss (57–59) 
     
Regulator of SNAP25 and VAMP2; migration of 
ENCCs (33) 
     
Inhibitor of MMP2 that is important for migration of 
ENCCs (60) 
Sox10 2.596 1.56E-03 9 19.8 Known HCSR gene (61) 
Ret 2.359 9.10E-05 29 16.5 Known HSCR gene (62,63) 
Mapk10 2.195 6.71E-03 5 22.7 Deletion in HSCR patient (64) 
     
Phosphorylates APP and STMN2 (65,66) 
Elavl1 2.183 1.98E-02 16 5.4 
 
Timp1 1.890 1.38E-02 7 7.9 




Adora2a 1.941 8.39E-02* 10 1.9 
 
Npy2r 1.727* 2.58E-03 4 1.9 
Maps to HSCR susceptibility locus 4q31.3-q32.3 
(88) 
Regulatory genes in ENCCs were predicted by IPA Upstream Regulator Analysis. Significant Upstream 
Regulators were defined as having an activation z-score >1.8 and p-value of overlap <0.05. From the 
Upstream Regulator Analysis, genes were selected that were expressed >5 times higher in ENCCs than 
in the gut, or that were >1.8 times up-regulated by GDNF. Many Upstream Regulators can be linked to 
ENS development and HSCR (also see Figure 4). *: Near-significant values. 




transcription factor that is required for survival of ENCCs and maintenance of their 
progenitor state44,45. The identification of Ret and Sox10 as regulatory genes in 
ENCCs demonstrates the validity of the Upstream Regulator Analysis and suggests 
that the remaining Upstream Regulators and their respective pathways are key 
regulators of ENS development. These remaining Upstream Regulators are Bdnf, 
App, Mapk10 and Timp1. 
Brain-derived neurotrophic factor (Bdnf) is expressed by ENCCs and the 
mucosa and its receptors TRKB and p75/NGFR are abundantly expressed in the 
human and mouse ENS46,47. BDNF signaling promotes neuronal survival, growth 
and differentiation and functions in the mature ENS by controlling peristalsis and 
colonic emptying48,49. 
Amyloid precursor protein (App) is the precursor of Amyloid-β plaques in 
Alzheimer disease. The endogenous function of APP is not completely understood, 
but APP has been shown to be involved in synapse formation and plasticity and is 
expressed in the human ENS50–53. 
Mitogen-activated protein kinase 10 (Mapk10/Jnk3) is highly expressed by 
ENCCs32. MAPK10 is involved in a broad range of processes, including 
proliferation, differentiation, inflammation, cellular stress and neuronal apoptosis 
and is regulated by RET signaling in ENCCs34. 
Timp1 encodes a metallopeptidase inhibitor and is a predicted Upstream 
Regulator of gene expression in ENCCs. To our knowledge, the expression of Timp1 
in the ENS has not been described before. Besides Timp1, Timp2 and Timp3 are 
also more abundantly expressed in ENCCs than in the gut in our data. TIMP1 might 
contribute to ENS development in several ways. TIMP1 is involved in Epithelial-
Mesenchymal Transition and thereby for the delamination of neural crest cells 
from the neuroepithelium54. In CNS development, TIMP1 regulates neural stem cell 
chemotaxis and neurite outgrowth in cortical neurons and might serve similar 
functions during ENS development55,56. 
 
Adenosine and Neuropeptide Y signaling modulate GDNF-induced changes in 
gene expression 
Upstream Regulator Analysis of GDNF-induced changes in gene expression did not 
result in any genes that have both a significant activation z-score and p-value. 
There are, however, two Upstream Regulators with near-significant z-scores and p-
values; the adenosine receptor A2a (Adora2a) and the neuropeptide Y receptor Y2 
(Npy2r). Adenosine regulates intestinal secretion, motility and immune responses 
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and acts through adenosine receptors A1, A2a, A2b and A3. The adenosine A2a 
receptor is expressed by the myenteric- and submucosal plexuses in both the small 
and large intestine67. ADORA2A modulates intestinal motility by inhibiting motor 
activity in the duodenum and colon of mice and humans, respectively68,69, thereby 
allowing relaxation of the bowel. 
Npy2r encodes the Neuropeptide Y receptor Y2, a receptor for 
neuropeptide Y (NPY) and peptide YY (PYY)70. NPY and PYY induce colonic smooth 
muscle relaxation and inhibit intestinal contractility and motility in response to 
feeding, which is exerted through the neuropeptide Y1 and Y2 receptors71,72. 
 
Synergistic regulation of gene expression 
The predicted Upstream Regulators each have between 4 and 157 downstream 
targets, combining up to 377 unique genes. Although a single Upstream Regulator 
regulates the expression of most of these genes, there are also 67 genes that are 
regulated by multiple regulatory genes (Figure 3). Many of the genes that are 
regulated by three or more Upstream Regulators are known to play a role in the 
ENS, such as Il-6, c-Jun, (p75/)Ngfr, Prnp, App, Napb, Nos1 and Npy. Hierarchical 
clustering of downstream target genes showed that there are clusters of co-
regulated genes with similar functions. For example, Gap43, Bdnf, Mapt, Mbp, Penk, 
Snap25, Syn1, Syn2, Syp, Tubb3 and Vamp2 all are involved in synaptic signaling 
and are synergistically regulated by Bdnf and App. Likewise, Cdc25c, Ccna2, 
Igf2bp3, Mki67, Skp2 and Tmpo are all involved in cell division and are regulated by 
both Cdkn2a and Nupr1. The synergistic regulation of downstream target genes by 
multiple Upstream Regulators provides insight into the molecular networks 





In this study we have analyzed gene expression profiles of GDNF-treated and 
untreated mouse ENCCs (isolation time E14.5) and E14.5 mouse embryonic gut. 
Unbiased, systematic Gene Ontology analysis showed that, compared to the whole 
gut, ENCCs highly express genes involved in cell adhesion, neuronal differentiation 
and synaptic signaling, representing various aspects of ENS development. These 
data corroborate findings by Heanue and Pachnis32. These authors compared gene  






Figure 3. Upstream Regulators regulate gene expression synergistically. The regulation of 
downstream target genes (right-hand side) by Upstream Regulators (bottom) is shown for all genes 
that are regulated by two or more Upstream Regulators. Red and blue boxes indicate regulation by an 
Upstream Regulator in naïve and GDNF-treated ENCCs, respectively. Yellow indicates that the gene is 
not regulated by the specific Upstream Regulator. 
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expression profiles of E15.5 ganglionic (Ret+/+) and aganglionic (Retk-/k-) gut and 
found that ENCCs express markers of early differentiating glia and neurons, 
terminally differentiated neurons, axonal outgrowth and synaptogenesis. In fact, of 
the 47 genes that were confirmed to be expressed in the ENS by in situ 
hybridization in that study, 35 genes (74%) were highly expressed by ENCCs in 
our study. Likewise, the gene expression study by Vohra et al. confirmed 
expression in the ENS for 38 genes by in situ hybridization, of which 23 genes 
(61%) were differently expression between ENCCs and the gut in the present 
study33. Of the 105 ENCC-expressed genes found by Iwashita et al., 19 genes (18%) 
overlap with our data31. Importantly, this shows that the 14 days in vitro culturing 
of ENCCs in our study did not lead to major changes in gene expression. Of the 975 
genes that were higher expressed in ENCCs than in total gut tissue, 848 genes 
(87%) were not reported in any of the three expression studies mentioned above. 
However, part of these 848 genes are already known to be involved in ENS 
development73,74. This study therefore represents a more complete catalog of 
known and newly identified genes that are expressed in the developing ENS. 
 
Regulators of gene expression in ENCCs are putative HSCR genes 
Cdkn2a, Nupr1, Ret, Sox10, Bdnf, App, Mapk10, Elavl1 and Timp1 were identified as 
genes that are highly expressed in ENCCs and that regulate the expression of other 
ENCC-expressed genes. Of these regulators, RET and SOX10 are known HSCR genes. 
Mutations in RET and SOX10 contribute to HSCR in humans and mice with null 
mutations for Ret and Sox10 display total intestinal aganglionosis9,62,63,61,75,76. Given 
the known neuronal functions of Bdnf, App, Mapk10 and Timp1, this raises the 
hypothesis that these regulatory genes might also be implicated in HSCR and other 
neuropathies, such as intestinal pseudo-obstruction, incontinence or constipation. 
Mapk10 is a highly interesting regulator of gene expression in ENCCs with regard 
to HSCR. MAPK10 modulates neuronal differentiation through phosphorylation of 
APP and STMN265,66. STMN2 (SCG10) interacts with Kinesin Binding Protein (KBP, 
KIAA1279) and mutations in KBP have been linked to the HSCR-associated 
Goldberg-Shprintzen Syndrome77,78. Loss of MAPK10 could therefore contribute to 
HSCR through impaired APP and/or STMN2 signaling in enteric neuron 
differentiation. Since Mapk10 was reported to be highly expressed in ENCCs, it was 
included in a copy number variant screen for candidate genes in HSCR64. The 
authors reported one deletion in MAPK10 among 18 HSCR patients. Segregation 
analysis showed that the MAPK10 deletion was neither necessary nor sufficient to 




cause HSCR in this family and the authors therefore hypothesized that the deletion 
in MAPK10 acts as a modifier for developing HSCR64. 
ENS development is of interest in relation to Down syndrome (Trisomy 
21). The incidence of HSCR in Down syndrome is 2.6%, which is over a hundred 
times higher than in the general population79. This suggests that the duplication of 
one or more genes on chromosome 21 contributes to the onset of HSCR. APP is 
located on chromosome 21 in humans and App is an Upstream Regulator of gene 
expression in the developing murine ENS. It has been shown that overexpression 
of wild type human APP in mice causes loss of cholinergic neurons through 
disruption of Nerve Growth Factor transport and impairs neurogenesis in the 
CNS57,58. Moreover, mice overexpressing an Alzheimer’s disease mutant form of 
APP show reduced neuronal density in the myenteric plexus and altered intestinal 
motility80. In the latter study it is not clear, however, whether the phenotype was 
caused by the increased expression level of APP or by the presence of the 
Alzheimer mutation in the overexpressed gene. These reports, combined with the 
regulatory function of App in ENCCs, raise the intriguing hypothesis that 
overexpression of APP might contribute to the high incidence of HSCR and other 
gastrointestinal abnormalities in Down syndrome patients.  
In our Upstream Regulator Analysis, App and Bdnf shared several 
downstream target molecules that are involved in synaptic signaling, including 
Snap25 and Vamp2. Snap25 and Vamp2 mediate the fusion of synaptic vesicles and 
the high expression of these genes in ENCCs was reported by Vohra et al., who 
subsequently showed that Snap25 and Vamp2 are important for ENCC migration 
and neurite outgrowth33. Since both genes are regulated by APP and BDNF, 
aberrant APP and BDNF signaling might result in similar defects in ENS 
development. 
The Upstream Regulator Timp1 is a natural inhibitor of matrix 
metalloproteinases (MMPs), a group of proteins that rearrange the extracellular 
matrix. MMP2 activity is inhibited by TIMP1 and pharmacological inhibition of 
MMP2 impairs the migration of ENCCs along the mouse gut60. Furthermore, the 
chemoattractive effect of TIMP1 on neural stem cells is mediated by β1-Integrin, 
and lack of β1-Integrin in ENCCs causes a HSCR-like phenotype in mice55,81. 
Another member of the TIMP family, TIMP2, is required for the migration of 
cardiac neural crest cells in avians82. These data highlight the importance of the 
extracellular matrix in neural crest migration and suggest a novel role for TIMP 
proteins in ENS development. 
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Of note, a metalloproteinase inhibitor domain that inhibits MMP2 has been 
identified in APP83, indicating that APP inhibits MMP2 activity directly. 
Additionally, APP may inhibit MMP2 indirectly, as it was shown that mice 
overexpressing Alzheimer mutant APP and Presenilin-1 have higher levels of 
TIMP1 in their ileum than wild-type mice84. Inhibition of MMP2 is another 
mechanism by which overexpression of APP might contribute to the development 
of HSCR in Down syndrome. 
As discussed here, the Upstream Regulators with neuronal functions are 
either known HSCR genes, or are linked to the molecular pathways underlying 
HSCR or animal models of aganglionosis. There is a large body of literature 
suggesting interactions between these genes, allowing us to construct a 
hypothetical network of regulatory genes in ENCCs (Figure 4). The transcription 
factor SOX10 binds to an enhancer of Ret, thereby regulating Ret expression85. In 
turn, RET activates the MAPK pathway, including MAPK1034,86. MAPK10 
phosphorylates APP, which regulates the expression of synaptic genes Snap25 and 
Vamp2 together with BDNF, and directly inhibits MMP2 activity and indirectly via 
TIMP165,83,84. MAPK10 also phosphorylates STMN2, leading to cytoskeletal 
remodeling in conjunction with KBP66,77. 
 
Modulators of RET-signaling in ENCCs 
Several signaling cascades are activated by RET, including Pi3K/AKT, ERK, p38-
MAPK and JNK pathways86. Little is known, however, how these pathways 
contribute to RET- induced proliferation, migration, differentiation and survival of 
ENCCs. Similar to our study, Ngan et al. analyzed the changes in gene expression 
induced by GDNF treatment of ENCCs and found that the expression levels of 29 
genes were increased by GDNF treatment. Only 4 of these 29 genes were up-
regulated by GDNF in our data. These different findings can be explained by two 
fundamental differences in study design, duration of GDNF stimulation and 
developmental stage of ENCCs. Ngan et al. investigated the short-term changes (8 
and 16 hour GDNF treatment) in E11.5 ENCCs, when RET is required for migration 
and proliferation. In the present study, on the other hand, we have analyzed the 
long-term changes (14 days GDNF treatment) in ENCCs at E14.5, a stage in which 
RET is involved in survival and differentiation. The four genes that are up-
regulated by GDNF treatment in both studies (Kcnd2, Vip, Olfm1 and Tagln3), are 
therefore likely to be critical modulators of RET signaling and are possibly 
involved in different aspects of ENS development. 




Long-term GDNF treatment of ENCCs resulted in reduced expression 
levels of genes involved in neuronal migration and early neuronal differentiation. 
Conversely, GDNF increased the expression of genes that are associated with 
terminal neuronal differentiation and synaptic signaling. Upstream Regulator 
Analysis showed that the adenosine receptor A2a and the neuropeptide Y receptor 
Y2 are near-significant modifiers of these cellular processes in GDNF-treated 
ENCCs. Signaling via NPY2R modulates the neurotrophic effect of GDNF on ENCCs, 
as a study by Anitha et al. has shown that GDNF treatment of ENCCs results in 
increased proliferation and reduced apoptosis of ENCCs in a NPY-dependent 
manner87. Of interest, the human orthologue of Npy2r maps to the HSCR 
susceptibility locus4q31.3-q32.3 and increased NPY levels have been reported in 




Figure 4. Hypothetical molecular network implicating Upstream Regulators in HSCR. The 
Upstream Regulators in ENCCs are either known HSCR genes (RET and SOX10), can be linked to a 
known HSCR gene (KBP), or can be linked to genes that are critical for colonization of the gut by ENCCs 
(SNAP25, VAMP2 and MMP2). The link of each Upstream Regulator to HSCR and the respective 
references are summarized in Table 1. Arrows indicate activation and blunted lines indicate inhibition. 
Solid lines represent direct interactions in ENCCs. Dotted lines represent indirect interactions and 
evidence from other cell types. 




In conclusion, systematic analysis of E14.5 ENCCs gene expression profiles showed 
that they express markers of neural migration, axonal outgrowth and neuronal 
signaling. Upstream Regulator Analysis predicted genes that serve critical 
regulatory functions during ENS development and we propose a mechanistic 
network of action for these regulatory genes. Additionally, we found that GDNF 
treatment of ENCCs caused terminal neuronal differentiation into a variety of 
neuronal subtypes. These regulatory genes in ENS development give insight into 
the molecular pathways regulating ENS development and provide novel candidate 
genes for HSCR. 
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De novo mutations (DNMs) play a major role in the development of rare genetic 
syndromes and more common neurodevelopmental disorders. Next-generation 
sequencing (NGS) allows for the unbiased analysis of DNMs in the human genome 
or exome. Detecting DNMs in NGS data is challenging, as the number of sequencing 
artefacts is far greater than the number of real DNMs. Thresholds for reference 
allele ratio, sequencing depth, and Genotype Quality have been shown to 
effectively reduce the number of sequencing artefacts. In this study, we used a 
training set of 22 confirmed DNMs and 59 false positives to test how thresholds 
settings for these sequencing parameters affect the sensitivity and specificity of 
detecting DNMs. We found that removing the maximum assigned value to the 
Genotype Quality score allows to distinguish confirmed DNMs from false positives. 
Sequencing depth and reference allele frequency also had good and moderate 
discriminative power, respectively. By combining thresholds for all parameters, we 
were able to detect DNMs with 100% sensitivity and 98.3% specificity in our 
training dataset. Validation of the filtering method successfully detected all 33 
confirmed and four novel DNMs in an independent dataset and produced 1 false 
positive. The findings of this study provide a guideline for the efficient detection of 
DNMs in NGS data. 
  






A de novo mutation (DNM) is an alteration in the genome that is present for the 
first time in a person as a result of a mutation in a germ cell (egg or sperm) of one 
of the parents or in the fertilized egg itself. Next-generation sequencing (NGS) has 
allowed the genome- and exome-wide detection of DNMs. Exome sequencing has 
revealed a role for DNMs in rare genetic syndromes and more common 
neurodevelopmental disorders1–13. These studies found an average of 1 to 2 exonic 
DNMs per proband. However, technical artefacts in NGS data poses a challenge for 
the identification of DNMs. Due to the large number of genotyped base pairs in 
exome sequencing, the number of incorrectly called genotypes is several orders of 
magnitude larger than the actual number of DNMs. Currently, DNM detection 
methods are not fully accurate and all methods still require confirmation by 
validation techniques such as Sanger sequencing to discriminate between real 
DNMs and false positives. As cohort sizes in sequencing studies are expanding and 
exome sequencing is being replaced by whole-genome sequencing, the number of 
candidate DNMs that require experimental validation can reach thousands14–16. It 
is therefore important to detect DNMs effectively and efficiently.  
It has been proposed that the accuracy of genotype calling can be 
improved by jointly calling the genotypes of multiple individuals17,18. Multiple-
sample genotype calling uses the observed alleles in other sequenced individuals 
to calculate the prior probability of finding a given genotype. For DNMs, which are 
typically found in only a single individual, the prior probability of finding a variant 
is low. This means that strong evidence is required to reliable call a variant. Joint 
genotype calling of multiple individuals has the additional benefit of annotating 
reference allele homozygous genotypes in the variant file at positions where a 
variant has been found in another individual. Since DNMs are absent in parents, it 
is important to be able to discriminate between reference allele homozygous 
genotypes and missing genotypes to efficiently detect DNMs.  
When applied to parents-proband trios, joint genotype calling can improve 
the detection of DNMs19. Several software packages were developed to detect 
DNMs in NGS data that all make use of trio-based joint genotype calling20–24. Each 
software package has its additional methodology to specifically detect DNMs. 
PolyMutt and DeNovoGear use genomic mutation rates to calculate the likelihood 
of finding a DNM at a specific position20,21. However, mutation rates vary between 
genomic regions and TrioDeNovo was developed to take region-specific mutation 
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rates into account22. DNMFilter uses machine learning to discriminate between 
DNMs and false positives based on several sequencing parameters23 and mirTrios 
uses sequencing parameters in a probabilistic model to detect DNMs24.  
Three sequencing parameters were shown to efficiently eliminate 
incorrect genotype calls, while retaining most of the true variants: the reference 
allele ratio, sequencing depth and Genotype Quality score25,26. In the present study, 
we aimed to assess the relative contribution of these parameters to DNM detection 
and analyzed how filtering thresholds for these parameters, in probands and 






DNA from 20 parents-proband trios was subjected to exome sequencing in three 
different centers (Table 1). Each center performed exome capture and NGS 
according to in house protocols. In short, the exomes of 5 trios were captured 
using the Illumina Truseq Exome Enrichment kit and sequenced on an Illumina 
GAIIX machine. The other two centers (5 and 10 trios, respectively) both used the 
Agilent SureSelect Exome Capture kit V4 and an Illumina HiSeq2000 sequencer. 
Sequencing reads from all 20 trios were aligned to the human reference genome 
hg19 (build 37) using standard BWA alignment27. Multi-sample genotype calling 
was performed on all individuals simultaneously using the Genome Analysis 
Toolkit (GATK) Unified Genotyper 2.028.  
 
 
Table 1. NGS technologies and validation results per center. 























55.7 X 95% 32 15 46.9% 1.5 
Parents-proband trios were sequenced in three different centers. Sequencing depth differed per center 
and affected the number of confirmed DNMs and validation success accordingly.  
 




Threshold setting to identify candidate DNMs 
DNMs were identified as heterozygous variants in probands that were absent in 
both parents. The Mendelian Disease Arguments function of the KGGSeq software29 
was used to extract DNMs from the multi-sample VCF file. Variants were selected 
to have: 1) call quality ≥50; 2) mapping quality ≥30; 3) read depth ≥5 in probands 
and parents; 4) Genotype Quality score ≥10 in probands and parents; 5) reference 
allele ratio ≥0.10 in heterozygous probands; 6) reference allele ratio ≤0.10 in 
reference allele homozygous parents; and 7) are in coding regions of the genome 
(Figure 1).  
These low thresholds settings preserved most real variants in the data, yet 
removed many low quality variants25. To further reduce the number of DNM 
candidates, variants with a minor allele frequency above 1% in dbSNP137, 
1000Genomes 201204, ESP6500AA and ESP6500EA were excluded.  
 
Visual inspection and further selection of DNMs 
Candidate DNMs after low threshold filtering were visually inspected in the 
Integrative Genomics Viewer (IGV)30 to select the most likely DNMs. Candidate 
DNMs were discarded if 1) all alternative allele reads were from the same strand, 
2) more than two alleles were observed, 3) the proband showed the alternative 
allele in <20% of the sequencing reads and a parent in >5% of the sequencing 
reads, 4) only a single sequencing read supported the alternative allele, 5) ≥50% of 
the sequencing reads had a base PHRED quality score <10.  
 
Validation of DNMs 
Candidate DNMs were Sanger sequenced in the proband and the parents by two 
individual sequencing runs in opposite directions.  
 
Comparison between confirmed DNMs and false positives 
The reference allele ratio, sequencing depth and (unmaximized) Genotype Quality 
score of confirmed DNMs and false positives were entered and plotted in GraphPad 
Prism 5. Parameters values were compared between confirmed and false positive 
DNMs and between probands and parents by Mann-Whitney test. GraphPad Prism 
5 was subsequently used to generate receiver operating characteristic (ROC) 
curves and calculate the area under the curve (AUC).  
  




Figure 1. DNM filtering pipeline. DNMs were identified as heterozygous variants in probands that 
were absent in both parents. Low thresholds for sequencing parameters removed low quality DNM 
candidates. The most likely DNMs were selected for Sanger sequencing validation by visual inspection 
in IGV. Based on the characteristics of confirmed DNMs, candidates after initial filtering were re-









DNM validation cohort 
A second, independent exome sequencing dataset of 25 parents-proband trios was 
generated by the Beijing Genomics Institute (BGI). Exomes were captured using 
Agilent SureSelect Exome Capture kit V4, NGS was performed on an Illumina 
HiSeq2000 and variants were called for each sample individually by the GATK 
Unified Genotyper 2.0. DNMs were selected as describe for the training cohort, 
with slightly more stringent thresholds for three parameters; 1) read depth ≥15 in 
probands, 2) reference allele ratio ≥0.35 in probands, 3) Genotype Quality score = 





Identification of DNMs 
Exome sequencing data from 20 parents-proband trios, generated by three 
sequencing centers using two sequencing technologies, were used to screen for 
DNMs (Table 1). Candidate DNMs were identified by filtering at low thresholds for 
quality parameters and the 91 most likely DNMs (4.55 ± 3.35 per trio) were 
selected for Sanger sequencing validation (Figure 1). Eight DNM candidates could 
not be amplified successfully by PCR. Of the remaining 83 candidate DNMs, 24 
were confirmed as DNMs and 59 candidates proved to be false positives.  
The set of 91 candidate DNMs was obtained by variant filtering and 
selection of the best candidates in IGV. The selection of candidates in IGV was 
performed manually and was partially subjective. Therefore, all DNM candidates 
after initial filtering were filtered again, using more stringent threshold settings 
that were set after evaluation of the confirmed and false positive DNMs (Figure 1). 
This last, more stringent analysis identified three additional candidate DNMs that 
had been missed in the first selection in IGV. Sanger sequencing validation showed 
that all three additional candidate DNMs were false positives. 
 
Mosaic DNMs 
Within the confirmed group of DNMs there were two outliers. In these two the 
reference allele ratios observed were 0.80 and 0.76, respectively. In line with the 
skewed distribution of reference and alternative alleles in the NGS data, Sanger 
sequencing validation of these two mutations showed a higher peak for the 
reference allele than for the alternative allele. This finding suggests that these 
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DNMs were present in only part of the DNA sample and are somatic, rather than 
germline DNMs. Since our focus was on the identification of germline DNMs, the 
two somatic DNMs were excluded from the comparison between confirmed DNMs 
and false positive DNM candidates. 
 
Characteristics of confirmed DNMs are different from false positives 
To assess what the discriminating features of true DNMs are in NGS data, reference 
allele ratio, sequencing depth and Genotype Quality score were compared between 
the 22 confirmed germline DNMs and 59 false positives. 
 
Reference allele ratio 
In probands, the average reference allele ratio did not differ between confirmed 
DNMs and false positives (p=0.0585), but confirmed DNMs fell within a smaller 
range (0.44-0.70) than false positives (0.20-0.86) (Figure 2A). In the homozygous 
reference parents, base calls for the alternative allele are not expected, but were 
nevertheless identified in a total of 5 sequencing reads in three different parents. 
All 5 alternative allele calls had base call quality scores below 10 and were 
therefore likely to be technical artefacts. In contrast, most of the reads underlying 
the DNM had a high quality (PHRED>20). If the low-quality base calls do not 
represent artefacts, then there likely is a low-level mosaicism at that position in 
the parent. Low-level mosaicisms of a few percent cannot be detected by Sanger 
sequencing, but can be identified by deep-sequencing NGS. Sequencing reads 
supporting the alternative allele were observed in 26.3% of the false positive DNM 
candidates and with higher base call quality scores. The presence of (low-quality) 
alternate reads in the parents therefore suggests that a DNM candidate is likely, 
but not necessarily, a false positive.  
 
Sequencing Depth 
The average sequencing depth of confirmed DNMs was higher than that of false 
positives, in both probands and their parents (p=1.87E-7 and p=1.30E-10, 
respectively) (Figure 2B). In probands, the lowest observed sequencing depth of 
confirmed DNMs was 17, while 53% of false positives had a lower sequencing 
depth (Figure 2B). With a minimal of 9 reads, parents showed a lower minimal 
sequencing depth for confirmed DNMs than probands, although the average 
sequencing depth did not differ between probands and parents (p=0.300).  
 


















Figure 2. Characteristics of confirmed 
DNMs and false positives in probands 
and parents. Reference allele ratio, 
sequencing depth and second smallest 
genotype likelihood were plotted for all 
individual data points. Lines represent 
mean values. A) Reference allele ratio in 
probands ranges from 0.44 to 0.70, 
whereas this range was wider for false 
positives. Although many false positives 
showed reads with the alternative allele 
in parents, these were found at low 
frequency in confirmed DNMs as well.  
B) Sequencing depth of confirmed DNMs 
was higher than that of false positives, in 
both probands and parents. The 
minimal depth of confirmed DNMs was 
17 in probands and 9 in parents. C) The 
second smallest PHRED-scaled genotype 
likelihood (ssPL) represents the 
unmaximized Genotype Quality score. 
With all values over 200, ssPL values 
were remarkably high for confirmed 
DNMs in probands. 
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Genotype Quality score 
A genotype call is produced for each covered position in NGS data, which can be 
either AA, AB or BB. For each of these three genotypes, a likelihood score is 
calculated that indicates how likely the genotype is to be true, considering the 
number of reads and their qualities supporting the A and B alleles. The most likely 
one of the three genotypes is selected as the genotype at that position. The 
likelihood scores for the three possible genotypes are defined as a PHRED score (–
10*log10[p-value]), and is referred to as the PHRED-scaled Genotype Likelihood 
(PL). The PHRED-scaled Genotype likelihoods (PL) scores are normalized such that 
the most likely genotype receives a score of 0. The Genotype Quality (GQ) score 
(not to be confused with the Genotype Likelihood (PL) score) is defined as the 
second smallest of the three Genotype Likelihood (PL) scores (the smallest always 
being 0). So if the two alternative genotypes are very unlikely, they will have high 
Genotype Likelihood (PL) scores and hence the Genotype Quality (GQ) score will 
also be high. The maximum value that is assigned to the Genotype Quality (GQ) 
score is 99, meaning that all values above 99 will be set to this maximum.  
The Genotype Quality (GQ) score is a commonly used quality parameter in 
NGS data and was therefore used to compare confirmed DNMs and false positives. 
All confirmed DNMs and 35 of 59 (59.3%) false positives had a Genotype Quality 
(GQ) score of 99 in probands, suggesting that confirmed and false positive DNMs 
had very similar Genotype Quality (GQ) scores. However, the Genotype Likelihoods 
(PL) of the other two possible genotypes are specified in a VCF file as well, and no 
maximum value is assigned to these scores. The second smallest PHRED-scaled 
Genotype Likelihood (ssPL) can therefore be regarded as the unmaximized 
Genotype Quality (GQ) score. These ssPL scores were significantly higher in 
confirmed DNMs than in false positive DNM candidates, in probands (p=3.85E-14) 
and in parents (p=2.61E-12) (Figure 2C). All ssPL scores in probands were above 
200, whereas 84.7% of all false positives had ssPL values below 200. The ssPL 
score provides a good distinction between true and false positive DNMs. The high 
minimum ssPL values for confirmed DNMs were not observed in parents, where 
the lowest ssPL value was 27.  
 
Discriminative power of different parameters 
Having compared the characteristics of confirmed DNMs and false positives, we 
analyzed how the thresholds for the reference allele ratio, the sequencing depth 
and the ssPL influenced the sensitivity and specificity of detecting DNMs. DNMs 




could not be accurately detected based on thresholds for reference allele ratio, 
neither in probands nor in parents (Figure 3A,B). A sequencing depth threshold 
around 30 allowed the detection of DNMs with both a sensitivity and specificity of 
~75%, in both probands and parents (Figure 3C,D). An ssPL threshold of 200 in 
probands detected DNMs with 100% sensitivity and 84.7% specificity (Figure 3E). 
In comparison, selection of DNMs based on a maximum Genotype Quality score of 
99 identified DNMs with a specificity of only 40.7%. In parents, 79.2% sensitivity 
and 88.0% specificity can be obtained by a ssPL threshold of 80 (Figure 3F).  
Receiver Operating Characteristic (ROC) curves were generated to 
determine the discriminative power of the different sequencing quality 
parameters. The ssPL in probands was the best predictor for DNMs, with an area 
under the curve (AUC) of 0.9607 (Figure 4). ssPL in parents and sequencing depth 
in probands and parents were to a lesser extent able to discriminate DNMs from 
false positives (AUC = 0.8321, 0.8463 and 0.8077, respectively). The reference 
allele ratio had low predictive power. The AUC in probands was 0.6140, hardly 
better than a variable that has no predictive power (AUC of 0.5). The specificity of 
detecting DNMs on the basis of reference allele ratio in parents never reached 
above 26.3% and the corresponding AUC is 0.6052. By combining thresholds that 
allow maximum sensitivity (100%), only 1 false positive was observed (98.3% 
specificity). Six false positives were found (89.8% specificity) when respecting the 
maximum Genotype Quality score of 99.  
 
Validation on independent data set 
The characteristics of confirmed DNMs and false positives were based on NGS data 
from three different centers, using two different technologies. The parameters 
described thus reflect the characteristics of DNM across multiple datasets. The 
applicability on independent NGS datasets was further evaluated using a dataset 
with 33 confirmed DNMs. Using conservative filtering thresholds (see Methods), all 
confirmed DNMs were successfully detected with only 1 false positive. Moreover, 
four additional DNM candidates were identified that had been missed in the initial 
DNM screening of the confirmation set. These DNM candidates had been ignored 
because they showed the alternative allele in 1.2-3.0% of the sequencing reads in 
the parents. However, all four candidates were confirmed to be DNMs by Sanger 
sequencing validation. A total of 9 reads with the alternative allele were observed 
in these four DNMs. Three had a low base call quality (≤9), whereas the base call  
 




Figure 3. Effect of filtering thresholds on sensitivity and specificity of DNM detection. The 
sensitivity and specificity with which DNMs were detected are plotted against filtering thresholds for 
the different parameters. The threshold for reference allele ratio in probands is a maximum value 
threshold, whereas other thresholds are minimum value thresholds. 




quality for the other six was high (≥29). It is unclear whether these represent 






The specific detection of DNMs is difficult due to the relatively high number of 
incorrect genotype calls in NGS data. Joint genotype calling in trios reduces the 
number of potential DNM candidates and several software packages have been 
developed that use probabilistic modelling to further improve the specificity of 
DNM detection20–24. Reference allele ratio, sequencing depth and Genotype Quality 
have been shown to efficiently filter Mendelian errors in NGS data25,26. Here we 
assessed if and how these parameters can discriminate between confirmed DNMs 
and false positives. To this purpose, we used a set of 22 confirmed germline DNMs 
and 59 false positives that were initially deemed plausible DNMs. 
Using threshold settings for reference allele ratio, sequencing depth and 
Genotype Quality, we were able to detect DNMs with 100% sensitivity and 98.3% 
specificity. The key to reaching high specificity was to remove the maximum 
assigned value to the Genotype Quality score. By using the second smallest PHRED-
scaled genotype likelihood instead of the (maximized) Genotype Quality score, the 
specificity of detecting DNMs using this single parameter increased from 40.7% to 
84.7% (at 100% sensitivity). This raises the question why the Genotype Quality 
score has a maximum value? First of all, it requires more space to save values of 
more than 2 digits, especially considering that thousands of Genotype Quality 
scores are saved in each VCF file. Secondly, a Genotype Quality score of 99 
corresponds to a chance of 1.26E-10 that the genotype call is incorrect. Higher 
Genotype Quality scores are therefore not deemed more informative. Nonetheless, 
we found that all 22 confirmed DNMs had a second smallest genotype likelihood 
score of at least 200 in probands, which translates to a ≤1E-20 chance of making an 
incorrect genotype call. Since the majority of false positive DNMs had ssPL scores 
below 200, the discriminative power of the ssPL in probands was high, with an 
AUC of 0.9607. Also in parents, the ssPL proved a useful parameter to distinguish 
DNMs from false positives, just like sequencing depth in both probands and 
parents. The reference allele frequency in probands and parents had limited 
discriminative power.  
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In addition to the 22 germline DNMs, two DNMs were identified that had 
likely occurred somatically. These mutations showed an underrepresentation of 
the alternative allele in both the NGS data and the Sanger sequencing validation. 
This finding is in line with a study reporting that 6.5% of all DNMs are mosaic and 
have occurred somatically31. The accurate detection of somatic DNMs is important, 
as they are involved in cancer and other disorders32,33. However, mosaic DNMs are 
more difficult to detect than germline DNMs, especially if the frequency of the 




Figure 4. Receiver Operating Characteristic (ROC) curves of the sequencing parameters. The Area 
Under the ROC Curve (AUC) was calculated as a measure of the discriminative power of a parameter. 
The ssPL value in probands was the most powerful parameter to distinguish between confirmed DNMs 
and false positives. 




Existing software packages for the detection of DNMs in NGS data rely on 
joint genotype calling and probabilistic models to predict DNMs. Although different 
programs use different models, they reach similar sensitivity and specificity24. In 
the present study we show that filtering thresholds for the unmaximized Genotype 
Quality score, in combination with sequencing depth and reference allele 
frequency, provides an easy and straightforward filtering approach to detect DNMs 
with high sensitivity and specificity across exome sequencing data from different 
sequencing centers. We propose that incorporation of the ssPL score in 
probabilistic models may further enhance the specificity of detecting DNMs and 
urge the use of this this parameter in future analyses. Whether removing the 
maximum value of the Genotype Quality score has benefit in the detection of other 
types of genetic variation is unclear, but deserves further investigation.  
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The genetic architecture of common, heritable diseases is complex, with 
involvement of both common and rare genetic variants. Association studies for 
rare variants are challenging, as the low frequency of rare variants and large 
multiple-testing correction require large sample sizes. In this study we focused on 
the prioritization of rare variant identified by exome data from 48 Hirschsprung 
disease (HSCR) patients and 212 controls. HSCR is a complex genetic disorder that 
is characterized by incomplete development of the enteric nervous system (ENS) 
in the distal colon.  
 We sampled almost exclusively extreme phenotypes and selected rare, 
pathogenic variants. All variants per gene were collapsed and a meta-analysis was 
performed on data from three centers. The burden test we performed gave every 
gene a nominal p-value and the 48 most promising genes, with a nominal p-value 
<0.01, were subsequently ranked by seven gene prioritization tools.  
CELSR1, CLOCK, FASN and CACNA1H were among the top 5-ranked 
candidate genes based on average ranking and were among the top 13 genes with 
the most significant nominal p-values in the burden test meta-analysis. 
Subsequently, gene expression data from the developing mouse gut and ENS 
progenitor cells were used to assess whether these candidate genes are 
abundantly expressed in the cell types relevant for HSCR. Of these four highly-
ranked candidate genes, Fasn and Cacana1h were expressed by ENS progenitor 
cells, but were not differentially expressed between ENS progenitors, gut and 
controls tissues. Celsr1 and Clock were expressed at lower levels in ENS progenitor 
cells than in the rest of the gut, but Celsr1 expression did increase upon activation 
of RET, a receptor in ENS progenitors and the major risk gene in HSCR. Clock, Fasn 
and Cacna1h expression was not affected by RET signaling.  
In conclusion, we show that burden tests, gene prioritization tools and 
gene expression data from a relevant cell type can be used to identify candidate 
genes for HSCR in an underpowered genetic study. These genes should be studied 










Both common and rare variants contribute to the onset of complex genetic 
diseases1–4. Common variants (minor allele frequency > 5%) have been found 
associated to complex genetic diseases in genome-wide association studies 
(GWAS)5,6. Although large GWAS generally uncover multiple disease-associated 
loci, the common variants in an associated haplotype contribute but do not cause 
the disease. The common variants in GWAS-associated loci collectively explain only 
20-60% of the observed heritability7. Part of the missing heritability likely is 
explained by rare variants (minor allele frequency < 1%). Resequencing of genes in 
GWAS-associated loci has indeed identified rare variants in these genes8–10. In 
addition, highly heritable forms of complex diseases can present in families and in 
isolated populations, suggesting a role for highly penetrant, rare variants11,12. This 
suggests that both common and rare variants in the same gene(s) can contribute to 
the development of genetically complex diseases13. 
Genome-wide genetic analysis, by array-based genotyping or exome/ 
genome sequencing, provides an unbiased approach to identify disease-associated 
genes. However, this advantage comes at a cost. A multiple-testing correction has 
to be applied to the large number of tested loci, thereby reducing the statistical 
power of the study. With up to 2.5 million genetic markers, the multiple testing 
corrections applied to GWAS are considerable. The number of genotyped bases is 
even larger in sequencing studies, as the exome alone contains ~30 million base 
pairs. Statistical power in sequencing studies further suffers from the low 
frequency of genetic variants. Whereas GWAS make use of common variants to 
increase statistical power, sequencing studies capture all genetic variation, most of 
which is in fact rare14,15. As a result of the large multiple testing correction and low 
allele frequencies, power calculations in exome sequencing studies show that 
10,000 to 100,000 individuals are required to find genetic associations of rare 
variants, especially in complex disorders16–18. 
Several solutions for the lack of statistical power in exome/genome 
sequencing studies have been proposed. First of all, rare variants are 
overrepresented in extreme disease phenotypes, so sampling of patients with 
extreme phenotypes increases the power of finding rare variant associations19,20. 
Secondly, case-control analysis can be restricted to genetic variants that (are 
predicted to) disrupt protein function. Since (predicted) damaging variants are 
likely to be disease-causal, they will be less frequently found in controls due to 
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negative evolutionary selection. Thirdly, all rare variants in a gene or pathway can 
be collapsed into a single variable to increase the variant frequency, reduce the 
number of association tests and thereby increase the power21. It goes without 
saying that meta-analysis of multiple smaller studies can be an effective strategy to 
increase the statistical power22,23.  
Even when the abovementioned strategies are applied to increase 
statistical power, true associations may not reach the significance threshold that is 
dictated by multiple testing for 20,000 genes. It has been postulated that such 
associations may be uncovered in replication cohorts where only a limited number 
of ‘top hits’ are analyzed, leading to a lower multiple testing-corrected significance 
threshold24. Top hits can be specified as the associations with the lowest nominal 
p-value, and biological plausibility can also be taken into account.  
Gene prioritization tools have been developed to identify the disease-
causal gene in a set of candidate genes from genetic studies, using genes that are 
known to be relevant to the phenotype as so-called seed genes25,26. Different 
strategies can be employed to identify plausible seed or candidate genes. For 
example, some gene prioritization tools require the user to specify seed genes27–30, 
whereas other tools extract known disease genes from the Online Mendelian 
Inheritance in Man (OMIM) database31–35. Similarity measurements between 
candidate genes and seed genes can be based on a variety of data sources, such as 
functional annotation, protein interactions, co-expression, sequence similarity and 
text mining. In addition to gene-level information, variant level information such as 
allele frequency and predicted pathogenicity can be used to rank candidate 
genes34,35. 
In this study, we focused on Hirschsprung disease (HSCR) as an example of 
a disease with a complex genetic architecture. HSCR is characterized by the lack of 
neuronal innervation in the distal colon, resulting from incomplete colonization of 
the bowel by enteric neural crest cells (ENCCs), the progenitor cells of the enteric 
nervous system (ENS). The incidence of HSCR is approximately 1 in 3,500 in Asians 
and 1 in 6,500 in Caucasians36. Over 15 genes have been linked to HSCR, but these 
genes explain only around 25% of the heritability13,36. As in many complex genetic 
diseases, identification of new genes in HSCR has initially focused on linkage 
analysis in familial cases and isolated populations and revealed a role for the RET 
and EDNRB pathways in HSCR37–39. More recently, GWAS on sporadic HSCR 
patients have been performed. The genes associated with HSCR in these GWAS are 
RET, NRG1 and the SEMA3 gene locus40,41. In addition to the common variants, rare 




variants in these genes and other HSCR-associated genes have been reported13,42,43. 
To study the role of rare variants in HSCR on a genome-wide level, we sampled 
extreme phenotypes, selected rare pathogenic variants, collapsed all variants per 
gene, performed a meta-analysis on data from three different centers and used 






Forty-eight sporadic, non-syndromic HSCR patients were selected from five clinical 
centers. Fourteen patients were of Chinese origin and 34 patients were of 
Caucasian ancestry. We prioritized the most severe and most rare HSCR cases for 
this study, namely patients with long segment or total colonic aganglionosis (Table 
1). Sixteen patients had previously tested negative for coding variants in RET. 
Control individuals without neurological or psychological disorders were selected 
in each center to match ethnicity and sequencing technology. Parental informed 
consent was obtained from all participants.  
 
Exome sequencing 
DNA samples were subjected to exome sequencing at four sequencing centers 
using local, in-house technologies. The exome-capture kits and sequencing 
platforms used per center are summarized in Table 1. Sequencing data from 
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16 32 48  212 
     
Overview of the numbers of patients and controls that were sequenced by each center and the 
sequencing technologies that were used. 
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two centers with identical sequencing platforms were analyzed together in 
downstream analyses. Alignment of Illumina sequencing reads were mapped to the 
genome using BWA and Solid sequencing reads were mapped using Bfast44. All 
sequencing reads were mapped to the human reference genome version 19 (hg19). 
Quality Control (QC) of sequencing data was carried out using the FastQC toolbox, 
Picard’s metric summary and the GATK Depth-of-Coverage module. After QC, 
sequencing data were preprocessed for local indel realignment, PCR duplicate 
removal and base quality recalibration45. SNPs and Indels were called using the 
GATK unified Genotyper 2.046 and stored in standard VCF files. Each sequencing 
center performed variant calling simultaneously on their respective HSCR patients 
and control subjects. KGGSeq47 was used to extract variants that 1) had a 
sequencing quality score ≥ 50; 2) mapping quality ≥20; 3) Fisher strand bias score 
≤60; 4) genotype quality score ≥20; 5) sequencing depth ≥8; 6) reference allele 
ratio <0.75; 7) are exonic; 8) are non-synonymous SNPs or indels; 9) have minor 
allele frequency <1% in dbSNP137, 1000 Genomes and NHLBI Exome Sequencing 
Project; 10) were successfully genotyped in ≥80% of patients and ≥80% of 
controls; 11) were predicted deleterious by KGGSeq’s logistic regression analysis 
of dbNSFP v3.0 functional impact scores48.  
 
Burden test 
The number of rare variants per gene in patients and controls was analyzed by 
three different centers individually, using the same protocol. The Combined 
Multivariate and Collapsing (CMC) test in Rvtests package was used to collapse all 
variants identified within the same gene21. P-values were calculated by asymptotic 
chi-square distribution. Meta-analysis of the summary statistic of three centers 
was performed using sample-size weighted z-score. 
 
Candidate gene prioritization 
Genes with a nominal association p-value <0.01 in the burden test were selected as 
seed genes for downstream candidate gene prioritization. Gene prioritization was 
performed in Endeavour Web Server (http://www.esat.kuleuven.be/ 
endeavour)27,28, ToppGene (http://toppgene.cchmc.org)29, ToppNet (part of the 
ToppGene suite29), GPSy (http://gpsy.genouest.org)30, FunSimMat (http:// 
funsimmat.bioinf.mpi-inf.mpg.de)31–33, Exomiser (http://www.sanger.ac.uk/ 
science/tools/exomiser)34 and ExomeWalker (http://compbio.charite.de/ 
ExomeWalker)35. The gene prioritization tools differ in the data sources that are 




used to compare candidate genes to seed genes. For gene prioritization in 
Endeavour all 19 available databases in Endeavour were used. ToppGene was run 
using default parameters, with ‘Interaction’ as additional training feature and 
ToppNet was run using default settings. Moreover, Endeavour, ToppGene and 
ToppNet require the user to select a set a genes (specific seed genes) that are 
known to be relevant to the disease. For this we assembled a list of 45 seed genes 
that are either genetically linked to HSCR in humans, or loss of these genes causes 
aganglionosis in mouse models (Supplementary Table 1).  
In contrast to a self-made list of genes as required for Endeavour, 
ToppGene and ToppNet, GPSy was run using ‘Nervous system’ and ‘Homo sapiens‘ 
as selected topic and species, respectively, with otherwise default parameters. The 
‘disease candidate prioritization’ function in FunSimMat was run using OMIM term 
#142623 (Hirschsprung disease) and were ranked by Biological Pathway (BP). 
Gene prioritization in Exomiser was performed using the hiPHIVE prioritiser and 
Orphanet ID 388 (Hirschsprung disease). OMIM term #142623 (Hirschsprung 
disease) was selected as phenotype in ExomeWalker. No variant quality filters 
were applied in Exomiser and ExomeWalker, since these were applied in the 
upstream filtering and annotation by KGGSeq. Overall gene ranking was based on 
the average rank per gene in the different prioritization tools.  
 
Gene expression analysis 
Publically available expression data from E14.5 mouse embryos and was combined 
with in-house expression data from embryonic mouse gut and ENCCs isolated from 
E14.5 mouse embryos that expressed YFP under control of the Wnt1 promoter. 
Expression data from control tissues were extracted from the Gene Expression 
Omnibus49: testis and ovary (GSE6881), kidney (GSE4230)50, gonad (GSE6916)51 
and cardiac tissue (GSE1479)52. Moreover, additional intestinal tissue expression 
sets were obtained: stomach, pylorus and duodenum (GSE15872)53. Probe set 
summaries from the raw Affymetrix data (cel files) were calculated using BRB-
ArrayTools version 4.5.0 - Beta_2 (http://linus.nci.nih.gov/BRB-ArrayTools.html). 
The probes were annotated by Bioconductor (www.bioconductor.org), R v3.2.2 
Patched (2015-09-12 r69372) and the annotation package mouse4302.db (version 
3.0.0). ‘Just GCRMA’ (GC content – Robust Multi-Array Average) was used from the 
‘GCRMA’ package available in Bioconductor. The just GCRMA algorithm adjusts for 
background intensities (optical noise and non-specific binding), normalizes each 
array using quantile normalization and includes variance stabilisation and log2 
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transformation. Replicate spots within an array were averaged. Genes showing 
minimal variation across the set of arrays were excluded from the analysis (if less 
than 10% of expression data had at least a 1.5 fold change in either direction from 
gene's median value, or at least 50% of arrays had missing data for that gene). 
Probes were present on the Affymetrix mouse4302.db chip for 45 of the 48 
candidate genes (DEFB132 and OR10K1 do not have a mouse orthologue and Or2d2 
does not have probes on the chip). Genes whose expression differed by at least 1.5 
fold from the median in at least 20% of the arrays were retained. The minimum 
fold change for the class comparisons was set at 1.5, statistics were performed 
using a two-sample T-test with random variance model. The permutation p-values 
for significant genes were computed based on 10,000 random permutations and 
the nominal significance level of each univariate test was set at 0.05. 
 
Power calculations 
The Genetic Power Calculator54 was used to calculate the statistical power of the 
present study and the number of patient required in a future replication study. The 
prevalence of HSCR was set to 0.0002 (1:5000 live born individuals36). D-prime 
was set to 0.8, assuming that the sensitivity of detecting variants in exome 
sequencing data is 80% (Table 1). Calculations for cohort sizes assumed the same 
case : control ratio as for the 48 HSCR cases and 212 controls (1 : 4.417). 
Significance levels were set at 0.05 and were not adjusted for multiple testing. 





Sampling of extreme phenotypes 
Rare variants have a relatively large contribution to disease in patients with an 
extreme phenotype19,20. Therefore we prioritized the most severe form of HSCR for 
exome sequencing. A variable segment of the gut can be aganglionic in HSCR. In 
80% of the cases, only a short-segment of the colon is affected, whereas a long-
segment of the colon is aganglionic in the remaining 20%36. Long-segment HSCR 
has a high heritability and a dominant mode of inheritance with reduced 
penetrance55. Moreover, in long-segment HSCR there is a relative large 
contribution of rare variants in RET, the major HSCR gene55,56. Therefore, the 
highest contribution of rare variants is expected in patients with long-segment 




HSCR. In three different cohorts, a total of 32 cases of long-segment HSCR were 
sampled for exome sequencing and were supplemented with 16 cases of short-
segment HSCR, resulting in 66.7% long-segment cases in our cohort (Table 1).  
 
Exome sequencing and variant filtering 
Exome sequencing was performed on 48 sporadic HSCR patients in three different 
centers using different sequencing technologies (Table 1). The average 10X 
coverage per center ranged from 79% to 95% (Table 1). Rare variants were 
selected from the exome sequencing data that lead to a loss of function (nonsense, 
splice site and frameshift mutations) or are missense mutations that were 
predicted to be deleterious. This yielded between 194 and 296 rare variants per 
individual on average per center.  
 
Gene burden test and meta-analysis 
The low frequencies of individual rare variants hamper the statistical power to 
find a significant association to a disease. Therefore, all rare variants per gene that 
were predicted to be pathogenic were collapsed into a single variable; the number 
of variants per gene. The statistical power of finding disease-associated genes 
depends on frequency at which mutations are found in comparison to a control set 
of samples. This frequency varies among genes: 2.4% of all genes carried rare, 
damaging variants in ≥5% of the controls, 20.8% of the genes had a variant 
frequency of 1-5% in control samples and 27.5% a frequency <1% in our controls. 
No rare, damaging variants were found in the controls in the remaining 49.3% of 
all genes (Figure 1A).  
Given the mutation frequencies per gene, the power of detecting true 
associations was calculated for different genotype relative risks. For genes with a 
high variant frequency of 5% our study with 48 patients and 212 controls could 
detect true associations (at nominal p-value), even at low relative risk (Figure 1B). 
Also for genes with a 0.5-1% variant frequency there was sufficient power to 
detect damaging variants with a moderate or high relative risk. For genes that 
carried rare, damaging variants less frequently in controls, there was limited 
statistical power, even at a high relative risk. Increasing the size of the study to for 
instance 100 cases and 442 controls would increases the statistical power, but up 
to 1000 cases and 4417 controls are required to obtain sufficient power to detect 
associations for genes that carry variants in 0.01% of the controls (at nominal p-
value) (Figure 1C,D).  
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The variant frequency per gene was compared between patients and 
controls in three independent centers. A meta-analysis was performed on data 
from three different sequencing centers, representing different ethnicities and 




Figure 1. Frequency distribution of rare, damaging variants per gene and its effect on statistical 
power. A) Histogram displaying the number of genes that carry rare, damaging variants at a specified 
frequency in the control population. B) Statistical power of detecting a significant association (at a 
nominal p-value of 0.05) in our cohort of 48 HSCR cases and 212 controls, given the genotype relative 
risk and frequency of variants in the gene. C,D) Statistical power of detecting significant associations if 
cohort sizes would have been increased to 100 cases and 442 controls (C) or 1000 cases and 4417 
controls (D).  




observed distribution of p-values followed the expected distribution, for individual 
case-controls studies as well as for the meta-analysis (Figure 2). This suggests that 
there were no confounding factors producing artificial associations. The most 
significant associations in the meta-analysis were found for KLHDC4 (p=1.43x10-5) 
and CR1 (p=2.07x10-5), but didn’t reach genome-wide significance (2.5x10-6, after 
Bonferroni correction for 20,000 genes) (Table 2).  
 
Candidate gene prioritization 
Due to the low power of the rare variant association study, there may have been 
real pathogenic variants in genes that did not reach genome-wide significance. 
Small-scale replication studies have greater power to detect true associations, but 
require a selection of candidate genes to follow up on24.  
Gene prioritization tools have been developed to identify plausible genes 
in a set of candidate genes and can therefore be used to select the best candidate 
genes for follow-up studies25,26. Forty-eight genes had a nominal p-value <0.01 and 
were selected to be ranked by seven gene prioritization tools to identify the best 
candidate HSCR gene among them. CELSR1 achieved the highest average rank 
across seven gene prioritization tools, followed by CLOCK, GRM4, FASN and 
CACNA1H (Figure 3A). The overall ranking by the gene prioritization tools was 
compared to the nominal p-value of the genes in the burden test meta-analysis and 
four of the five highest-ranked genes (CELSR1, CLOCK, FASN and CACNA1H) were 
among the 13 most significantly associated genes (Figure 3B). Although these 
genes have no known functions in ENS development, biological functions and 
expression in neural cells has been reported for CELSR1, CLOCK, FASN and 
CACNA1H57–60.  
The correlation between ranking results from different gene prioritization 
tools varied substantially (Figure 3C). The highest correlation coefficient was 
found between Exomiser and ExomeWalker (r = 0.54), but ExomeWalker showed 
no correlation to any other tool. Endeavour and ToppGene showed a moderate 
correlation with all other tools, except ExomeWalker.  
 
 
Expression in the gut and in ENCCs 
Gene prioritization tools use a variety of data sources to rank candidate genes, 
including gene expression data. However, the expression data used in gene 
prioritization tools is generally not derived from the cell type studied. As HSCR 
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results from incomplete colonization of the bowel by ENCCs (the progenitor cells 
of the ENS), the expression levels of the mouse orthologues of the 48 candidate 
HSCR genes obtained in the burden test were analyzed in the developing mouse 
gut, and more specifically in the ENCCs. Two genes (DEFB132 and OR10K1) do not 




Figure 2. Quantile-quantile plot of the association p-values. The observed p-values follow the 
expected distribution, for individual centers and for the meta-analysis. The highest associated genes in 
the meta-analysis, KLHDC4 (p=1.43x10-5) and CR1 (p=2.07x10-5), are indicated. 




probes on the chip. Of the 45 candidates genes for which expression data were 
available, all but one (Cr1) were expressed by ENCCs. Clock, Grm4, Fasn and 
Cacna1h, whose human orthologues were highly ranked by the gene prioritization 
tools, were not abundantly expressed by ENCCs compared to control tissues 
(testis, ovary, heart and kidney), or in the intestinal samples. Celsr1 was not highly 
expressed in ENCCs or the gut, but its expression level was increased by activation 
of the RET receptor with its ligand GDNF.  
Of the 48 candidate genes selected from the burden test, Clstn2, Cdk12, 
Cpxm2, Ghdc, D8Ertd82e (mouse orthologue of SGK223) and Mrps34 were higher 
expressed in ENCCs than in control tissues. These ENCC-expressed genes, with the 
addition of Pprc1 and Ddc, were also expressed at higher levels in intestinal 
samples compared to control tissues (Table 3). The remaining candidate genes 
from the burden test were expressed by ENCCs (with the exception of CR1), but 
were not differentially expressed between ENCCs and the gut. Of the genes that are 
highly expressed in the gut, the human orthologue of Ghdc was the seventh most 
significantly associated gene to HSCR in the burden test meta-analysis (nominal p-
value: 1.87x10-4). GHDC (GH3 domain containing) only ranked at position 35 of the 
48 candidate genes in the overall gene prioritization. The biological function of 
GHDC is unknown and the gene could therefore not be linked to the known ENS 
genes. However, Exomiser and ExomeWalker, both taking into account the 
pathogenicity score of the identified variants, ranked GHDC at position 6 and 3, 
respectively, suggesting that the identified variants in GHDC are highly pathogenic. 
Combined with the expression of Ghdc in the developing mouse ENS and the high 
rank in the burden test, this makes GHDC an excellent candidate gene for HSCR. 
These data indicate that the use of tissue-specific gene expression data is a 
complementary approach to identify candidate genes that were not picked up by 
the gene prioritization tools due to lack of functional characterization of the gene.  
Another potentially interesting candidate gene that was highly expressed 
by ENCCs is Cdk12. Cdk12 was ranked as the 10th best candidate gene by the gene 
prioritization tools and is involved in neuronal differentiation in the murine CNS61. 
Given its high expression in ENCCs, Cdk12 may also be involved in ENS 
development and contribute to HSCR. Clstn2, Cpxm2, Mrps34 and D8Ertd82e 
(orthologue of SGK223) were highly expressed by ENCCs, but did not rank high in 
the gene prioritization and were not among the most significantly associated genes 
in the burden test. 
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Table 2. Genes with a nominal p-value of association <0.01. 
Gene Description HK SP NL Meta 
KLHDC4 kelch domain containing 4 1.09E-03 2.30E-04 1 1.43E-05 
CR1 complement component (3b/4b) receptor 1 0.022 9.51E-03 0.011 2.07E-05 
ATP13A5 ATPase type 13A5 0.015 0.067 0.011 1.31E-04 
FASN fatty acid synthase 0.022 2.30E-04 1 1.58E-04 
GPRIN1 
G protein regulated inducer of neurite 
outgrowth 1 
0.059 9.51E-03 0.044 1.63E-04 
CLOCK clock homolog (mouse) 0.019 9.51E-03 0.148 1.68E-04 
GHDC GH3 domain containing 0.022 9.51E-03 0.148 1.87E-04 
ZNF76 zinc finger protein 76 (expressed in testis) 0.022 9.51E-03 0.148 1.87E-04 
XPO6 exportin 6 1.09E-03 9.51E-03 1 3.01E-04 
ZFAND4 Zinc Finger, AN1-Type Domain 4 0.408 2.30E-04 0.148 3.05E-04 
ERN2 ER to nucleus signaling 2 0.022 9.51E-03 0.446 6.43E-04 
CELSR1 
cadherin, EGF LAG seven-pass G-type 
receptor 1 
0.408 5.20E-03 0.039 9.30E-04 
CACNA1H 
calcium channel, voltage-dependent, T type, 
alpha 1H 
1 5.20E-03 2.98E-03 1.11E-03 
NINL ninein-like 0.721 1.43E-03 0.062 1.34E-03 
POLR1A polymerase (RNA) I polypeptide A, 194kDa 1 1.80E-04 0.148 1.51E-03 
ALX3 ALX homeobox 3 0.022 9.51E-03 1 2.26E-03 
CDK12 Cdc2-related kinase, arginine/serine-rich 0.022 9.51E-03 1 2.26E-03 
DDC dopa decarboxylase 0.022 9.51E-03 1 2.26E-03 
HOGA1 4-Hydroxy-2-Oxoglutarate Aldolase 1 0.022 9.51E-03 1 2.26E-03 
HSD3B2 
hydroxy-delta-5-steroid dehydrogenase, 3 
beta- and steroid delta-isomerase 2 
0.022 9.51E-03 1 2.26E-03 
IMPG1 interphotoreceptor matrix proteoglycan 1 0.022 9.51E-03 1 2.26E-03 
OR10K1 
olfactory receptor, family 10, subfamily K, 
member 1 
0.022 9.51E-03 1 2.26E-03 
APOBEC1 
apolipoprotein B mRNA editing enzyme, 
catalytic polypeptide 1 
1 5.85E-06 1 2.58E-03 
GPR179 G protein-coupled receptor 179 0.022 0.290 0.039 2.65E-03 
RNF17 ring finger protein 17 0.022 0.016 1 3.33E-03 
MCM8 
minichromosome maintenance complex 
component 8 
1 9.51E-03 0.011 3.41E-03 
ACADL 
acyl-Coenzyme A dehydrogenase, long 
chain 
0.408 9.51E-03 0.148 3.91E-03 
CPXM2 carboxypeptidase X (M14 family), member 2 0.408 9.51E-03 0.148 3.91E-03 
CLSTN2 calsyntenin 2 0.022 5.20E-03 0.481 4.31E-03 
P4HA3 prolyl 4-hydroxylase, alpha polypeptide III 0.019 0.067 0.597 4.78E-03 
ACSM5 
acyl-CoA synthetase medium-chain family 
member 5 
0.022 0.025 1 4.89E-03 
LMOD3 leiomodin 3 (fetal) 0.022 0.025 1 4.89E-03 
OR2D2 
olfactory receptor, family 2, subfamily D, 
member 2 
0.022 0.025 1 4.89E-03 
DEFB132 defensin, beta 132 0.187 0.697 1.82E-06 5.80E-03 
DAAM1 
dishevelled associated activator of 
morphogenesis 1 
0.187 9.51E-03 0.597 6.18E-03 
VTI1B 
vesicle transport through interaction with t-
SNAREs homolog 1B 
0.022 9.51E-03 0.481 6.51E-03 
TMEM67 transmembrane protein 67 0.022 0.290 0.148 6.64E-03 
GABPB1 
GA binding protein transcription factor, beta 
subunit 1 
1 9.51E-03 0.039 6.96E-03 
MRPS34 mitochondrial ribosomal protein S34 1 9.51E-03 0.039 6.96E-03 
NCKAP5L NCK-Associated Protein 5-Like 1 9.51E-03 0.039 6.96E-03 
SGK223 homolog of rat pragma of Rnd2 0.620 9.51E-03 0.148 7.05E-03 
ZSWIM5 zinc finger, SWIM-type containing 5 0.015 0.637 0.039 7.12E-03 
TRPM2 
transient receptor potential cation channel, 
subfamily M, member 2 
1 0.025 0.011 7.16E-03 
KNTC1 kinetochore associated 1 0.968 9.51E-03 0.062 8.57E-03 
PPRC1 
peroxisome proliferator-activated receptor 
gamma, coactivator-related 1 
0.187 5.20E-03 1 8.74E-03 
DMRT3 
doublesex and mab-3 related transcription 
factor 3 
1.09E-03 0.117 0.481 9.36E-03 
PRDM7 PR domain containing 7 0.408 2.30E-04 0.481 9.44E-03 
GRM4 glutamate receptor, metabotropic 4 0.022 9.51E-03 0.315 9.92E-03 




Statistical power of a replication study for selected genes 
Using gene prioritization tools and gene expression data from the developing ENS, 
we identified CELSR1, CLOCK, FASN, CACNA1H and GHDC as the best candidate 
genes for HSCR. However, follow-up experiments are required to establish 
whether these genes are involved in HSCR, as our study was underpowered to find 
genome-wide significant associations. The data presented in this study were used 
to calculate the power of a replication study. Using the variant frequencies per 
gene in patients and controls, relative risks were calculated per gene. These ranged 
from 7.4 for CLOCK to 26.5 for CACNA1H. Consequently, 14 to 33 unrelated patients 
are required to find a significant association of these genes to HSCR with 80% 
power and 23 to 41 patients are required for 95% power54 (Table 4). Since no 
mutations were found in FASN and GHDC in our control cohort, it was not possible 
to calculate the relative risk and required number of patients in a replication study 





Resequencing studies on GWAS-associated genes or candidate genes from 
functional studies has revealed a role for rare, coding variants in complex genetic 
diseases, including HSCR41,62. However, the contribution of rare variants to 
complex genetic diseases is difficult to study, as statistical power is negatively 
affected by locus heterogeneity, low allele frequency and large multiple-testing 
correction17. Using HSCR as a model of a complex genetic disease, we combined 
several strategies to perform a rare variant (gene) association study.  
 
Burden test 
To maximize the statistical power of our rare variant association test, we 
prioritized long-segment HSCR cases, collapsed all rare, damaging variants per 
gene and performed a meta-analysis on three case-control studies. This approach 
gave our study sufficient power to detect associations at nominal p-value for genes 
in which variants are relatively abundant or have a high relative risk. However, the 
meta-analysis was underpowered to reach genome-wide significance.  
Mutations in RET, the main HSCR gene, are normally found in 15-35% of 
sporadic HSCR patients63,64. However, we did not find RET or any other known 
HSCR genes among the highest associated genes in the burden test. The most  





Figure 3. Candidate gene ranking results from the gene prioritization tools. A) Gene prioritization 
results from the seven tools. Highly ranked genes are shown in dark blue and genes with a low rank in 
light blue. Genes are shown by overall rank. B) Relationship between the p-value of association in the 
burden test and the overall rank in the gene prioritization. C) Heatmap showing the correlations 
between the ranking results of the different tools.  
 




significantly associated known HSCR gene was NRG1, with a nominal p-value of 
0.015. The reason for not finding the HSCR genes is due to the fact that we selected 
mainly patients without mutations in the known HSCR genes, this increases the 
likelihood of identifying new HSCR genes. Coding mutations in all HSCR genes 
other than RET are rare and are mainly associated with syndromic rather than 
isolated HSCR13,42,43. Lack of association of these genes with HSCR in our data was 
therefore also not unexpected.  
 
Gene prioritization tools 
The 48 genes with a nominal p-value <0.01 in the burden test performed, were 
selected to be prioritized by seven gene prioritization tools. Different prioritization 
tools use seed genes from different sources to look for similarity with candidate 
genes. Endeavour, ToppGene and ToppNet require the user to specify genes that 
are known to be involved in the disease or underlying biological process27–29. The 
benefit of this approach is that the seed genes are very specific for the phenotype. 
Other tools lack this user specific input and do not use all known genes that are 
critical for ENS development. For example, Hlx65 and Hoxb566,67 are not included as 
general ‘nervous system development’ seed genes by GPSy30. GPSy therefore 
misses connections with these seed genes. User-specific input also has its 
drawbacks as the focus is on ‘known’ genes. GPSy may therefore uncover novel 
pathways in ENS development as many genes that are involved in neuronal 
development in the CNS might also be relevant to the ENS. FunSimMat, Exomiser 
and ExomeWalker extract seed genes from OMIM31–35. Although this yields seed 
 
 
Table 3. Differentially expression of the 48 candidate genes in E14.5 mouse embryo. 
Case Control High expression Low expression 
Mouse whole gut 
Testis, ovary, 
heart and kidney 
Cdk12, Mrps34, D8Ertd82e, 
Ghdc, Zfand4 
Gabpb1, Trpm2, Celsr1, 
Polr1a, Hoga1, Clock, Grm4, 
Daam1, Rnf17 
Mouse ENCC Mouse whole gut 
Cpxm2,D8Ertd82e, Ghdc, 
Cdk12, Clstn2, Mrps34 
Celsr1, Polr1a, Gabpb1, Grm4, 
Kntc1, Clock, Mcm8, Hoga1 
Mouse ENCC 
Testis, ovary, 
heart and kidney 
Cpxm2, D8Ertd82e, Ghdc, 
Cdk12, Clstn2, Mrps34 
Celsr1, Polr1a, Gabpb1, Grm4, 
Kntc1, Clock, Mcm8, Hoga1 
Mouse ENCC + 
GDNF 
Testis, ovary, 
heart and kidney 
Cpxm2, Ghdc, D8Ertd82e, 
Vti1b, Celsr1, Clstn2, Cdk12, 
Mrps34 
Kntc1, Gabpb1, Polr1a, Clock, 
Hoga1, Grm4, P4ha3, Mcm8 
Mouse ENCC + 
GDNF 
Mouse ENCC Celsr1 Ddc 
Of the top candidate genes from the gene prioritization tools, Celsr1 and Clock were less abundantly 
expressed by ENCCs than in the gut or in control tissues, but Celsr1 expression was upregulated in 
ENCCs after activation of the RET receptor by its ligand GDNF. 
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genes that are well established in the disease, the number of disease genes in 
OMIM may be an underrepresentation of the number of genes involved. In the case 
of HSCR, only four genes can be retrieved from OMIM (RET, GDNF, EDNRB and 
EDN3), whereas the manually assembled list of ENS development genes that was 
used in Endeavour, ToppGene and ToppNet, contained 45 seed genes.  
The gene prioritization tools also differ in the data sources that are used to 
compare candidate genes to seed genes. Endeavour, ToppGene and GPSy use a 
wide range of data sources, such as functional annotation, expression, interaction 
and sequence similarity. ToppNet, FunSimMat, Exomiser and ExomeWalker rely on 
a single data source to connect candidate genes to seed genes (protein interaction, 
functional annotation, phenotypic similarity to mouse models and protein 
interaction, respectively). Exomiser and ExomeWalker are specifically designed for 
exome sequencing studies, and take the frequency and predicted pathogenicity of 
the identified genetic variants into account. The different strategies implemented 
by gene prioritization tools are reflected by the differences in gene ranking results. 
Correlations between prioritization results from different tools varied 
substantially. Endeavour and ToppGene showed moderate correlation with all 
other tools, except ExomeWalker. ExomeWalker combines variant level 
information from exome sequencing with protein interactions between candidate 
genes and disease genes derived from OMIM. However, no interactions with the 
known HSCR genes RET, GDNF, EDNRB and EDN3 were found for any of the 
candidate genes. Gene ranking by ExomeWalker was therefore solely based on the 
frequency and predicted pathogenicity of the identified variants. The variant level 
 
 









80% power 90% power 95% power 
cases/controls cases/controls cases/controls 
CELSR1 0.125 0.014 8.83 25 110 33 146 41 181 
CLOCK 0.104 0.014 7.36 33 146 44 194 54 239 
FASN 0.063 0.000 ∞ 
      
CACNA1H 0.125 0.005 26.5 14 62 19 84 23 102 
GHDC 0.063 0.000 ∞ 
      
Power calculations for a rare-variant association replication study on selected candidate genes. Given 
the frequencies of rare, damaging variants in the candidate genes in the burden test, the relative risk 
and number of cases and controls were calculated.  




information is also used by Exomiser, explaining why ExomeWalker results 
correlated with those from Exomiser, but to no other tools tested in this study.  
Despite the variable correlations between ranking results, several genes 
were consistently highly ranked by the gene prioritization tools. CELSR1, CLOCK, 
FASN and CACNA1H were among the top 5-ranked candidate genes based on 
average rank and were among the 13 most significant nominal p-values in the 
burden test meta-analysis.  
 
Function of the proposed top 4 candidate genes 
CELSR1 (Cadherin, EGF LAG Seven-Pass G-Type Receptor 1) is an adhesion 
molecule that is involved in planar cell polarity; the organization of cells in a plane 
or sheet68. CELSR1 mutations have been associated with the neural tube defect 
craniorachischisis in humans, a finding that is corroborated by improper closure of 
the neural tube in Celsr1 mouse models68–70. Additionally, Celsr1 is involved in the 
directional migration of facial branchiomotor neurons71. Planar cell polarity genes 
are involved in ENS development, where Celsr3 and Fzd3 regulate guidance and 
growth of neuronal projections72. Ablation of Celsr3 in ENS progenitor cells causes 
constriction of colonic segments, distention of the proximal segment, and reduced 
gut transit time, symptoms that are all hallmarks of HSCR72. These results 
demonstrate a role for planar cell polarity genes in ENS development, making 
CELSR1 an excellent candidate gene for HSCR.  
CLOCK encodes a core component of the circadian clock. Gastrointestinal 
motility follows a circadian rhythm and neurotransmitters that regulate gut 
contractility, such as Vip and nNos, are rhythmically expressed in the distal murine 
colon73,74. Clock genes are expressed in intestinal epithelial cells and enteric 
neurons in mice and may well be responsible for the rhythmic innervation of the 
gut73.  
FASN (fatty acid synthase) is an enzyme that catalyzes fatty acid synthesis. 
In the murine CNS, Fasn is highly expressed in neurogenic areas and is required for 
maintenance of neural stem cell pools75. As the development of the ENS depends 
on propagation of stem cells, FASN may be involved in ENS development.  
The mouse homologue of CACNA1H (Calcium channel, voltage-dependent, 
T type, alpha 1H subunit) is expressed by migrating ENCCs76. Although Cacna1h 
and other Ca2+ channels are expressed by ENCCs at different developmental time 
points, blockage of Ca2+ channels in gut explants does not impair ENCC migration 
or neurite outgrowth76.  
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Additional candidate genes  
Combining different strategies as proposed in this study reduces the number of 
candidate genes dramatically. Ending up with a small number of candidate genes 
makes genetic studies surveyable and amenable for functional analysis. However, 
it also raises the question whether we do not exclude potentially valid candidates. 
For instance, GHDC and to a lesser extent CDK12 are excellent candidates for HSCR 
because of their high expression in ENCC, pathogenicity of identified variants and 
low nominal p-value in the burden test. Therefore, one should be critical in 
excluding genes too easily.  
 
Conclusions  
Although our rare variant association study was underpowered to detect genome-
wide associations to HSCR, the study serves as a pilot study to direct future 
research. Power calculations for genetic studies rely on prior knowledge of variant 
frequencies and effect size, and these parameters can be estimated from the data 
presented here. It should be noted that the frequency of variants in a gene is 
variable between genes, meaning that for some genes there is higher statistical 
power than for others. Therefore our approach will be useful only for genes that 
carry relatively many rare, damaging variants in the general population. In 
addition to calculating the statistical power for such genes in a small-scale 
replication study, we prioritized the top hits from our burden test to select the 
most promising candidate genes to follow up on. Only a limited number of 
unrelated patients are required in such a follow-up study.  
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Supplementary Table 1. List of seed genes used in Endeavour, ToppGene and ToppNet. 
Gene Gene name Human phenotype Refs 
ALDH1A2 aldehyde dehydrogenase 1 family, member A2 
 
1 
ASCL1 achaete-scute complex homolog 1 CCHS 2,3 
DCC DCC Netrin 1 Receptor 
 
4 
DSCAM Down Syndrome Cell Adhesion Molecule HSCR-associated 5,6 
ECE1 endothelin converting enzyme 1 
Hirschsprung disease, cardiac 
defects and autonomic dysfunction 
7,8 
EDN3 endothelin 3 
Hirschsprung disease Waardenburg 
syndrome type 4 
9–11 
EDNRB endothelin receptor type B 
Hirschsprung disease 
Waardenburg syndrome type 4 
12–15 
ERBB2 
v-erb-b2 erythroblastic leukemia viral oncogene 
homolog 2  
16 
ERBB3 
v-erb-b2 erythroblastic leukemia viral oncogene 
homolog 3  
17,18 
FOXD3 Forkhead Box D3 
 
19 
GDNF glial cell derived neurotrophic factor Hirschsprung disease 20–25 
GFRA1 GDNF family receptor alpha 1 Hirschsprung disease 26,27 
GFRA2 GDNF family receptor alpha 2 
 
28 
GLI1 GLI family zinc finger 1 
 
29,30 
GLI2 GLI family zinc finger 2 
 
29,30 
GLI3 GLI family zinc finger 3 
 
29,30 
HAND2 Heart And Neural Crest Derivatives Expressed 2 
 
31,32 
HLX H2.0-like homeobox 
 
33 
HOXB5 Homeobox B5 
 
34,35 




inhibitor of kappa light polypeptide gene 
enhancer in B-cells, kinase complex-associated 
protein 
Familial dysautonomial  37,38 
ITGB1 integrin beta 1 
 
39,40 
KIF1BP KIF1 Binding Protein Goldberg-Shprintzen syndrome 41–43 
L1CAM L1 cell adhesion molecule Partial agenesis of corpus callosum 44–47 
NKX2-1 NK2 Homeobox 1 Single HSCR patient 48 
NRG1 neuregulin 1 Hirschsprung disease 49,50 
NRG3 neuregulin 3 Hirschsprung disease CNVs 51,52 
NRTN neurturin Hirschsprung disease 53–55 
NTF3 Neurotrophin 3 
 
56 
NTRK3 neurotrophic tyrosine kinase, receptor, type 3 
 
56,57 
PAX3 paired box 3 
Waardenburg syndrome type 1 and 
type 3 
58 
PHOX2B paired-like homeobox 2b 
Neuroblastoma with Hirschsprung 
disease 
59–61 
PSPN Persephin Single HSCR patient 54 
PTCH1 patched homolog 1 
 
62,63 
RET ret proto-oncogene Hirschsprung disease 64–66 
SALL4 sal-like 4 Duane-radial ray syndrome 67 
SEMA3A 
sema domain, immunoglobulin domain (Ig), 
short basic domain, secreted, (semaphorin) 3A  
68,69 
SEMA3C 
sema domain, immunoglobulin domain (Ig), 
short basic domain, secreted, (semaphorin) 3C 
Hirschsprung disease 68 
SEMA3D 
sema domain, immunoglobulin domain (Ig), 
short basic domain, secreted, (semaphorin) 3D 
Hirschsprung disease 68,69 
SHH sonic hedgehog homolog 
 
36,70 
SOX10 SRY (sex determining region Y)-box 10 Waardenburg syndrome, type 4C 71–74 
SPRY2 sprouty homolog 2 
 
75 
TCF4 Transcription Factor 4 Pitt-Hopkins syndrome 76–78 
ZEB2 zinc finger E-box binding homeobox 2 Mowat-Wilson syndrome 79,80 
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Hirschsprung disease (HSCR) is characterized by the absence of enteric ganglia in 
the distal region of the gastrointestinal tract, leading to severe intestinal 
obstruction. Around 12% of patients with HSCR have a chromosomal abnormality, 
the most of which have Down Syndrome (DS), trisomy 21. Moreover, individuals 
with DS have a >100-fold higher risk of developing HSCR than the general 
population. This suggests that overexpression of human chromosome 21 (Hsa21) 
genes contribute to the etiology of HSCR. To identify the gene(s) contributing to 
HSCR in DS, we overexpressed candidate genes in a reporter zebrafish, Tg(-
8.3bphox2b:Kaede) where neural crest derived cells express the fluorescent kaede 
protein. We prioritized 21 genes and overexpressed them by microinjecting 
capped mRNAs in single-cell stage zebrafish embryos and scored them at 5 days 
post fertilization (dpf). We show that overexpression of ATP5O (ATP synthase, H+ 
transporting, mitochondrial F1 complex, O subunit) leads to a disturbed enteric 
nervous system (ENS) with a reduced number of enteric neurons, strongly 
implicating ATP5O as a contributor to a HSCR phenotype. The ATP5O gene encodes 
a component of the F-type ATPase found in the mitochondrial matrix and 
participates in ATP synthesis coupled proton transport. ATP5O does not link to the 
known HSCR pathways, and although we show expression of the protein in the 
enteric ganglia, its involvement in disease development and ENS development is 










Hirschsprung disease (HSCR, MIM #142623) is a complex congenital gut motility 
disorder resulting from a failure in the development of the enteric nervous system 
(ENS) of the gastrointestinal (GI) tract. It is characterized by the absence of enteric 
ganglia in a variable length of the distal gut. HSCR is recognized by a failure to pass 
meconium in the first 48 hr after birth, abdominal distention, vomiting, and 
neonatal enterocolitis. It leads to severe intestinal obstruction and life threatening 
constipation. The prevalence of HSCR is 1 in 5000 live births and there is an 
unexplained sex bias of four males to one female1. The lack of neurons in the distal 
part of the GI tract results from a failure of enteric neural crest cells (NCC) to 
migrate, differentiate, proliferate or survive and thereby colonize the gut and form 
a functional network of neurons and glia (reviewed by Sasselli et al., 20122). 
HSCR is considered as an inherited disease, based on the fact that there 
are familial cases (~5%), and the 200-fold increased risk of HSCR to siblings of 
patients3. Highly penetrant, coding mutations, in approximately 15 genes, have 
been identified to cause or contribute to HSCR (for review see4). The major gene in 
HSCR is RET, with a mutation prevalence of 50% in familial HSCR and 15% in 
sporadic HSCR5,6. However, cumulatively all the mutations in HSCR-associated 
genes explain only a small fraction of cases. In addition to the high penetrant 
coding mutations, common low-penetrance polymorphic variants at RET, in the 
region containing SEMA3C/SEMA3D and in NRG1 are also associated with HSCR7-10. 
However, all together the heritability of the vast majority (~80%) of HSCR cases is 
still to be uncovered. Finding genetic factors that may explain the missing 
heritability could come from analysis of known HSCR linkage regions, syndromic 
HSCR cases, or from the chromosomal abnormalities often identified in HSCR 
patients.  
HSCR is associated with chromosomal abnormalities in 12% of all cases. In 
this study we focused on the most common chromosomal abnormality found in 
HSCR, Trisomy 21. Trisomy 21, leading to Down Syndrome (DS), is the most 
frequent cause of learning difficulties with an incidence of 1 in 750 live births11. 
The incidence of DS among HSCR patients ranges from 2% to 10%3. Moreover, DS 
patients have >100 fold higher risk of developing HSCR than the general 
population3. This suggests that overexpression of one or more genes on 
chromosome 21 may have a substantial contribution to HSCR development in DS-
associated HSCR cases. However, none of the established HSCR genes are localized 
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on chromosome 21. Existing animal models for DS have not, as yet, been explored 
in detail for any ENS related defects and despite the vast knowledge available, this 
association still remains poorly understood. 
Here we aimed to identify the gene(s) on chromosome 21 that could 
contribute to the HSCR phenotype. We injected mRNA of selected Hsa21 genes into 
a transgenic zebrafish reporter model, and found that elevated levels of one of the 
chromosome 21 genes, ATP5O, resulted in altered ENS development and a HSCR-
like phenotype. Moreover, we show that ATP5O is expressed in the zebrafish gut 





Prioritizing Hsa21 candidate HSCR Genes  
In this study we first prioritized candidate genes based on genetic data and 
literature. The genetic data we used was: conservation of the genes between 
human and mouse12,13; expression of the genes in mouse enteric NCC (in-house 
RNA sequencing data); whether genes encode transcription factors and; presence 
of the genes in segmental duplicated regions of chromosome 21 in DS/HSCR 
patients14. In our literature search we took in consideration: previous studies on 
associations between DS and HSCR; Hsa21 genes that are involved in ENS and gut 
development; genes related to neuronal development; genes involved in neuronal 
signaling; known animal models of DS. 
 
Hsa21 clone sets  
To be able to microinject capped human mRNAs into 1-cell stage Tg(-
8.3bphox2b:Kaede) zebrafish, the set of prioritized Hsa21 genes were sub-cloned in 
pCS2+ and were grown overnight followed by plasmid isolation and purification 
using the NucleoBond® Xtra plasmid purification system (Marchery-Nagel, Nagel, 
2012). All the constructs were verified by DNA sequencing. A pSG5-huAPP-695 
construct was used for the APP clone. 
 
Zebrafish husbandry and strains 
The Tg(-8.3bphox2b:Kaede) zebrafish line expresses the fluorescent Kaede protein 
in phox2b expressing cells, including those of the ENS15. retsa2684/+ zebrafish line 
was obtained directly from Zebrafish International Resource Center (ZIRC)16. Both 




the Tg(-8.3bphox2b:Kaede) and retsa2684/+ zebrafish lines were maintained by 
pairwise mating. A cross between retsa2684/+ and Tg(-8.3bphox2b:Kaede) was 
performed to generate Tg(-8.3bphox2b:Kaede); retsa2684/+ fish. Zebrafish were 
maintained at 28°C according to the standard zebrafish laboratory protocols17. 
Embryos were scored for ENS defects and abnormal phenotypes at 5 dpf as 
described below. The institutional review board for experimental animals of 
Erasmus MC, Rotterdam approved the use of zebrafish embryos for this study. All 
procedures and fish experiments were performed in accordance with Dutch animal 
welfare legislations and those of the Erasmus Dierexperimenteel Centrum (EDC).  
 
In vitro transcription of mRNA and microinjections into zebrafish embryos 
In order to generate capped mRNA for microinjections, the plasmids were 
linearized with an appropriate restriction enzyme. After digestion, the plasmid 
DNA was cleaned using a phenol chloroform extraction method followed by 
ethanol precipitation. The linearized plasmids were used for in vitro synthesis of 
capped mRNA using the mMEssage mMachine SP6 kit (Ambion Inc., AM1340). 
Total RNA was purified using the RNeasy mini kit (Qiagen,Inc., 74104) and loaded 
on a 2% agarose gel to assess RNA quality and integrity. Capped mRNA 
quantification was done using the Nanodrop8000 (Thermo). RNA samples were 
stored at -80ºC. Capped mRNA was diluted in nuclease free water and 
microinjections were done in 1-cell stage zebrafish embryo to overexpress the 
genes, as described previously18. Different dosages of each mRNA (5pg, 10pg, 50pg, 
100pg, 150pg, 200pg and 250pg) were injected to determine their effect on ENS 
development. The mRNA-injected animals were raised in E3 media until 5dpf at 
28°C. Non-injected control (NIC) embryos served as positive controls for survival. 
 
Imaging and neuronal counting in zebrafish 
Zebrafish embryos injected with capped mRNA and NIC were scored using a Leica 
MZ16FA microscope for any visible phenotype under bright field and by using a 
GFP filter to image phox2b-positive enteric NCC. To analyze the zebrafish embryos, 
they were anesthetized using tricaine in E3 media and then mounted on 0.3% 
agarose gel for capturing the images. The digital images were made using a Leica 
MZ16FA microscope. Fluorescent imaging was made under the same settings for 
each image. Images were processed with Leica LAS and Adobe Photoshop CS 
software. To count the number of enteric neurons, we used an in-house made 
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algorithm with image analysis software from FIJI in a semi-automated way (Figure 
1C,D). 
 
Whole mount in situ hybridization in zebrafish 
A fragment of 686bp of zebrafish atp5o cDNA was amplified using RT-PCR using 
primer pair 5’-TTTCATCCCAGACCAGTACG-3’ (forward) and 5’-
GGTATCCCTGATCAGCTTGG-3’ (reverse). The amplified PCR product was ligated 
directly into the pCR®II-TOPO vector using the Dual Promoter TA cloning kit 
(Invitrogen). Positive clones were confirmed by DNA sequencing for the 




Figure 1. Schematic overview of experimental procedure. A) Schema for overexpression of 
prioritized candidate genes from Hsa21. B) Tg(-8.3bphox2b:Kaede) zebrafish line in bright field and 
under GFP filter, phox2b expressing neural crest cells are marked with fluorescent kaede protein. C) The 
enteric neurons of the intestinal region corresponding to 8 myotomes from the urogenital opening were 
selected as shown. D) Using FIJI software, the enteric neurons were counted as represented in the 
picture.  




probes to detect atp5o mRNA expression. Whole-mount in situ hybridization was 
carried out as previously described19. We used the DIG RNA labelling kit (Roche) to 
generate digoxygenin-labeled riboprobes against atp5o. Stained embryos were 




Tg(-8.3bphox2b:Kaede); retsa2684/+ embryos were grown until 5dpf for phenotyping. 
DNA was extracted from individual embryos and genotyping PCR was performed 
to distinguish mutants from wildtype using the gene-specific primers ret-wt-F1 
(5’GATCTCGTTCGCCTGGC3’), ret-mut-F1 (5’GATCTCGTTCGCCTGGT3’) and ret-wt- 
R1 (5’GGGGGCGTGTGACTAATTT3’). 
 
Immunohistochemistry on human colon material  
Control postnatal human colon tissues were obtained from the Pathology 
Department repository of the Erasmus University Medical Center. 
Immunohistochemical (IHC) staining was performed using the Ventana 
Benchmark Ultra automated staining system (Ventana Medical System, Tuscon, AZ, 
USA). Briefly, after deparaffination the sectioned specimens for IHC detection of 
ATP50 were processed for 60 min antigen retrieval using Cell Conditioning 
Solution (CC1, Ventana 950-124). After 30 minutes incubation with the primary 
antibody at 36°C (ATP5O 1:200), detection with UltraView Universal DAB detection 
kit (Ventana 760-500) was performed after amplification with Ultraview 
amplification kit (Ventana 760-080). The sections were counterstained with 
hematoxylin II (Ventana 790-2208).  
 
Epistasis between ATP5O and ret in zebrafish 
1 ng of translation-blocking antisense morpholino against ret20 and 50 pg of ATP5O 
capped mRNA were co-injected in 1 cell-stage Tg(-8.3bphox2b:Kaede) embryos. 
Embryos injected with either ret morpholino or ATP5O capped mRNA served as 
controls. At 5 dpf, embryos were imaged and enteric neurons present in the three 
myotome-length long, distal-most intestine were counted and compared.  
 
Cell culture and transfections 
The SK-N-SH Neuroblastoma cell line (ATCC # HTB-11) was cultured according to 
the ATCC’s protocol (LGC Standards, Middlesex, UK) and incubated at 37oC, 
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supplied with 5% of CO2. Approximately 106 cells were cultured in 1 well of a 6-
wells plate for 24 hr prior to transient transfections. Cells were transfected with 
1µg of DNA construct containing ATP5O (pCS2+/ATP5O) or empty vector (pCS2+) 
and we used untransfected (UT) cells as a negative control. Transfections were 
done using 4µl GeneJuice transfection reagent (Novagen, 70967, Millipore) 
according to the manufacturer’s instructions. Cells were starved in serum free 
media for 48 hr prior to harvesting and analysis. 
 
Cell apoptosis and cell proliferation assay 
Cell apoptosis was assessed by FACS analysis using PE Annexin V Apoptosis 
Detection Kit I (BD PharmingenTM) as per manufacturer’s instructions. Cells were 
washed with PBS. Early apoptotic cells were identified as PE Annexin V-positive 
and 7AAD-negative, while cells positive for both, PE Annexin V and 7AAD were 
marked as apoptotic cells. For cell cycle staining assays, ethanol fixed cells were 
stained with propidium iodide (PI) for 30 min at room temperature. Stained cells 
were analyzed on a FACS flow cytometer (BD Biosciences, San Jose, CA) and for 
both assays data analysis was performed using FlowJo. 
 
Statistical analysis 
Results are presented as means ± standard deviation (SD). Data were analyzed by 






Prioritization of candidate genes and generation of cDNA clones  
To test which gene(s) on chromosome 21 contribute(s) to HSCR in DS patients, a 
selection of the most promising candidate genes was made. A total of 169 genes 
were initially assembled for screening. They consisted of 149 Hsa21 genes that are 
conserved between human and mouse and another 20 genes that are non-
conserved, but are potentially interesting, and human specific12,13. From these 169 
candidates we selected genes encoding transcription factors, genes involved in 
neuronal development and genes reported as involved in DS with or without gut 
abnormalities (such as HSCR). Following these criteria, we generated a subset of 
65 candidate genes and among them we further prioritized the genes based on 




their expression in E14.5 mouse enteric NCC (in-house RNA sequencing data), and 
based on functional evidence from studies in other model organisms. This pipeline 
resulted in a shortlist of 28 genes (Table 1) and we were able to synthesize 21 
capped mRNAs (technical difficulties made us exclude 7 genes). A list of prioritized 




Table 1. List of prioritized 28 genes in Hsa21 for overexpression. 









1 APP 27252861 NM_201414 Yes Yes 
2 ATP5O 35275757 NM_001697 Yes Yes 
3 BACH1 30566392 BC063307 Yes Yes 
4 BRWD1 40556102 NM_001007246 Yes Yes 
5 BTG3 18965971 NM_001130914 Yes Yes 
6 CBR1 37442239 NM_001757 Yes Yes 
7 CHAF1B 37757676 NM_005441 Yes Yes 
8 CHODL 19165801 NM_024944 Yes Yes 
9 DSCAM 41382926 AB384859 Yes Yes 
10 DYRK1A 38739236 BC156309 Yes Yes 
11 HMGN1 40714241 NM_004965 No Yes 
12 PCBP3 47063608 BC012061 Yes Yes 
13 PDE9A 44073746 NM_001001567 Yes Yes 
14 PIGP 38435146 NM_153681 Yes Yes 
15 PKNOX1 44394620 NM_004571 Yes Yes 
16 RCAN1 35885440 BC002864 Yes Yes 
17 RUNX1 36160098 BC069929 Yes Yes 
18 SH3BGR 40817781 NM_001001713 Yes Yes 
19 SIM2 38071433 NM_005069 Yes Yes 
20 SOD1 33031935 NM_000454 Yes Yes 
21 SUMO3 46191374 NM_006936 Yes Yes 
22 DSCR3 38591910 BC110655 Yes No 
23 ETS2 40177231 NM_005239 Yes No 
24 HLCS 38123493 NM_000411 Yes No 
25 ITSN1 35014706 BC116186 Yes No 
26 TIAM1 32361860 BC117196 Yes No 
27 TTC3 38445571 BC137345 Yes No 
28 WRB 40752170 NM_004627 Yes No 
Overview of the 28 prioritized genes for overexpression. mRNA was injected into the Tg(-




CHAPTER 6  
 
166 
Tg(-8.3bphox2b:Kaede); retsa2684/+ mutants display ENS defect 
In humans, loss of function mutations in the RET gene result in HSCR. In this study 
we used the retsa2684/+ zebrafish that was identified in a ENU mutagenesis project as 
a positive control for a HSCR-like phenotype16. The retsa2684/+ line was crossed with 
the Tg(-8.3bphox2b:Kaede) reporter zebrafish line and the number of enteric 
neurons was scored at 5dpf followed by genotyping. The retsa2684/+ mutant embryos 
contained significantly less enteric neurons in the gut, indicating an HSCR-like 
phenotype, when compared to control animals (Figure 2A-D). The quantification of 
enteric neurons, corresponding to 8 myotomes from the urogenital opening, 
demonstrated a significant reduction in number of enteric neurons in retsa2684/+ fish 
(88 ± 41) compared to WT fish (158 ± 23) (p<0.0001, Figure 2G). These data show 
that the Tg(-8.3bphox2b:Kaede) is a suitable animal model for HSCR-like 
aganglionosis.  
 
Overexpression of selected candidate gene mRNA in a zebrafish model 
Capped mRNAs of the 21 selected Hsa21 genes were injected into Tg(-
8.3bphox2b:Kaede) zebrafish (Figure 1A,B), which were subsequently examined at 
5 dpf (as described in the Methods section). The mRNA dosage was titrated in a 
range of 5pg to 250pg, to find the optimal dosage for each mRNA based on the 
lethality and phenotype observed. Injections of mRNAs resulted in normal ENS 
phenotypes for all mRNAs, except one. Only when overexpressing ATP5O (100pg), 
a reduction in the number of enteric neurons was observed along the entire 
intestine with normal gross morphology when compared to the non-injected 
controls (Figure 2E,F). The percentage of zebrafish displaying reduction in enteric 
neurons remained similar at higher dosage (150pg). Counting the enteric neurons 
within the gut, corresponding to 8 myotomes from the urogenital opening, 
 
 
Figure 2. Reduced numbers of enteric neurons in the retsa2684/+ mutant fish and ATP5O mRNA 
injected fish. A,B) The control Tg(-8.3bphox2b:kaede) fish at 5 dpf in the bright field and under GFP 
filter showing fluorescently tagged phox2b expressing cells and the gut is completely colonized with 
enteric neurons until the urogenital opening. The asterisk indicates the urogenital opening. C,D) Enteric 
neurons along the gut of the Tg(-8.3bphox2b:Kaede); retsa2684/+. Heterozygous ret mutant displayed less 
neurons in the gut at 5dpf and discontinuity of colonization of the gut is indicated by arrowhead. E,F) 
The zebrafish injected with ATP5O mRNA at 100pg dosage show less enteric neurons in the gut. G) 
Quantification of enteric neurons in the intestine corresponding to 8 myotomes of 5dpf ret mutant 
compared to the control fish, marked significant reduction. H) Quantification of enteric neuronal count 
of non-injected controls compared to the ATP5O overexpressed embryos. A total of 37.5 % of embryos 
injected with 100pg of ATP5O displayed reduction in enteric neurons. 





CHAPTER 6  
 
168 
the average count for the controls was 178 ± 23 neurons (Figure 2H). We classified 
a gut as hypo-neuronal when the fish contained 2 SD less enteric neurons 
compared to the average control zebrafish. For the fish injected with ATP5O mRNA 
we found that 37.5% (15/40) of the embryos displayed such a reduction in the 
number of enteric neurons in the gut. The enteric neuron count in the affected 
embryos displaying reduced enteric neurons was 113 ± 18 (Figure 2H), showing 
that elevated levels of ATP5O interfere with normal development of the ENS.  
 
Expression of atp5o in zebrafish 
Whole mount in situ hybridization (ISH) was used to determine the spatio-
temporal expression pattern of atp5o between 1dpf and 5dpf of zebrafish 
development. RNA in situ hybridization revealed expression of atp5o in different 
organs at different developmental stages. At 1dpf, atp5o expression was seen 
ubiquitously (Figure 3B,C). At 2dpf the expression was restricted to the 
cerebellum, the otolith and the whole gut (Figure 3E,F). Between 3dpf to 5dpf 
atp5o was predominantly expressed in the intestine and cerebellum (Figure 
3E,F,H,I,K,L,N,O). At 5dpf, high atp5o expression was observed in the proximal and 
mid intestine along with the caudal vein (Figure 3N). The sense probe did not show 
any staining at 1dpf – 5dpf stages (Figure 3A,D,G,J,M), confirming the specificity of 
the probe. 
 
Expression of ATP5O in postnatal human colon 
To assess whether ATP5O is also expressed in the human colon, 
immunohistochemistry was performed on postnatal colon from healthy 
individuals. ATP5O was specifically detected in the ganglia present in the 
submucosal (Figure 4A,B) and myenteric plexuses (Figure 4C,D). In addition, 
ATP5O was also detected in the colon epithelium. These results suggest that ATP5O 
may be important for ENS development in humans as well. 
 
 
In vitro assays for cell apoptosis and cell cycle analysis 
To examine whether ATP5O overexpression affects early apoptosis or the cell cycle 
and thereby leads to less neurons in zebrafish gut, we used a human 
neuroblastoma cell line (SK-N-SH) and assayed cell apoptosis and cell cycle. SK-N-
SH cells expressing ATP5O were cultured in the absence of serum for 48 hr and 
tested for both alterations in apoptosis and cell cycle. Flow cytometry analysis 




didn’t indicate any significant changes in the early and late apoptosis in cells 
expressing ATP5O, when compared to other conditions (Supplementary Figure 




Figure 3. Spatio-temporal expression of atp5o in zebrafish. atp5o expression at indicated 
developmental stages ranging from 1–5dpf in zebrafish embryos (lateral view) detected using ISH. 
atp5o is expressed along the GI tract in all the stages. It is expressed ubiquitously at 1dpf (B,C) and the 
expression becomes restricted to cerebellum, otolith and whole gut by 2dpf (E,F). Arrowheads indicate 
expression in the brain and arrow marks indicate expression in the gastrointestinal tract 
(E,F,H,I,K,L,N,O). The sense probe shows no staining at 1–5dpf developmental stages as shown 
(A,D,G,J,M). 
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flow cytometry, we observed a slight increase in the fraction of cells in the G1 
phase as a result of ATP5O overexpression (Supplementary Figure 1B). Although 
the observed difference is not statistically significant, it could indicate that there 
can be some effect on the cell cycle arrest in ATP5O-overexpressing cells.  
 
Epistasis between ATP5O and ret in zebrafish  
To investigate whether ATP5O interacts with RET during the development of the 
ENS and in the pathogenesis of HSCR in DS, we knocked down ret and 
overexpressed ATP5O simultaneously by co-injecting ret translation-blocking 
morpholino (1 ng) and ATP5O capped mRNA (50 pg) and compared enteric 
neurons in distal intestine at 5 dpf to controls injected with either ret morpholino 
or ATP5O mRNA alone (Figure 5). The doses were chosen so that neither was 
sufficient to induce severe ENS defect by itself, and any synergistic effect between 
ret knockdown and ATP5O overexpression would readily be observed. The ret 
morpholino caused a mild decrease in enteric neuron number in the distal 
intestine compared to ATP5O mRNA control. However, co-injection of ret 
morpholino and ATP5O mRNA did not result in further significant reduction, 
suggesting limited or no synergistic effect between ret knockdown and ATP5O 
overexpression. 
 
Other phenotypic effects of injection of DSCAM and SIM2 mRNA 
The use of this zebrafish model and its optical transparency allowed us to detect 
other gross developmental abnormalities upon overexpression of the prioritized 
genes. Injection of two candidate genes (SIM2 and DSCAM) resulted in an abnormal 
phenotype. Overexpression of SIM2 (100 pg) resulted in notochord defects in 66% 
of the injected embryos at 5dpf (Figure 6A,C) and 33% among them also displayed 
craniofacial abnormalities (Supplementary figure 2A,B). Overexpression of DSCAM 
(200 pg) resulted in deformed notochord and myotomes in 68% of the embryos at 
5dpf (Figure 6B,D). The majority of these embryos also lacked the swim bladder. 
Microinjection of higher dosages (>200 pg for DSCAM and >100 pg for SIM2) of 












This study reports a role for a chromosome 21 gene, ATP5O, in the development of 
the ENS in zebrafish using an mRNA overexpression screen, as overexpression of 
ATP5O results in reduced numbers of enteric neurons in the zebrafish gut. This 
phenotype is comparable to that of the retsa2684/+ zebrafish line that carries a 
mutation in ret, a known HSCR gene in humans. This makes us hypothesize that 
elevated levels of ATP5O, as likely in the case of DS, could contribute to the high 
prevalence of HSCR among DS patients. 
 
The zebrafish as a model organism for human enteric neuropathies 
The intestinal architecture and anatomy of zebrafish closely resembles that of 
mammals21. The zebrafish gut undergoes rapid development and by 5dpf the 




Figure 4. Expression of ATP5O in postnatal human colon. Expression of ATP5O detected by 
immunohistochemistry on paraffin embedded post-natal colon sections. Arrowheads indicate 
expression of ATP5O in submucosal plexus (A,B) and myenteric plexus (C,D). ATP5O is also expressed in 
the gut epithelia as shown by arrows (A, B). 
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it lacks submucosal layer and myenteric neurons are arranged as neuronal pairs or 
single neurons21. The zebrafish ENS is also derived from NCC, as in other 
vertebrates23. In zebrafish, NCC migrate as two parallel chains of cells to colonize 
the whole gut and differentiate into enteric neurons and glia24. Despite these 
differences, the organization of the ENS, which modulates functions such as 
motility, homeostasis and secretion, is comparable but less complex compared to 
mammals making it a good model for human GI diseases25. Previous studies have 
shown that perturbation of zebrafish orthologues of known human HSCR genes 
using morpholino mediated knockdown, but also some mutant zebrafish for genes 
not connected to HSCR, leads to loss of enteric neurons in zebrafish gut and 
recapitulates the human HSCR phenotype10,20,24,26-29. In particular RET is known to 
be the major player in HSCR and in ENS development4,30. For these reasons we 
included the retsa2684/+ mutant zebrafish line as positive control. Indeed when 
quantifying the number of neurons in the hindgut, the most distal part of zebrafish 
intestine, the region in which mostly the aganglionosis in HSCR patients is 
observed, the number of neurons in this mutant fish was reduced. 
 
ATP5O overexpression results in reduced enteric neurons  
Microinjection of ATP5O mRNA resulted in reduced numbers of enteric neurons in 
the zebrafish gut comparable to what was found in case of the Tg(-
8.3bphox2b:Kaede); retsa2684/+ zebrafish (Figure 2A-H). ATP5O was the only gene for 
which overexpression resulted in ENS defects. The fact that overexpression results 
in fewer enteric neurons might not be a real surprise as mouse Atp5o is highly 
expressed in mouse enteric NCC (in-house RNA sequencing data). ATP5O is also 
expressed in the ganglia of submucosal and myenteric plexuses as shown in our 
studies using control postnatal colon sections. Similarly, atp5o is also expressed in 
the zebrafish gut during early embryonic development and the ENS also forms 
during this period. Furthermore, meta-analysis of DS phenotypes in segmental 
trisomy’s and its association with congenital gut abnormalities such as HSCR, 
duodenal stenosis and intestinal atresia suggested a critical GI region of <13 MB. 
This region also includes ATP5O14. Previous identity-by-descent (IBD) and 
association mapping in a large (inbred) Mennonite population also showed that 
ATP5O is within the IBD region associated with HSCR31. All these data suggest that 
ATP5O might well be responsible, or at least contribute to, the HSCR phenotype 
often seen in DS patients. 
 




The role of ATP5O in HSCR  
ATP5O is a mitochondrial gene, which encodes the ATP synthase H+ transporting, 
mitochondrial F1 complex, O subunit protein and is also known as Oligomycin 
Sensitivity Conferral Protein (OSCP). It is a component of ATP synthase (F(1)F(0) 
ATP synthase or Complex V) found in the mitochondrial matrix. ATP synthase is 
composed of an extramembranous catalytic core (F1) and a peripheral membrane 
proton channel (F0). The encoded protein appears to be part of the connector 
linking these two subunits and may be involved in transmission of conformational 
changes or proton conductance. It produces ATP from ADP via oxidative 
phosphorylation in the presence of a proton gradient across the mitochondrial 
membrane. Electron transport complexes of the respiratory chain generate this 
gradient32,33. The gene ontology (GO) annotation of ATP5O associates it with drug 
binding and transporter activity. It was hypothesized that overexpression of 
ATP5O could interfere with the normal subunit composition of ATP synthase, 
resulting in an impairment of oxidative phosphorylation34. An imbalance of 
expression, as generated in our zebrafish, could potentially impair the subunit 




Figure 5. Epistasis between ATP5O and ret. Quantification of enteric neurons at 5dpf in the distal 
most intestine corresponding to 3 myotomes of zebrafish embryos for epistatic interaction between 
ATP5O and ret. Embryos were injected with ATP5O (50ng), ret MO (1ng) and a combination of both and 
the enteric neuronal count is plotted in the graph. There are no significant differences between ATP5O 
(50pg) vs 1 ng ret MO (p=0.6587), 1 ng ret MO vs ATP5O (50pg) + 1ng ret MO (p=0.5437) and ATP5O 
(50pg) vs ATP5O (50pg) + 1 ng ret MO (p=0.2146). 
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eventual perturbed proliferation of these cells. We found a slight but not significant 
effect on cell cycle arrest (G1 phase) upon overexpression of ATP5O in SK-N-SH 
cells. It has also been shown that disruption of oxidative phosphorylation can have 
a neurotoxic effect on neuronal progenitor cells35, and overproduction of ATP 
synthase in Escherichia coli has already been implicated in cell division and 
growth36. During early ENS development, the enteric NCCs migrate, proliferate 
extensively and differentiate into neurons and glia. ATP5O overexpression could 
potentially affect enteric NCC proliferation and lead to fewer neurons in zebrafish 




Figure 6. Notochord defects in SIM2 and DSCAM mRNA injected zebrafish. Overexpression of SIM2 
and DSCAM lead to defects in the notochord, as represented by arrows in the bright field images of 5dpf 
embryos as compared to respective controls (A, B). The notochord is discontinuous and deformed in 








ATP5O does not interact with ret 
A previous study showed over-representation of the enhancer 
polymorphism RET+9.7 (rs2435357:C>T) in DS-HSCR37. The disease-associated 
allele was significantly different between individuals with DS alone, HSCR alone, 
and those with HSCR and DS, demonstrating an association and interaction 
between RET and chromosome 21 gene dosage. However, our zebrafish data did 
not demonstrate any interaction between ret and ATP5O in ENS development, 
suggesting that they acted independently in separate pathways. 
 
Additional phenotypes due to overexpression of Hsa21 genes 
In this overexpression screen of 21 candidate genes from Hsa21, we also identified 
phenotypic defects other than that of the ENS for DSCAM and SIM2. Zebrafish 
dscam is highly expressed in the developing brain. It is thought to be involved in 
shaping the nervous system and early morphogenesis of the zebrafish embryo38. 
The expression pattern of sim2 in zebrafish has been reported using whole mount 
ISH; it is expressed mainly in the diencephalon, the midbrain and the pharyngeal 
arches39. Overexpression of DSCAM and SIM2 in zebrafish displayed defects mainly 
in notochord development and in the floor plate, exhibiting discontinuity with 
some twists and folds upon overexpression of these genes. The notochord is 
essential for proper vertebrate development by producing secreted factors that 
signal to the surrounding tissues. It is also important for specification of the 
ventral fates in the CNS and it plays an important role in patterning and in a proper 
structural integrity. The defects in notochord development are possibly due to 
uneven cell patterning or selective cell death or defects in signaling pathways 
required for normal notochord development (reviewed by Stemple, 200540). 
Moreover, besides notochord defects we also observed craniofacial abnormalities 
on overexpression of SIM2 in a subset of embryos at 5dpf along with notochord 
defects (Supplementary Figure 2A,B), indicating its prospective contribution to the 
phenotype observed in DS affected individuals. To our surprise, some candidates 
(such as DSCAM, SIM2, and APP) already associated with ENS phenotypes, based on 
previous genetic studies and murine models did not display any visible ENS 
phenotype following their overexpression in the zebrafish model. DSCAM has been 
highlighted as a predisposing locus to HSCR in patients with DS14,31,41. Our previous 
studies, using in vitro methods, have shown that overexpression of SIM2 leads to a 
down regulation of the RET gene8. Similarly, a transgenic APP mouse model 
displayed reduction in myenteric neuronal density and delay in gut transit42. These 
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are characteristic features of HSCR in humans, but we were not able to recapitulate 
similar phenotypes in the zebrafish model upon their overexpression. This could 
be due to the fact that the regulatory mechanism required for efficient translation 
of certain human RNAs was not equally efficient in zebrafish, or that the human 
protein does not have the same effect as the zebrafish protein or alternatively the 
threshold dosage of RNA required resulting in a phenotype may not have been 
achieved in our study. Furthermore, we cannot rule out any unknown feedback 
mechanisms resulting in the net neutrality of overexpression. On the other hand, a 
phenotypic effect may simply require a combinatorial overexpression of more than 
one gene. 
Within the list of 21 genes we did not include COL6A4 although it was 
recently shown that overexpression of Col6a4 in transgenic mice could lead to a 
HSCR-like phenotype43. The reason for not including it was the fact that we had not 
found any direct or indirect evidence for the involvement of Col6a4 with ENS 
development nor did we see the gene being expressed in the mouse enteric NCC at 
E14.5 (in-house RNA sequencing data).  
 
Conclusions 
Although the association of DS with HSCR is well recognized, the causative link 
between them is not well understood. The majority of DS affected individuals 
exhibit GI abnormalities44, which might be related to abnormal ENS development. 
Here, we used a transgenic zebrafish line, whose ENS is marked with the 
fluorescent Kaede protein, to assay the functional effects of overexpression of 
Hsa21 candidate genes. We found that ATP5O affects ENS development in 
zebrafish. The use of a vertebrate model to find the missing link between DS and 
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Supplementary Figure 1. In vitro apoptosis and cell cycle assays. SK-N-SH neuroblastoma cells 
were transected with construct containing ATP5O and the cells were starved for 48 hours and assayed 
for apoptosis and cell cycle assays by FACS analysis. Data are represented as mean ± SD for two 
independent experiments. A) Cells that were PE Annexin V-positive and 7AAD-negative were classified 
as early apoptotic, while cells positive for both PE Annexin V and 7AAD were marked as apoptotic. 
There were no differences between ATP5O-transfected cells and controls. B) Cell cycle analysis using 
propidium iodide (PI) DNA staining indicated no major differences between the cell phases, but there 
was a slight increase in G1 phase for ATP5O-transfected cells as compared to the controls.  
 




Supplementary Figure 2. Craniofacial abnormalities by SIM2 overexpression. A) Control embryo 
at 5dpf. (B) SIM2 (100pg) overexpressing embryo at 5dpf displaying craniofacial abnormality as shown 
by arrows in 33% of them along with the notochord phenotype. The lower jaw appears dislodged 
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Hirschsprung disease (HSCR) is a congenital disorder in which the muscles in a 
variable segment of the distal colon are unable to relax. This results in 
constipation, vomiting and distention of the bowel proximal to the affected 
segment. The lack of colonic relaxation in HSCR stems from an incomplete 
development of the enteric nervous system (ENS). During embryonic development 
almost all enteric neural crest cells (ENCCs) that form the ENS enter the foregut 
and proliferate, survive and migrate towards the distal hindgut, before they 
differentiate into neurons and glial cells1. A distortion of any of these processes 
leads to an incomplete colonization of the colon by ENCCs, lack of neuronal 
innervation, and hence failure of the colonic smooth muscles to relax.  
 HSCR is an inherited disease for which mutations in over 20 genes and 5 
associated genomic loci have been found. Collectively they explain ~25% of the 
observed heritability2–4. The majority of these genes has been identified by linkage 
analysis and sequencing of candidate genes. However, over the past decade genetic 
research has been greatly facilitated by technological developments in genome-
wide association studies (GWAS) and next-generation sequencing (NGS). Three 
GWAS on predominantly sporadic HSCR patients have been conducted5–7. In 
addition, rare variants in the associated loci and in yet undiscovered HSCR genes 
will likely contribute to the genetic risk of this complex genetic disease. These 




NEXT-GENERATION SEQUENCING IN COMPLEX GENETIC DISEASES 
 
Study designs to identify rare, pathogenic variants 
Common variants have successfully been associated with disease in GWAS, but 
have a low penetrance. Rare disease-associated variants on the other hand usually 
have a higher penetrance and are therefore more informative for understanding 
disease etiology and in genetic counseling8. Rare variants can be identified on a 
genome/exome-wide scale by NGS, but large-scale rare variant association studies 
are far less abundant than GWAS. The main reason for this is the high cost per 
sample in NGS compared to GWAS. Genetic power calculations show that rare 
variant associations studies require similar numbers of cases and controls as 
GWAS, meaning that NGS studies have less statistical power than equally expensive 
GWAS9. However, the cost of NGS is declining rapidly, thereby opening new 




opportunities for rare variant association studies. However, even at reducing costs 
sequencing thousands of cases and controls remains an expensive ordeal and 
patient numbers may not be available for diseases that are rare. For these reasons 
the question arises whether it is worthwhile to sequence small numbers of 
patients (and controls) in complex genetic diseases. 
Case-control analysis on a limited number of sporadic patients will not 
have sufficient statistical power to find genome-wide significance, but other study 
designs may be successful with small numbers of individuals. Multiplex families 
remain a valuable source for genetic testing. For example, exome sequencing of 29 
patients and 11 controls from 14 late-onset Alzheimer disease pedigrees 
successfully identified rare variants in PLD3 in two families10.  
If sporadic patients are being studied, several approaches have been 
suggested to increase the power of a rare variant association study. In chapter 5 
we applied these strategies to analyze exome sequencing data from 48 sporadic 
HSCR cases and 212 controls. We maximized the power of the study by prioritizing 
long-segment HSCR cases (which have the highest heritability), selecting rare, 
pathogenic variants, collapsing all variants per gene and performing a meta-
analysis on data from three sequencing centers. Since we found no genome-wide 
associations, we analyzed whether the highest associated genes (by nominal p-
value) are good candidate genes for HSCR. Gene prioritization tools consistently 
predicted CELSR1, CLOCK and FASN as the most likely disease-causal genes. In 
addition, GHDC is a poorly characterized gene for which no connection to the ENS 
was found, but the gene was highly expressed by ENCCs and contained disrupting 
variants.  
Predicting the most likely disease-causal genes in an underpowered 
genetic study based on gene function or expression is yet no evidence for 
involvement in the disease. Even when assuming that there are no real 
associations with HSCR, some genes will have more significant p-values than 
others and these genes could be of interest in the disease context just by chance. 
The gene prioritization and gene expression data do therefore not identify new 
disease-associated genes, but should be regarded as means to identify the best 
candidate genes for follow up studies on a limited number of genes. Moreover, 
small rare variant association studies can be used to assess the frequency of rare 
variants in the candidate genes in cases and controls, which can be used to 
calculate odds ratios. These are important for power calculations in follow-up 
studies.  
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Identification of de novo mutations in NGS data 
As said small studies are almost all underpowered. However, NGS can be 
successfully applied on relatively small numbers of sporadic disease patients for 
the identification of de novo mutations (chapter 2). Exome sequencing studies 
have revealed a role for de novo mutations in the genetic etiology of rare congenital 
syndromes and more common neurodevelopmental disorders11. However, the 
identification of de novo mutations in exome sequencing data is not trivial, since 
the number of true de novo mutations is much lower than the number of false 
positives that arise from sequencing errors and incorrectly called genotypes. Joint 
genotype calling of offspring-parent trios12 and statistical modelling efforts13–17 
have improved de novo mutation detection significantly. In chapter 4 we analyzed 
if and how de novo mutations can be detected by applying filtering thresholds for 
reference allele ratio, sequencing depth and Genotype Quality score. We found that 
by removing the maximum assigned value of the Genotype Quality score, de novo 
mutations could be detected with high sensitivity and specificity in our training 
data and in a second, independent dataset.  
We restricted our analysis to three sequencing parameters (reference 
allele ratio, sequencing depth and Genotype Quality score) that were reported to 
efficiently filter errors from NGS data18,19. However, other parameters such as 
calling quality, mapping quality, quality/depth ratio and [depth in 
proband]/[depth in parent] ratio have also been proposed as discriminating 
parameters for de novo mutation detection17. A combined approach where the 
unmaxized Genotype Quality score and other sequencing parameters are 




GENETICS OF HSCR 
 
Identification of four new HSCR genes in a de novo mutation screen 
In our exome sequencing on sporadic, non-syndromic HSCR patients, we 
predominantly included patients with long-segment HSCR, since this subtype has 
the highest heritability and follows a dominant mode of inheritance with 
incomplete penetrance20. Rare variants with a large effect size are therefore 
expected to make a large contribution to long-segment HSCR. In chapter 2 we 
tested the hypothesis that rare variants in sporadic, long-segment HSCR occur de 




novo. We identified 28 de novo mutations in 24 HSCR patients. Eight of these de 
novo mutations were found in RET, the major HSCR gene, supporting a role for de 
novo mutations in the etiology of long-segment HSCR. Moreover, this finding, and 
the overrepresentation of loss of function de novo mutations, suggests that de novo 
mutations in other genes may contribute to HSCR as well.  
To overcome the mentioned problems one encounters when sequencing 
small cohorts of patients, we carried out unbiased in silico and in vivo analyses for 
the 20 genes (besides RET) that harbor de novo mutations to determine whether 
they are involved in the development of the ENS. RET and CKAP2L were enriched 
for rare variants in HSCR patients compared to controls, but only RET could be 
replicated in an independent cohort. The 20 genes with de novo mutations could 
not be linked to the signaling pathways in HSCR, but all were expressed by either 
ENCCs from E14.5 mouse embryos or by human iPS cell-derived neural crest cells. 
Since our in silico analyses did not yield convincing evidence for a role of the de 
novo mutated genes in HSCR, we decided to functionally test our candidate genes 
using the transgenic Tg(-8.3phox2b:Kaede) zebrafish model21. Morpholino-
mediated knockdown of the 12 genes that had non-synonymous de novo mutations 
and an orthologue in the zebrafish resulted in HSCR-like aganglionosis for four 
genes (DENND3, NCLN, NUP98 and TBATA).  
To find a disease-mimicking phenotype for four out of 12 candidate genes 
is a great success. However, questions have been raised about the specificity of 
morpholinos to study gene function, as up to 70% of morpholino-induced 
phenotypes cannot be reproduced by genome-editing techniques22. Does this mean 
that the HSCR-like phenotypes we observed are false positives? We think not. 
Second, non-overlapping morpholinos were used to confirm the results for all 
genes that showed a phenotype in the initial screen and appropriate 5-nucleotide 
mismatch controls were used. The morpholino experiments were repeated 
independently in a second laboratory and phenotypes were reproducible. 
Moreover, morpholinos were co-injected with a morpholino against p53 to test 
whether the phenotype was caused by p53-induced apoptosis. Since the results 
from all control experiments are in line with a specific morpholino-induced 
phenotype, we confidently conclude that the four identified HSCR genes are 
indispensable for ENS development. Nevertheless, confirmation of the phenotype 
by a genetically engineered mutant would further strengthen this conclusion.  
Mutations in the four novel HSCR genes were infrequent in our replication 
cohort and not significantly associated to HSCR. A larger replication cohort is 
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required to assess to what extent mutations in these genes contribute to HSCR. 
This question is currently being addressed by the International Hirschsprung 
Disease Consortium. DNA from approximately 300 HSCR patients and controls will 
be analyzed for mutations in the four genes and other candidate genes by targeted 
NGS. This study will be informative for the frequency of mutations in the four novel 
genes. It is also unclear how mutations in the four genes contribute to 
aganglionosis in the HSCR patients that carry the mutations. Functional studies on 
how these genes are involved in the migration, proliferation, survival and 
differentiation of ENCCs are therefore warranted. Such studies could be performed 
in vivo in animal models, for example in the zebrafish model that was used to 
screen the candidate genes, or in transgenic mouse models. Alternatively, in vitro 
model systems, such as primary ENCCs, iPS cell-derived neural crest cells, neural 
crest-like cell lines or cultured gut explants can be applied to delineate the role of 
DENND3, NCLN, NUP98 and TBATA in ENS development.  
 
How to identify additional HSCR-associated variants? 
Functionally testing candidate genes identified in a genetic study, as we applied in 
chapter 2, resulted in the identification of four new disease genes that would not 
have been identified by statistical evidence only and which were not connected to 
the known signaling pathways in HSCR. This emphasizes the importance of 
unbiased functional testing. Although there should be no doubt that the plethora of 
bioinformatic predictions that is available has contributed massively to our 
knowledge of biology, one should realize that our understanding of cellular 
processes is limited. Using functional analysis, although costly and time 
consuming, we were able to unveil new and unexpected genes for HSCR, that 
would not have been found when solely relying on bioinformatic predictions. One 
might conclude that we should perform more functional assays to include or 
exclude identified variants. Clearly this is not realistic for all identified variants. 
Burden tests might help but as mentioned in small cohorts these tests are not 
informative. An alternative might be the screening of a selection of genes based on 
gene function and expression. 
 
Gene expression analysis in the developing ENS 
Another approach to deal with low statistical power in genetic studies is to select a 
number of candidate genes, rather than performing a genome-wide study. The low 
statistical power of genome-wide studies stems from the large multiple testing 




correction and this correction is considerably lower in studies on limited numbers 
of genes. Candidates genes for HSCR can be prioritized based on genetic pilot 
studies (chapter 5), or on their expression in the developing ENS. Previous gene 
expression studies on the ENS found that known HSCR genes are expressed by 
ENCCs and uncovered new genes and pathways in ENS development23–26. Using a 
transgenic mouse model to specifically isolate ENCCs and a novel analytical 
approach to identify regulatory genes, we analyzed the gene expression profile of 
ENCCs in more detail in chapter 3. Gene Ontology analysis showed that ENCCs 
expressed markers of early and late neuronal differentiation and activation of the 
RET receptor by its ligand GDNF induced neuronal maturation of ENCCs. 
Moreover, we applied an Upstream Regulator analysis to identify genes that are 
predicted to regulate the expression of differentially expressed genes. The known 
HSCR genes Sox10 and Ret were predicted regulators of gene expression in ENCCs, 
suggesting the Upstream Regulator analysis is a powerful approach to identify 
relevant signaling molecules. Other predicted regulators, Bdnf, App, Mapk10 and 
Timp1, are therefore likely to be important for ENS development as well and may 
play a role in HSCR. The predicted Upstream Regulators could be linked together in 
a molecular network underlying ENS development. Likewise, Adora2a and Npy2r 
(mapping to the HSCR susceptibility locus 4q31.3-q32.327) were near-significant 
regulators of terminal neuronal differentiation in GDNF-treated ENCCs.  
Our study resulted in a list of good candidate genes, however this list is far 
from complete. In our gene expression study ENCCs were isolated from mouse 
embryos at developmental stage E14.5 and were cultured in vitro. The single time 
point of analysis and in vitro culturing are limitations of this study. ENS 
development in mice takes place between E9 and E1528. ENCCs invade the gut, 
proliferate and migrate along the intestinal wall, and differentiate into neurons and 
glia. ENCCs make up a heterogeneous cell population at any moment during ENS 
development, where cells in the proximal regions start differentiating when 
migratory ENCCs have not yet reached the hindgut29,30. At E14.5, the time point of 
our expression analysis, ENCCs have reached the hindgut and we found that 
markers of early and late neuronal differentiation were expressed. At earlier stages 
of ENS development there will be more migratory and fewer differentiating ENCCs 
and the corresponding expression profile would likely be different from that at 
E14.5. A temporal expression analysis between E9 and E15 would give more 
insight in the changes that ENCC undergo as they colonize the gut. Also the GDNF-
responsive genes will likely be different at earlier time points, as GDNF is 
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important for the proliferation, migration, survival and neuronal differentiation of 
ENCCs, depending on the developmental stage and position in the gut31–34. 
Moreover, as HSCR originates from incomplete colonization of the gut by ENCCs, it 
would be interesting to compare gene expression profiles of ENCCs at the 
migratory wavefront and non-migrating cells behind the wavefront. Such an 
experiment would provide information about the genes involved in the migration 
of ENCCs and the gene expression changes that are associated with a halt in 
migration.  
Moreover, not all genes that are important for ENS development are highly 
expressed by ENCCs. For example, the known HSCR genes GDNF, NRTN, EDN3, 
ECE1 and SEMA3A are ligands that are secreted by the gut mesenchyme. Other 
ligands, such as BMPs, NT-3 and SHH contribute to ENS development as well, but 
are not highly expressed by ENCCs35. So genes important for ENS development 
may have been missed by exclusively looking at expression in ENCCs. Furthermore, 
these data suggest that when new receptors are identified, it is worthwhile to also 
study the function of its ligand(s).  
Ideally, isolated ENCCs should not be cultured prior to RNA isolation, as 
cell culture conditions may affect gene expression. Nevertheless, in our gene 
expression study we cultured isolated ENCCs to be able to study the effect of GDNF 
on gene expression. In addition, we needed to expand our ENCC cultures in vitro to 
obtain sufficient amounts of RNA for microarray analysis. Currently, microarrays 
are being replaced by RNA sequencing to quantify gene expression and RNA 
sequencing requires a lot less input material. In vitro culturing of isolated ENCCs 
can therefore be circumvented in future gene expression experiments. In 
comparison to microarrays, RNA sequencing is also more sensitive in detecting 
low-abundance transcripts, can discriminate between different transcripts of a 
gene, allows for the identification of genetic variants, and can be used to compare 
the relative expression of different genes within a sample36.  
 
Non-coding variants and disease 
In addition to selection of candidate genes, gene expression data can be used in 
disease gene discovery by expression quantitative trait locus (eQTL) mapping. It 
has been suggested that eQTL mapping has greater power of finding risk SNPs than 
investigating the association of SNPs with the presence of absence of disease37. In 
HSCR it is assumed that reduced expression levels of RET and other HSCR genes 
impair colonization of the bowel and common variants in intron 1 of RET have 




been shown to affect RET expression38,39. A genome-wide survey of common or 
rare variants affecting the expression of known ENS genes is therefore likely to 
identify novel genes underlying ENS development and HSCR.  
 
Low penetrant mutations  
There is a relatively large contribution of common variants to short-segment 
HSCR. The two published GWAS by the International Hirschsprung Disease 
Consortium analyzed 371 patients and 856 controls and 629 HSCR trios, 
respectively5,7. A third GWAS on HSCR included 123 patients and 432 controls6. 
Meta-analysis of these three GWAS showed that 34±11% of the HSCR risk is 
attributable to common variation, but only 6% can be explained by the three 
associated loci (RET, NRG1 and SEMA3) (Tang et al., unpublished data). This 
suggests that there are undiscovered HSCR loci that may not have reached 
genome-wide significance. Increasing patient cohorts in GWAS generally leads to 
more associated loci40–42. Increasing cohort sizes in GWAS on HSCR to several 
thousand cases and controls will therefore uncover additional associations and 
lead to the identification of new HSCR genes. However, such an undertaking is 
expensive and the collection of large numbers of HSCR patients may be 
troublesome.  
It must be noted that although the GWAS on HSCR uncovered new 
signaling pathways in ENS development5–7, common variants explain only part of 
the heritability in HSCR. The missing heritability may come from rare variants in 
both previously associated and as yet undiscovered HSCR genes.  
 
A molecular link between the CNS and the ENS 
The four newly identified HSCR genes were expressed not only in the gut during 
zebrafish development, but also in the anterior central nervous system (CNS). This 
suggests a role for these genes in the development of both the ENS and the CNS. 
Although the developmental origins of the CNS (neural tube) and ENS (neural 
crest) are different, there are many similarities between the two nervous systems. 
Like the CNS, the ENS is composed of efferent, afferent and interneurons that use 
largely the same repertoire of neurotransmitters43,44. Moreover, the genes involved 
in late ENS development show a large overlap with those expressed in the 
developing CNS (chapter 3). Various CNS pathologies, such as autism, stroke, 
Parkinsonian disease, multiple sclerosis and spinal cord injury can be associated 
with constipation, suggesting that these conditions affect the proper function of the 
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ENS45,46. Vice versa, the HSCR genes KBP, SOX10, NRG1, SEMA3A, IKBKAP and ZEB2 
all contribute to CNS pathologies47–53. Further evidence for the link between the 
ENS and CNS comes from the HSCR-associated syndromes, most of which show 
neurological involvement2. The most prevalent HSCR-associated syndrome is 
Down syndrome (DS, or Trisomy 21) with an incidence of 7.3% among HSCR 
patients54. Conversely, DS patients have a 130-fold elevated risk of HSCR compared 
to the general population54). This suggests that the triplication of one or more 
genes on chromosome 21 poses a risk for developing HSCR. In chapter 6 we 
explored the genetic link between DS and HSCR by overexpressing selected human 
chromosome 21 genes into the Tg(-8.3bphox2b:Kaede) reporter zebrafish model. 
We found that injection of ATP5O mRNA resulted in hypoganglionosis, 
predominantly in the distal intestine. atp5o was expressed in the zebrafish gut and 
cerebellum between day 1 and 5 post-fertilization. In post-natal human colon 
ATP5O was expressed in the myenteric and submucosal plexuses, as well as in the 
epithelium. These data suggest that ATP5O is relevant for ENS development and 
that triplication of ATP5O likely contributes to HSCR in DS patients.  
 
Implications for genetic counseling 
The revolution in genetic screening, due to the introduction of NGS, has improved 
genetic counseling enormously. For example in patients with intellectual disability 
20 percent more causative mutations are being found, which more or less doubles 
the number of diagnoses that can be made. 
For rare diseases, such as HSCR, however, this is slightly more 
complicated. The study presented in chapter 2 nicely illustrates the problems and 
opportunities one is facing when screening a rare disease. On the one hand NGS 
improved genetic counseling as some RET mutations that were missed in the 
original screening were detected (not mentioned in the paper). However, what to 
do with the identified de novo mutations? Do we have sufficient evidence that the 
mutations identified are really disease causing? We did show in a zebrafish model 
that knocking down the expression of the gene resulted in an HSCR-like phenotype, 
but is this sufficient in combination with in silico prediction and the fact that then 
mutations were de novo? In our case one could argue that the combination of all 
data should suffice. But what to do when no functional assays are or can be 
performed? Is in silico prediction in combination with a de novo appearance 
enough? Criteria should be made how to deal with these de novo findings. 




For de novo mutations these criteria might be relatively easy but what to 
do with a gene in which an inherited mutation is found only once (even 
truncating)? In particular when one of the healthy parents is also carrying the 
mutation? Burden tests will likely not give statistical evidence for involvement. 
Should these all be functionally tested? This is not realistic. One could decide, 
based on function and mutation type to use the mutation in counseling, but what is 
known about the penetrance of the mutation? Again criteria need to be set how on 
what to do with this type of mutations in rare diseases  
Clearly, we need rules on how to work with these mutations as this type of 





The work in this thesis describes for the first time the application of NGS to study 
the contribution of rare, coding variants to sporadic HSCR. We show that a rare 
variant association study has limited power to find genome-wide associations, but 
does provide information on mutation frequencies per gene and odds ratios. NGS is 
more powerful when applied to identify de novo mutations. Although the 
identification of de novo mutations in NGS data is technically challenging, 
combining de novo mutation screening and functional genomics shows that the 
identified de novo mutations make a large contribution to sporadic, long-segment 
HSCR. This finding is of importance for genetic counseling in HSCR and underlines 
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The enteric nervous system (ENS) is the nervous system of the gastrointestinal 
tract. The ENS is responsible for the peristaltic movements of the bowel, regulation 
of blood flow and secretions in the gut. The ENS is composed of neurons and glia 
that are organized in clusters named ganglia along the entire length of the gut. In 
patients with Hirschsprung disease (HSCR) these ganglia are missing in the most 
distal region of the large intestine. This lack of enteric ganglia is referred to as 
aganglionosis. HSCR is a hereditary disease that is usually diagnosed within a few 
days after birth. Due to the absence of neurons in the bowel the muscles in the gut 
of HSCR patients are unable to relax. This results in tonic contraction of these 
muscles, life-threatening constipation, vomiting, and dilatation of the region of the 
gut where feces is accumulating. The clinical and genetic aspects of HSCR are 
discussed in chapter 1 of this thesis.  
 One in every 5,000 live born children is affected by HSCR and the 
incidence is four times higher in males than in females. Although HSCR is a genetic 
disorder, in most families the disease does not follow the classical Mendelian rules 
of inheritance. When HSCR occurs in a familial form it can be dominant or 
recessive. This is seen in approximately 10% of the HSCR cases. However, in 90% 
of cases the patient is the only family member that is affected, called a sporadic 
patient. In these sporadic cases the mode of inheritance is considered complex 
with many genes and environmental factors involved. There is also variation in the 
length of the gut segment that is aganglionic. A short segment is affected in 80% of 
the cases, whereas ganglia are absent in a longer segment of the gut in 20% of the 
patients. The latter is referred to as long-segment HSCR and is the most heritable 
form of the disease. 
 Mutations in over 15 genes have been identified in HSCR patients, of which 
RET is the most important gene. Mutations in the protein coding regions of RET 
have been found in ~50% of familial patients and in 15-35% of sporadic patients. 
Mutations in other HSCR genes are much more rare and are mainly found in 
familial or syndromic cases. It is therefore likely that mutations in other, not yet 
associated genes also contribute to the development of HSCR.  
 Chapter 2 describes the identification of novel HSCR genes by screening 
for de novo mutations in sporadic patients. De novo mutations are new genetic 
changes that are found for the first time in the offspring, but are absent in both 
parents. In recent years de novo mutations have been implicated in the etiology of 




developmental disorders such as autism, schizophrenia and intellectual disability. 
In our study we identified 28 de novo mutations in 24 patients, eight of which were 
found in RET, the major HSCR gene. The remaining 20 genes that harbored de novo 
mutations could not be linked to the known gene networks in ENS development. 
Therefore, we decided to functionally test the role of the genes in which we 
identified possible pathogenic mutations (loss of function or missense mutations) 
in ENS development in an animal model. We opted for a transgenic zebrafish 
model that expresses a fluorescent protein in ENS progenitor cells and in mature 
enteric neurons. Knockdown of four of the 12 genes with possible pathogenic de 
novo mutations (DENND3, NCLN, NUP98 and TBATA) resulted in reduced numbers 
of enteric neurons in the distal gut of the zebrafish, reminiscent of the 
aganglionosis observed in human HSCR patients. The four genes have known 
functions in the development of the central nervous system (CNS). Our data 
suggest that these genes are involved in the development of both the ENS and the 
CNS. 
 Many known HSCR genes are expressed by the progenitor cells of the ENS. 
In chapter 3 we analyzed the gene expression profile of ENS progenitors to better 
understand the molecular mechanisms behind ENS development and to identify 
new candidate genes for HSCR. Genes that were highly expressed by ENS 
progenitors are involved in various stages of neural development and in adhesion 
of migrating cells. That our approach is working well for the identification of HSCR 
candidates is suggested by the identification of the known HSCR genes Ret and 
Sox10 as critical genes in ENS development. Our data suggest that Bdnf, App, 
Mapk10 and Timp1 are prefect candidates for HSCR. In addition, we showed that 
activation of RET, the major HSCR gene, causes maturation of enteric neurons.  
Next-generation sequencing (NGS) is a new technology for DNA 
sequencing. NGS can be applied to sequence the entire genome and generates 
enormous amounts of DNA sequence data. Because of the large amount of data in 
NGS experiments it is inevitable that errors occur in the obtained DNA sequence. 
This poses a challenge for the detection of de novo mutations, as the number of de 
novo mutations is much lower than the number of errors in NGS data. Chapter 4 
presents an analysis on how de novo mutations can be distinguish from sequencing 
errors based on three commonly used quality parameters. We found that the most 
informative quality parameter is the Genotype Quality score. Generally a maximum 
value is assigned to the Genotype Quality score, but we found that de novo 
mutations can be identified more specifically by removing the maximum value of 
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this parameter. By selecting the optimal threshold values for the three quality 
parameters, we were able to identify de novo mutations with an accuracy of 98.3%, 
without missing any de novo mutations.  
 Complex genetic diseases are caused by a combination of common and 
rare genetic variants. Rare variants can be identified by NGS, but since they are 
found in only few patients it is difficult to obtain statistical evidence for their 
contribution to disease development. In chapter 5 we analyzed how a 
combination of strategies can be applied to extract useful information from an NGS 
study on HSCR patients, despite the lack of statistical evidence. We identified 
several candidate genes for HSCR by assessing which genes have plausible roles in 
ENS development. We present ways in which even a small-scale genetic study can 
be used to test whether these genes are indeed involved in the development of the 
ENS.  
In 30% of all cases HSCR occurs as part of a syndrome, most commonly 
Down syndrome. Seven percent of people with Down syndrome also suffer from 
HSCR. Down syndrome is caused by an extra copy of chromosome 21. It is 
therefore likely that the extra copy of one or more genes on chromosome 21 
contributes to the development of HSCR in Down syndrome patients. We tested 
this hypothesis in chapter 6 by overexpressing several chromosome 21 genes in 
the zebrafish model with the fluorescent ENS. Overexpression of one gene (ATP5O) 
resulted in a reduced number of enteric neurons in the intestine of the zebrafish, 
similar to what is observed in human HSCR patients. The extra copy of this gene 
may contribute to the development of HSCR in patients with Down syndrome.  
 Chapter 7 describes the implications of the research described in this 
thesis. We conclude that rare genetic variants contribute to sporadic HSCR and 
emphasize that functional testing of candidate genes from genetic studies is of 
great value in the identification of new disease genes. Suggestions are made for the 
identification of new HSCR genes in future studies. Moreover, the implications of 
this research for genetic counseling to HSCR patients and their families are 
discussed.  
  










In de wand van onze darmen bevinden zich spieren die door samen te trekken 
ontlasting door de darm duwen. Deze spieren worden aangestuurd door het 
zenuwstelsel van de darmen, het enterisch zenuwstelsel. Dit zenuwstelsel bestaat 
uit zenuwcellen die in clusters verspreid zijn over de gehele lengte van de darm. 
Deze clusters heten ganglia. In patiënten met de ziekte van Hirschsprung (HSCR) 
zijn deze ganglia afwezig in het laatste deel van de dikke darm. Deze afwezigheid 
wordt ook wel aganglionose genoemd. HSCR is een erfelijke ziekte die doorgaans 
wordt vastgesteld in de eerste levensdagen van een pasgeboren kind. Door de 
afwezigheid van zenuwcellen in de dikke darm kunnen de spieren in de darm zich 
niet ontspannen in HSCR patiënten, wat leidt een sterk samengeknepen stuk darm 
wat met een levensbedreigende verstopping, braken en het opzwellen van het deel 
van de darm waar voedsel zich ophoopt als gevolg. De klinische en genetische 
aspecten van HSCR worden besproken in hoofdstuk 1 van dit proefschrift. 
HSCR wordt gediagnosticeerd in één op de 5000 levend geboren kinderen 
en komt vier keer vaker voor bij jongens dan bij meisjes. Ondanks dat HSCR een 
erfelijke ziekte is, volgt het niet de wetten van de klassieke genetica. Ongeveer 
10% van de HSCR gevallen komt voor binnen families, maar meestal is de patiënt 
het enige familielid met de ziekte (sporadische patiënt). Tevens is er variatie in de 
lengte van het deel van de darm waarin de aganglionose voorkomt. In 80% van de 
gevallen is een kort deel van de darm aangedaan, terwijl in de overige 20% van de 
patiënten zenuwcellen afwezig zijn in een groot deel van de dikke darm. Dit 
noemen we ook wel lang-segment HSCR. Lang-segment HSCR is de meest erfelijke 
vorm van HSCR. 
Tot op heden zijn in HSCR patiënten mutaties gevonden in meer dan 15 
genen, met RET als het belangrijkste gen. Mutaties die de eiwitstructuur van RET 
veranderen zijn gevonden in ~50% van de familiaire HSCR patiënten en in 15-35% 
van de sporadische patiënten. Mutaties in de overige HSCR genen zijn veel 
zeldzamer. Vermoedelijk zijn er daarom meer, nog onbekende genen die bijdragen 
aan het ontstaan van de ziekte.  
Hoofdstuk 2 beschrijft de identificatie van vier nieuwe genen voor HSCR 
door te zoeken naar de novo mutaties. De novo mutaties zijn nieuw ontstane 
genetische veranderingen die niet worden gevonden in de ouders, maar wel in het 
kind. In recente jaren zijn dit soort mutaties in verband gebracht met 
ontwikkelingsstoornissen zoals autisme, schizofrenie en verstandelijke handicaps. 




In onze studie vonden we 28 de novo mutaties in 24 patiënten, waarvan 8 mutaties 
in het belangrijkste HSCR gen RET. De overige 20 genen met de novo mutaties 
konden niet worden gekoppeld aan de bekende gen-netwerken die betrokken zijn 
bij de ontwikkeling van het zenuwstelsel van de darm. Daarom besloten we de rol 
van deze genen in de ontwikkelingen van het zenuwstelsel van de darmen te testen 
in een proefdiermodel. Hiervoor hebben we gebruik gemaakt van een zebravis 
waarin de zenuwcellen in de darm fluorescent oplichten en daardoor makkelijk 
zichtbaar zijn. Met behulp van dit diermodel vonden we dat inactivatie van vier 
van de genen met de novo mutaties (DENND3, NCLN, NUP98 en TBATA) leidde tot 
afwezigheid van zenuwcellen in het uiteinde van de darm van de zebravis, 
vergelijkbaar met aganglionose die wordt gezien in HSCR patiënten. Van de vier 
genen is bekend dat ze betrokken zijn bij de ontwikkeling van het centrale 
zenuwstelsel in de hersenen. Wij hebben nu dus aangetoond dat ze ook een rol 
spelen in de ontwikkeling en functie van het zenuwstelsel van de darm. 
Veel bekende HSCR genen zijn actief in de voorlopercellen die uiteindelijk 
het zenuwstelsel in de darm vormen. In hoofdstuk 3 hebben we alle genen die 
actief zijn in de voorlopercellen in kaart gebracht, om zo beter te begrijpen hoe het 
zenuwstelsel van de darm zich ontwikkelt en om nieuwe kandidaat genen te 
vinden voor HSCR. De genen die actief waren, zijn betrokken bij de verschillende 
stadia van de ontwikkeling van neuronen, of zijn belangrijk voor het maken van 
verbindingen tussen zich verplaatsende cellen. Onze analyse laat zien dat bekende 
HSCR genen als Ret en Sox10 zo kunnen worden aangetoond. Dit geeft aan dat de 
methode die we gebruiken goed werkt. Naast de bekende genen vonden we ook 
een aantal veelbelovende kandidaten, te weten Bdnf, App, Mapk10 en Timp1. Deze 
genen spelen een belangrijke rol in de ontwikkeling van het zenuwstelsel van de 
darm en zijn dus potentiële HSCR genen. Daarnaast lieten we zien dat activatie van 
RET, het belangrijkste HSCR gen, belangrijk is voor de late ontwikkeling van 
zenuwcellen.  
Next-generation sequencing (NGS) is een nieuwe manier om de DNA 
volgordes vast te stellen. NGS kan worden gebruikt om de DNA volgorde van het 
hele genoom af te lezen en genereert dus enorme hoeveelheden DNA sequentie 
data. Door de grote hoeveelheid data in NGS experimenten is het onoverkomelijk 
dat er fouten optreden in het aflezen van de DNA volgorde. Dit bemoeilijkt de 
identificatie van nieuwe, de novo mutaties in NGS data. Het aantal de novo mutaties 
is namelijk veel lager dan het aantal fouten in NGS data en het vinden van de novo 
mutaties in NGS data is dus als het zoeken naar een speld in een hooiberg. In 
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hoofdstuk 4 wordt geanalyseerd hoe de novo mutaties onderscheiden kunnen 
worden van fouten in NGS data op basis van drie veelgebruikte 
kwaliteitsparameters. Hierbij vonden we dat de Genotype Kwaliteit score de meest 
informatieve parameter is. Normaal gesproken is er een maximale waarde die 
wordt toegekend aan de Genotype Kwaliteit score, maar wij ontdekten dat de novo 
mutaties specifieker gevonden kunnen worden door geen maximum te stellen aan 
de waarde van deze parameter. Door optimale waarden te kiezen voor de drie 
geteste parameters konden we de novo mutaties 98,3% accuraat identificeren, 
zonder mutaties te missen. 
Complexe genetische aandoeningen worden veroorzaakt door een 
combinatie van veel voorkomende en zeldzame genetische varianten. Zeldzame 
varianten kunnen worden geïdentificeerd met behulp van NGS, maar doordat 
zeldzame varianten slechts in enkele patiënten worden gevonden is het lastig om 
statistisch bewijs te vinden dat de gevonden mutaties ook echt betrokken zijn bij 
het ontstaan van een ziekte. In hoofdstuk 5 hebben we onderzocht hoe een 
combinatie van strategieën toegepast kan worden om zinvolle informatie te halen 
uit NGS data van HSCR patiënten, ondanks het gebrek aan sterk statistisch bewijs. 
Door te kijken welke genen een aannemelijke rol hebben in de ontwikkeling van 
het zenuwstelsel van de darm, hebben we een aantal kandidaat genen voor HSCR 
geïdentificeerd. Een kleinschalige genetische studie kan een eventuele rol van deze 
genen in HSCR bevestigen.  
In 30% van alle gevallen komt HSCR voor als onderdeel van een 
syndroom, waarvan het syndroom van Down het meest voorkomende is. Zeven 
procent van mensen met het syndroom van Down heeft ook de ziekte van 
Hirschsprung. Het syndroom van Down wordt veroorzaakt door een extra kopie 
van chromosoom 21. Het is daarom aannemelijk dat de extra kopie van één of 
meer van de genen op chromosoom 21 bijdraagt aan het ontstaan van HSCR in 
patiënten met het syndroom van Down. Deze hypothese hebben we getest in 
hoofdstuk 6 door een aantal genen die op chromosoom 21 liggen tot 
overexpressie te brengen in het eerdergenoemde zebravis model met de 
fluorescerende zenuwcellen in de darm. Overexpressie van één gen (ATP5O) leidde 
tot een vermindering van het aantal zenuwcellen in de darm in de zebravis, net 
zoals wordt gezien in HSCR patiënten. In patiënten met het syndroom van Down 
zou de extra kopie van dit gen kunnen bijdragen aan de ontwikkeling van HSCR. 
In hoofdstuk 7 worden de implicaties van het onderzoek in dit 
proefschrift beschreven. We concluderen dat zeldzame genetische varianten een 




rol spelen in sporadische HSCR en benadrukken dat functioneel testen van 
kandidaat genen in een diermodel van grote waarde is bij het vinden van nieuwe 
ziektegenen. Er worden suggesties gedaan voor de identificatie van nieuwe HSCR 
genen in toekomstige studies. Tevens wordt besproken wat de implicaties van dit 
onderzoek zijn voor genetische voorlichting voor families van patiënten met de 
ziekte van Hirschsprung. 
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LIST OF ABBREVIATIONS 
 
ATP5O ATP Synthase, H+ Transporting, Mitochondrial F1 Complex, O 
Subunit 
AUC  area under the curve 
CCHS  congenital central hypoventilation syndrome 
CNS  central nervous system 
CNV  copy number variation 
DENND3 DENN/MADD Domain Containing 3 
DNM  de novo mutation 
dpf  days post-fertilization 
DS  Down syndrome 
(E)NCC  (enteric) neural crest cell 
E14.5  embryonic day 14.5 
EDNRB  endothelin receptor type B 
ENS  enteric nervous system 
GATK  genome analysis toolkit 
GDNF  glial cell line-derived neurotrophic factor 
GQ  genotype quality 
GWAS  genome-wide association study 
(h)iPS cell (human) induced pluripotent stem cell 
hpf  hours post-fertilization 
Hsa21  human chromosome 21 
HSCR  Hirschsprung disease 
IGV  integrative genomics viewer 
indel  insertion and/or deletion 
IPA  Ingenuity pathway analysis 
LOF  loss of function 
MO  morpholino 
NCLN  nicalin 
NGS  next-generation sequencing 
NLB  neurosphere-like body 
NPC  neural progenitor cell 
NRG  neuregulin 
NUP98  nucleoporin 98kDa 
OMIM  online Mendelian inheritance in man 




RET  rearranged during transfection 
ROC  receiver operating characteristic 
SBMO  splice-blocking morpholino 
SEMA  semaphorin 
SNV  single nucleotide variation 
(ss)PL  second smallest PHRED-scaled genotype likelihood 
TBATA  thymus, brain and testes associated 
TBMO  translation-blocking morpholino 
VCF  variant call format 
WS  Waardenburg Shah syndrome 
YFP  yellow fluorescent protein 
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Het was vaak gezellig, maar ook voor serieuze dingen kon ik bij jullie terecht.  
Beste Ilia, ook wel gebombardeerd tot onze model PhD, omdat je altijd je 
zaakjes op orde had. Zie dat vooral als een compliment! Bedankt voor alle 
discussies over het schrijven van een proefschrift, opmaak, solliciteren, etc. I hope 
for you and Suping that you will be able to find your next jobs in the same place. 
Beste Sabrina, het was jammer je te zien vertrekken van de afdeling, maar ik ben 
erg blij dat je goed op je plek bent in het ERIBA. Dear Claudio, thanks for being a 
great office mate and climbing buddy. Sorry you had to endure ‘Dutch pasta’ 
several times before climbing. Beste Inge (Holtman), van alle collega’s op de 
afdeling kwam mijn werk af en toe het meeste overeen met dat van jou. Dank je 
voor de discussies en hulp bij het bioinformatische deel van mijn projecten en veel 
plezier en succes in San Diego. Dear Zhuoran, you were my ‘neighbor’ for most of 
the time during my PhD. I enjoyed practicing Dutch with you and Claudio and I had 
fun teaching you difficult Dutch and Frisian sentences. Thanks for always being so 
kind, positive and seemingly happy. Dear Xiaoming, I have a lot of respect for how 
much you have grown and developed in the last couple of years. It was fun to 
witness your unexpected great sense of humor. Dear Clarissa, thanks for all the 
nice, warm talks and good times. It was amazing! 
Beste Alain, het is bijzonder hoe je je ervaring met mensen met het 
syndroom van Down om hebt kunnen zetten naar een promotieonderzoek. Je 
persoonlijke betrokkenheid hierin valt te prijzen. Dear Chaitali, when we first met 
I got to know you as my colleague’s wife. It’s funny how things can change and we 
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became coworkers as well. I hope things will work out for you and Rajendra now 
that he is almost moving on and you are settled in Groningen. Dear Arun, thanks 
for all the social chats and discussions about work and other stuff in our office, and 
during our afternoon tea breaks in the first years of our PhD’s. Dear Kumar, thank 
you as well for the nice tea breaks. Don’t be too hesitant to practice your Dutch. 
Practice makes perfect and it may come in handy when you are looking for your 
next job within The Netherlands. Dear Sai, I was sorry to see that your time in the 
department didn’t work out as hoped. I hope you will find a place where you can 
find your happiness. 
To the former lab members Reinhard, Wandert, Vishnu, Zhilin, Ellie, 
Duygu, Ria, Ming-San, Thaiany and Divya, thank you for the coffee breaks, 
lunches, after-work drinks, nice talks and good times. I hope you are all doing well. 
Thanks to the two students, Eunice and Michelle, that I have supervised 
during my PhD. Supervising you has not only confirmed my idea that I like to teach, 
but also taught me how to be a better teacher. Thanks also to the many other 
students we have had in the lab over the years. There were too many of you to 
name all of you here in person (and frankly I forgot a few names), but you were 
always a welcome addition to social atmosphere in the department.  
 Beste Martijn, leuk dat je af en toe bij ons op de afdeling was te vinden, 
eigenlijk hebben we daarna te weinig contact gehouden. Veel geluk voor jou en 
Linda met jullie gezinnetje. Hola Alejandra, I always felt sorry for you when Koen 
and Martijn were mocking you. Thanks for considering me the nice guy among 
them. Dear Khayum, it is hard to find someone who is as energetic and 
enthusiastic as you. I’m sure that with your attitude you will find your way in 
whatever life will bring you. Wout, Astrid en Wouter, bedankt voor de avondjes 
klimmen, eerst in Gropo en later in Bjoeks! 
Lieve Lotte, meer dan vier jaar lang ben jij degene geweest met wie ik 
zowel mijn enthousiasme als mijn frustraties over mijn PhD heb kunnen delen. Ook 
al heeft het uiteindelijk niet gewerkt tussen ons, ik ben je dankbaar voor onze jaren 
samen en ik hoop dat het je goed gaat. 
Meer dan wie dan ook hebben mijn ouders bijgedragen aan het feit dat dit 
proefschrift er is. Heit en mam, jullie hebben Freerk, Aldert en mij altijd 
gestimuleerd om iets te doen wat goed bij ons past, zonder verwachtingen te 
hebben. Jullie hebben goed oog gehad voor wat ieder van ons nodig had om ons 
gelukkig en zelfredzaam in de maatschappij af te leveren. Ik ben er van overtuigd 
dat dit me meer dan wat dan ook heeft geholpen om te worden wie ik ben en te 




bereiken wat ik heb bereikt. Freerk en Aldert, het is mooi om te zien hoe jullie je 
weg vinden in het leven, zij het met Mirjam en de nieuwe aanwinst op komst in 
Ryptsjerk, dan wel met Karla, Jhosue en Jurre in Ecuador. Helaas hoort bij het 
volwassen worden ook dat we elkaar wat minder vaak zien, maar het feit dat dat 
soms lastig is bevestigt juist hoe goed we het hebben met z´n allen. Dank jullie wel 
voor alles.  
 
   
